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ROBERT PAUL AlTRING.

Metabolism of Branched-Chain Amino Acids by Rat

Skeletal Muscle: Regulation of Branched-Chain a-Keto Acid Dehydrogenase.

(Under the direction of Maria G. Buse.)

Catabolism of the essential branched-chain amino acids (BCAA) by
skeletal muscle of the rat was investigated.

In diaphragm muscles

incubated in vitro oxidation and transamination of leucine or valine
were accelerated by diabetes or starvation overnight.
of

pyruvate,

transamination

of

oxidation of BCAA by diaphragms

BCAA

by

diaphragms

In the presence
was

increased;

from diabetic or starved rats was

increased by pyruvate but was inhibited in diaphragms of normal, fed
rats.

The effects on transamination were verified by direct measure-

ments of the a-ketoisocaproate (KIe) product of leucine transamination.
The effect of pyruvate on KIC oxidation by diaphragms was similar to
the effect on leucine oxidation.
genase

(BCDH)

catalyzes the

Branched-chain a-keto acid dehydro-

conunitted step

in BCAA catabolism,

its

activity is regulated by a reversible phosphorylation-dephosporylation
cycle.
inactive)

A method to measure active (initial) and total (active +
BCDH in a

soluble preparation from muscle was developed.

Initial BCDH activity in fed,

postabsorptive rats was about 1 runol/

minI g muscle. Total acti vi ty was -35 nmol/min/ g muscle;
BCDH was in the active state.

thus -2% of

Intravenous infusion of leucine rapidly

increased BCDH activity in a dose-dependent fashion;

activity subse-

quently declined in parallel with plasma leucine concentration.

Valine

had no effect on BCDH activity while isoleucine was effective only at
high doses.

BCDH activity increased after

25% or 50% but not 9%

protein meals in rats fed an adequate protein diet.

Feeding a 50%

v

protein diet chronically increased postabsorptive BCDH.

Dose-dependent

response of BCDH to leucine was blunted in rats fed 9% protein chronically.

In insulinopenic diabetic rats plasma BCAA and muscle BCDH

activity were increased. Insulin therapy or adrenalectomy of diabetic
rats

decreased

plasma

BCAA

but

BCDH

activity

remained

elevated.

Starvation increased BCDH activity significantly only after four days.
BCDH activation in response to increased leucine was blunted in starved
or

diabetic

rats.

Conclusions:

In normal

fed

rats,

muscle BCDH

activity increases in response to hyper1eucinemia from meal consumption
or infusion.
tes,

The response to hyperleucinemia is attenuated by diabe-

starvation or consumption of a low protein diet.

In diabetes

increased muscle BCAA oxidation results from increased BCAA transamination and increased BCDH activity.
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Chapter I
General Introduction

The branched-chain amino acids (BCAA*; L-leucine, L-isoleucine and
L-valine) are among the nine essential amino acids in man and the rat
(156,158).

As a group the BCAA account for a large proportion, about

45% (157,158), of the total essential amino acid requirement in man.
The substantial requirement for these amino acids is reflected in their
abundance in proteins; they account for 35% of the essential and 14% of
the total amino acids in skeletal muscle (159), the largest repository
of metabolically active protein (44).

Among the essential amino acids

BCAA (and leucine in particular) are unique in several respects: 1)
they are metabolized extensively by peripheral tissues other than the
liver (77,126); 2) their circulating concentrations change markedly in
states such as altered protein intake, starvation, hepatic failure and
insulinopenic diabetes (172); and 3) there is evidence that leucine can
regulate protein turnover other than in its role as a precursor for
protein synthesis (29,127).
Catabolism of the BCAA.
The BCAA can be completely degraded by mammals and the catabolic
pathways for the amino acids were established by a number of investigators (reviewed in 125).

The essential features of their catabolic

pathways are shown in Figure 1.

*

The initial two catabolic steps are

Abbreviations used in this chapter are: BCAA, branched-chain

amino acids; BCKA, branched-chain a-keto acids; BCDH, branched-chain
a-keto acid dehydrogenase; BCAT, branched-chain amino acid aminotransferase; Kle, a-ketoisocaproate.
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Figure 1.

Catabolic pathways of the branched-chain amino acids.
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common to all three BCAA.
of

the

amino

(BCKA)

by

The first step (I), involves transamination

acid to its corresponding branched-chain a-keto acid

branched-chain

amino

acid

aminotransferase

(BeAT);

i.e.

leucine to a-ketoisocaproate (KIC), valine to a-ketoisovalerate, and
isoleucine to
step

a-keto-~-methylvalerate.

The second (II), and committed

(thus rendering these amino acids essential),

is irreversible

oxidative decarboxylation of BCKA catalyzed by branched-chain a-keto
acid dehydrogenase complex (BCDH).
branched-chain

acyl-CoA products

diverges

respect

with

to

the

Further catabolism of the three
of BCDH action on the three BCKA

enzymes

and

the

specific

catabolic

products but in general the pathways are similar to J3-oxidation of
fatty acids.
There are several noteworthy features of these catabolic pathways.
The ultimate products of leucine oxidation are acetyl-CoA and acetoacetyl-CoA, leucine catabolism therefore yields only ketogenic products
and

cannot contribute to gluconeogenesis.

3-Hydroxy-3-methylglutaryl-

CoA is an intermediate in leucine catabolism, thus its carbon skeleton
can

act

as

a

direct

precursor

oxidation to acetyl-CoA.
CoA,

and

therefore

for

cholesterol

synthesis without

Valine is ultimately catabolized to succinyl-

contributes

only

a

gluconeogenic

precursor.

Catabolism of isoleucine yields propionyl-CoA and acetyl-CoA thereby
providing precursors for both ketogenesis and gluconeogenesis.
The existence of additional catabolic pathways for leucine deserve
mention.

A cytosolic enzyme which catalyzes 02-dependent oxidative

decarboxylation of KIC has been identified in liver (161).

This enzyme

is an Fe-dependent dioxygenase (162.163) which catalyzes KIC oxidation

5

to

~-hydroxyisovalerate

(Figure 2).

The significance of this catabolic

sequence in disposal of leucine is unknown but the product of this
reaction

appears

to

be

an

ideal

precursor

for

sterol

synthesis.

requiring only activation to its CoA derivative to enter the sterol
synthetic pathway; experiments using rat liver homogenates designed to
demonstrate incorporation of a-ketoisocaproate carbons into cholesterol
under

conditions favoring utilization of this pathway were however

unsuccessful

(R.P.

Aftring.

M.

Owens,

and M.G.

Buse,

unpublished

observations).
Liver

of mammals

also

synthesizes a cobalamin-requiring enzyme

(leucine 2.3-aminomutase) which catalyzes the conversion of leucine to
~-leucine

(Figure

transaminated to

3;

ref.

147).

~-ketoisocaproate

The

resulting

~-leucine

can

be

(an inherently unstable a-keto acid)

which in a bacterial system was further catabolized to isobutyrate and
acetate.

In a group of patients with pernicious anemia serum leucine

concentration was decreased while serum

~-leucine

concentration was

increased. This observation suggested the possibility that the
cine pathway operated in the direction of synthesis (148).
more.

~-leucine

~-leu

Further-

was synthesized from valine, isobutyryl-CoA or bran-

ched-chain fatty acids

in vitro in a rat liver system (148).

The

importance of this metabolic pathway is unknown, but it suggests that
although leucine is essential in the diet (i.e. required for growth and
positive N balance), manunals may have limited capacity to synthesize
this amino acid.
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Figure 2.

Catabolism of a-ketoisocaproate by a cytosolic oxygenase.
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Metabolism of leucine by leucine 2,3-aminomutase.
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Branched-chain amino acid aminotransferases.
BGAT activity in tissues is comprised of at least three and perhaps
more

isoenzymes

with

somewhat

different

substrate specificities (reviewed in 95,96).

physical

properties

and

As a group they catalyze

a pyridoxal-5 1 -phosphate dependent transamination reaction similar to a
large

number

others

of

aminotransferase).
group

from

the

(e.g.

aspartate

aminotransferase,

alanine

The reaction catalyzed is the transfer of the amino

branched-chain amino

acid

to

an a-keto

acid with

production of the corresponding BCKA and amino acid (from the a-keto
acid, see Figure 1).

In general a-ketoglutarate is thought to be the

preferred amino group acceptor in vivo for this group of enzymes but
the branched-chain a-keto acids are also efficient amino group acceptors (13,174).
The BeAT enzymes are present in all mammalian tissues examined.

The highest

activities were

manunary gland,

found

in

stomach,

pancreas,

lactating

salivary gland and heart, intermediate activities in

kidney, brain, and muscle and low activities in liver, spleen and lung
(95,99).

Three isoenzymes of BCAT have been described in the rat.

Isoenzyme I was ubiquitous in tissues and actively transaminates all
three BCAA; isoenzyme III, also active with all BCAA, was found only in
brain, placenta and ovary (99).
was

active with

Isoenzyme II. present only in liver,

leucine and methionine and may exist as distinct

cytosolic and mitochondrial forms (97).

In human tissues isoenzyme III

was found in many tissues but isoenzyme I was the predominant BCAT;
isoenzyme II has not been identified in human tissues (72).

8

Branched-chain a-keto acid dehydrogenase complex.
The BCDH complex is analogous to the pyruvate and a-ketoglutarate
dehydrogenase complexes, requiring NAD+ and CoASH as cofactors for the
oxidation of

BCKA producing NADH and branched-chain acyl CoA (one

carbon shorter than the BCKA) as end products (45,150,199, see Figure
1).

BCDH is a large multienzyme complex, located on the inner aspect

of the inner mitochondrial membrane (119,180).

Active BCDH consists of

three enzymatic components (38,85,144,146): 1) a decarboxylase moiety
(E1) composed of nonidentical a and ~ subunits with thiamine pyrophos-

phate as a prosthetic group;
acid

as

a

2) a transacylase moiety (E2) with lipoic

prosthetic group;

and

3)

a

flavin-containing lipoamide

dehydrogenase moiety (E3) which is probably identical to that found in
the pyruvate and a-ketoglutarate dehydrogenase complexes (85,199).
BCDH activity is subject to several types of regulation.

The

complex is subject to feedback regulation by NADH, its branched-chain
acyl CoA products and perhaps catabolites of leucine distal to isovaleryl-CoA (reviewed in 150).

It was recently established that BCDH is

regulated by a phosphorylation-dephosphorylation cycle similar to that
described for pyruvate dehydrogenase (150,152).

BCDH is inactivated by

the action of a specific kinase which catalyzes ATP-dependent
phosphorylation of serine residue(s) of the a-subunit of the decarboxylase moiety (37,58,108,133).
bited by BCKA (KIC
142).

The

»

Purified BCDH kinase activity is inhi-

a-keto-a-methylvalerate > a-ketoisovalerate; ref.

non-physiological

compound,

a-chloroisocaproate,

is

a

relatively specific and highly potent inhibitor of BCDH kinase, in vivo
and in vitro (82).

Purified inactive BCDH can be reactivated in vitro

9

by dephosphorylation of phosphoserine by the action of a non-specific
phosphoprotein
(69).

phosphatase,

cytosolic

phosphoprotein

phosphatase

II

There is evidence for a specific phosphatase for BCDH, purified

from bovine kidney mitochondria, which may be responsible for reactivation of the complex in vivo (40).

BCDH phosphatase activity is

unaffected by divalent cations and is inhibited by several di- and
triphosphonucleosides

in

the

absence of Mg 2+ (40,152).

Phosphatase

activity is stimulated by protamine, poly(L-lysine), and histone H3 and
inhibited

by heparin,

catabolism (40,152).

CoASH and several acyl-CoA products of BCAA

Recently, a protein inhibitor of BCDH phosphatase

was purified from bovine kidney mitochondria.

The protein inhibitor is

distinct from protein phosphatase inhibitors -1 and -2 and appears to
be specific for BCDH phosphatase (39,41).

Mg 2+ and spermine reverse

the inhibitory effect of this protein on BCDH phosphatase (39,41).

The

system of a phosphoprotein phosphatase with a protein inhibitor is
reminiscent of the cytosolic protein phosphatases I and II with their
respective protein inhibitors I and II (reviewed in 36).

Whether the

BCDH phosphatase inhibitor is present in other tissues and if it has a
role in the regulation of BCAA catabolism are unknown.
Protein factors which can alter BCDH activity have been found in
several tissues and plasma (137,141).
which activates

BCDH

A cytoplasmic protein factor

in liver mitochondria has been prepared from

skeletal muscle and is also found in plasma t but not in smooth muscle,
kidney or liver (141).
Q-

This skeletal muscle factor also activates

ketoglutarate dehydrogenase but inhibi ts pyruvate dehydrogenase in

rat

liver mitochondria.

A protein

factor

from kidney and

liver

10
mitochondria activates phosphorylated BCDH, the effect does not involve
dephosphorylation of the complex (57,198).

This latter factor (termed

BCDH activator protein) has been purified and was identified as free E1
(decarboxylase) or an isoenzyme of E1, which presumably increases BCDH
activity by replacing inactive (i .e. phosphorylated) E1 in the BCDH
reaction (56,198).

It is noteworthy that phosphorylated E1 has lower

affinity for the complex than does the non-phosphorylated enzyme (38).
The role of these protein effectors of BCDH activity in regulation of
BCDH activity in vivo remains unknown.
The discovery of interconvertible forms of BCDH presents a problem
in the determination of BCDH activity in tissues, and casts doubt on
the

results

and

interpretation of early studies of BCDH activity.

Studies of BCDH activity which consider the active and inactive forms
find that BCDH is nonuniforrnly distributed between tissues (69,137,
183).

Liver,

(69,137,183).

kidney and heart have large total quantities of BCDH
In livers of fed rats nearly all of the BCDH was in the

active state, in kidney the complex was 50-70% active, and in heart the
acti vi ty state ranged between 7% and 50% in studies from different
laboratories (69,137,183).
lower

than

in

other

Total BCDH activity in skeletal muscle was

tissues

examined

(137,183),

although

direct

comparisons of the measured activities are difficult due to differences
in assay methods.

Pats ton et a1.

(137) estimated the BCDH was less

than 20% active in detergent extracts of muscle mitochondria but the
actual activity was below the limit of detection of their assay.

In

muscle homogenates Wagenmakers et ale (183) and Kasperek et a1. (100)
found about 5-6% of BCDH was in the active state in fed rats.

11

Interorgan cooperativity in BCAA catabolism.
A number of reports have established the importance of peripheral
(non-splanchnic) tissues

in BCAA catabolism.

Studies of amino acid

oxidation by eviscerated rat carcasses showed that of the essential
amino acids only the BCAA were oxidized in the peripheral tissues and
provided early evidence that BCAA are oxidized primarily by extrahepatic tissues, while other essential amino acids are oxidized by the
liver (126).

The importance of the peripheral tissues in BCAA oxida-

tion was confirmed in studies of hepatectomized dogs (122) and rats
(86),

in

which

the

concentrations

of most

amino

acids

increased

steadily while those of the BCAA remained unchanged or declined.

A

wide variety of extrahepatic tissues have the ability to oxidize BCAA,
including

skeletal muscle

(25,132),

kidney (46,47),

brain (21,35),

peripheral nerve (28), aorta (28), adipose tissue (59), and heart (25).
Determinations

of

the

clearance of

amino acids

in humans after a

protein meal (49,54) or amino acid infusion (2,49,54,67) demonstrated
that skeletal muscle is a prominent site for BCAA disposal (disposing
of 65-70% of infused leucine, ref. 67).
Although BCAT and BCDH are present in all tissues examined, their
distributions in various tissues are markedly different (i.e. liver had
low BeAT activity but high BCDH activity, muscle had high BCAT activity
but low BCDH activity, and kidney had relatively high activities of

BCAT and BCDH).

The observation that perfused rat hindlimbs release

substantial quantitities of BCKA when perfused with BeAA (90,91) led to
the suggestion that there is interorgan cooperativity in the catabolism
of BCAA (reviewed in 77).

In view of the low activity of hepatic BCAT
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it is thought that most BCAA entering the splanchnic circulation after

a protein meal pass through the liver unaltered.

Most BCAA from oral

ingestion therefore enter the systemic circulation for distribution to
peripheral tissues.

In the periphery BCAA are taken up for protein

synthesis and catabolism.

In muscle some fraction of the BCAA which

are transaminated to BCKA are oxidized by BCDH and the remaining BCKA
enter

the venous

system and are distributed to other tissues for

oxidation or reamination.
thought to be an

Since liver has high BCDH activity it is

important site for the clearance of BCKA in the

circulation and indeed hepatic-portal venous BCKA gradients in the rat
show that liver clears virtually all BCKA supplied to it (112).
The conceptual model of interorgan cooperation for BCAA metabolism
is well supported in the rat, but its applicability to humans has been
questioned (172).

Studies of leucine metabolism by human muscle in

vivo established that leucine is oxidized by muscle but consistently
found considerably less export of the transamination product KIC (2,49)
by human muscle than has been found for rat muscle (90,91).

The

difference in the systems was suggested to be due to different distributions of BCDH in human and rat tissues.

Khatra et a1. (102) reported

that 60% of human total body BCDH was present in muscle while only 15%
of the rat enzyme was present in muscle. However, these studies were
done without knowledge of the phosphorylation-dephosphorylation cycle
which regulates BCDH activity (as discussed above).

Furthermore the

BCDH activities obtained by these authors in rat tissues are much lower
than recent estimates of these activities (94,151); 4-6 fold lower in
liver and nearly 2 orders of magnitude lower in skeletal muscle.

At
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present,

in the absence of measurements of BCDH activity in human

tissues using more accurate methods it is difficult to assess the
similarity of BCAA metabolism in man and rat, but there appears to be
no compelling reason to dismiss data from the rat as inapplicable to
humans.
Alterations in BCAA metabolism by starvation, disease, and injury.
Dramatic changes in plasma BCAA concentrations are observed under
several conditions.

In starvation, diabetes mellitus, and after injury

the circulating concentrations of BCAA are elevated (4,18,51,139,154).
In contrast,

plasma BCAA are markedly depressed in hepatic failure,

while the concentrations of aromatic amino acids are increased (62).
These alterations

of

plasma BCAA concentrations presumably reflect

changes in supply and/or removal.

Despite increased plasma BCAA there

is evidence for increased BCAA oxidation by skeletal muscle in starvation, diabetes, and trauma (4,9,51).

These results seem paradoxical in

view of the fact that in short-term starvation, and probably in trauma
as well, the source of increased BCAA is thought to be skeletal muscle
(34,44).

There is some dispute over whether the increased BCAA oxida-

tion observed in vitro in incubated muscles represents the in vivo
response to starvation or diabetes.

Studies of leucine oxidation in

vivo in rats starved for three days however clearly demonstrated that
whole body oxidation of leucine was increased (182).

In vivo whole

body oxidation of leucine was also increased in patients with type I
diabetes

after

patients (4).

insulin

withdrawal

(154,179)

and

in

starved obese

Despite increased BCAA oxidation, the leucine clearance
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rate in diabetic patients (51) or in normal humans fasted for 3 (169)
or 4 (51) days was decreased.
Recent studies from Randle and coworkers (reviewed in 151) found
that BCDH activity in kidney and liver from rats was decreased by
alloxan-diabetes and 2 days starvation.

BCDH activity in heart was

unaffected by starvation but increased in diabetes.

Earlier studies

found no effect of starvation or diabetes on kidney or liver BCDH
activity (69,184) but did not take into account changes in the BCDH
activator

protein which

is

present

in

liver

and kidney.

It was

postulated that the decrease in whole body BCDH activity (considering
only changes in kidney,

liver and heart BCDH activity) in diabetes

could explain the increased circulating BCAA in diabetes (151).

This

explanation may be inadequate though since no consideration was given
to possible changes in BCDH activity in tissues such as skeletal muscle
or brain or to the observations of increased whole body oxidation of
BCAA in insulinopenic diabetes (154,179).

Indeed, Brosnan and cowork-

ers have demonstrated increased BCAA clearance by the brain in diabetic
rats (20), and determined that the activity state of BCDH in brain is
increased by diabetes (21).

Further study of protein degradation and

the regulation of BCAA disposal,

especially in skeletal muscle are

required to fully elucidate the factors which contribute to increased
BCAA in starvation, diabetes and trauma.
The depressions in plasma BCAA observed in hepatic failure are most

likely due to accelerated oxidation by peripheral tissues, as suggested
by studies in hepatectomized animals (86,122).
likely site for increased BCAA disposal.

Skeletal muscle is a

Indeed, increased clearance
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of BCAA by the leg was observed in patients with decompensated liver
cirrhosis (83).

The activity of skeletal muscle BCDH in liver failure

has not been determined and no factors

identified which may cause

increased BCAA clearance in hepatic failure.
Effect of diet and meal consumption on BCAA metabolism.
Plasma BCAA increased in parallel with the protein concentration of
the diet in rats maintained on diets with protein content varying
between 5% and 75% casein; other plasma amino acids remained constant
or declined (10,145).

These results suggest that BCAA oxidation does

not increase proportionately with their dietary intake.

This is in

contrast to other essential amino acids whose plasma concentrations are
essentially constant despite increased intake (145) .

The adaptive

advantage of this response to increased dietary intake of BCAA is
unclear since increased amino acid concentrations in general can be
toxic.
urine

This is certainly so for the BCAA as evidenced by Maple Syrup
disease,

a

congenital

disease

with

greatly

decreased

BCDH

activity (42) which results in large increases in plasma BCAA and BCKA
and is associated with mental retardation and diminished growth (43).
Nevertheless whole body leucine oxidation increased in rats fed diets
with increasing protein content (109), and in humans leucine oxidation
was increased following a protein meal (87).

Curiously, when animals

are fed diets containing adequate protein but excesses of leucine,
growth rates are diminished and circulating concentrations of valine
and isoleucine are depressed (reviewed in 77).

The site(s) of increa-

sed BCAA oxidation after a protein meal or during increased protein
intake is not known, nor is the cause of depressed valine and isoleu-
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cine

concentrations

in

the

presence of

elevated

leucine.

It

is

noteworthy however that BCDH activity in liver and kidney was greater
in rats fed a normal diet (20% protein) than those fed a 9% protein
diet (81,151).
BCAA as regulators of protein turnover.
In incubated diaphragm muscles from rats, leucine inhibited protein
degradation

and

promoted

protein

synthesis

(29,66,127).

Similar

effects on protein turnover were demonstrated in perfused rat hearts
(128); the effect on protein synthesis was thought to involve initiation of translation (128).
given

In fasted rats in vivo t a mixture of BCAA

intraperitoneally after

administration

of

insulin

stimulated

formation of more polysomes in the psoas muscle than were found after
insulin

alone

(23) .

In

skeletal muscles incubated in vi tro

J

the

effects of BeAA on protein synthesis were attributed to a specific,
concentration-dependent effect of leucine (31 t 66,127).

The inhibitory

effect of BCAA on protein degradation however required metabolism of
leucine to a-ketoisocaproate (127,176); proteolysis was inhibited by
high concentrations of 3-methylvalerate in one study (127).

It remains

unclear if the positive effects of BCAA on protein turnover obtain in
vivo.

In

isolated,

perfused rat hindlimbs high concentrations of

leucine increased protein synthesis in inunature rat preparations but
not in preparations from adult rats (Ill).

Bolus injection of 0.1 romol

of leucine in vivo had no effect on skeletal muscle protein synthesis
by fed t

starved or protein-deprived rats (123), while infusion of a

mixture of the three BCAA in starved rats stimulated protein synthesis
in certain muscles (32).

The mechanism(s) of the effects of leucine
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(or its metabolites) on protein turnover remain undefined.

However, a

recent study suggests that glycoprotein synthesis may be involved in
the stimulatory effect of leucine on protein synthesis since inhibitors
of glycoprotein synthesis abolished the effect of a mixture of BCAA but
not of insulin on protein synthesis in diaphragm muscles incubated in
vitro (149).
Therapeutic uses of BCAA.
The reported anabolic effects of BCAA coupled with evidence for
increased oxidation of BCAA in clinical states such as injury and
sepsis (9,51,160) have generated considerable interest in the use of
alimentation formulas supplemented wi th increased rations of BCAA in
clinical nutrition.

It is thought that increased supply of BCAA may be

beneficial in improving nitrogen balance in selected patients, both by
supplying additional substrate for oxidation and through their anabolic
effects (reviewed in 189).

The use of BCAA supplementation in injured

or surgical patients is being encouraged despite the incomplete understanding of BCAA metabolism and its regulation and inconclusive and
contradictory results in clinical studies.
BCAA catabolism by skeletal muscle.
The BeAA are among a limited number of amino acids which can be
oxidized by skeletal muscle (70,115); muscle has substantial capacity
for

the degradation of BCAA as

demonstrated with

isolated muscle

preparations and perfused rat hindlimbs (reviewed in 77).

Furthermore,

the apparent oxidation of BCAA by muscle is accelerated in protein
catabolic states such as diabetes (26,139), starvation (24,139), trauma
(9), and perhaps by exercise (74,110,194,196) as well.

The large pool
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of inactive BCDH in muscle suggests that increases in the activity
state of BCDH may account for accelerated BCAA catabolism observed in
the

condi tions

discussed

above.

Kasperek et

al.

found

that

the

activity state of muscle BCDH increased markedly during exercise and
declined toward the ini tial value in the postexercise period (100).
However, Wagenmakers et a1. found only a minimal change in the activity
state of muscle BCDH during exercise or starvation (183).

Different

assays were used in these studies and both are less than ideal for the
determination of the activity state of BCDH.
At present there is no method in use which fulfills the "ideal"
requirements of sampling the muscle in a manner to "trap" BCDH in its
in vivo activity state and from a single Imlscle sample render BCDH
soluble in a form allowing assay of both the in vivo activity and with
appropriate manipulation the total (sum of inactive and active) BCDH
activity.

In

the method of Wagenmakers and coworkers

(183)

BCDH

activity was measured in two homogenates of muscle prepared in an isoosmotic buffer with addition of fluoride and a-chloroisocaproate to the
sample used for in vivo activity determination but no effort was made
to determine if a transport barrier existed for the BCKA substrate or
if there was a difference in the two samples.
fluoride

the

tonicity is

altered and the mitochondria are likely to be uncoupled.

Hutson has

shown

(for measurement

that

BCKA

are

of

"in vivo"

In the sample containing

transported

by a

activity)

specific

transporter whose

activity is dependent on the mitochondrial pH gradient (92) and that
the rate of BCKA oxidation by muscle mitochondria was dependent on the
isolation procedure and media employed (94).

The method of Kasperek
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and coworkers

(100) also utilizes two homogenates, a homogenate for

determination of initial activity was prepared with fresh muscle while
the homogenate for total BCDH activity was prepared with frozen muscle.
The

BCDH assays were carried out in the presence of detergent (elimi-

nating the possiblity of a permeability barrier) over a 20 min period.
As observed by Hutson (94) assays performed over this time frame can
underestimate the true activity, even though the assay appears to be
linearly dependent on time.

BCDH activity is generally thought to be rate-limiting for BCAA
degradation,

since BeAT activity is much greater in skeletal muscle

than BCDH activity and BCKA are released by muscle.

Nonetheless it is

possible that under some conditions flux through BCDH may be limited by

BCKA production by BCAT.

The BCAT reaction is freely reversible thus

its activity in the direction of BCAA --) BCKA is determined by the
ratio of products to reactants.

Studies of purified BCAT isozyme I,

the isozyme present in muscle (99), found that
BCKA are the preferred amino group acceptors

reac t ion (1 74) .

a-ketoglutarate and
in the BCAA --) BCKA

In view of the the concentrations of the available

substrates and their affinities for the BeAT enzyme, it was suggested
that a-ketoglutarate is the amino group acceptor for 95% of BCAA transamination in skeletal muscle (131).

However in diabetes the gluta-

mate/a-ketoglutarate ratio was increased in diaphragm muscles (30),
which could slow tansamination of BCAA due to a relative deficiency of
amino group acceptor.

This raises the possibility that in muscles from

diabetic animals flux through BCDH may be restrained by the rate of
transamination.
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Despite the potential importance of skeletal muscle in the whole
body metabolism of BCAA there is little information on the activity
state of BCDH, which may be the rate-limiting enzyme for muscle BCAA
catabolism,

especially under conditions of altered BCAA metabolism.

Furthermore since muscle is likely the principal source of circulating
BCKA

to

be

metabolized

by

other

tissues,

information

on

factors

regulating flux through BeAT is important to understanding the degree
of

interorgan

detailed

in

cooperativity

the

following

in

BCAA metabolism.

chapters

will

address:

The experiments
1)

the

role

of

transamination in increased BCAA oxidation by muscle in diabetes and
fasting;

2)

the activity state of BCDH in skeletal muscle; and 3)

alterations of BCDH activity in skeletal muscle under physiolosgical
and pathological conditions.

Chapter I I

Catabolism of Branched-Chain Amino Acids
by Diaphragm Muscles of Fasted and Diabetic Rats

The contents of this chapter have been previously published in similar
form in Metabolism 34: 702-711, 1985.
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SUlllDary

In vitro catabolism of branched-chain amino acids, leucine and
valine, was investigated using diaphragm muscles from normal, streptozotocin-diabetic and overnight fasted rats.

Oxidation and transamina-

[1- 14C]branched-chain amino acids were both stimulated to a

tion of

similar extent by diabetes or fasting, when diaphragms were incubated
with glucose.

Transamination of leucine and valine was increased when

diaphragms were incubated with pyruvate; stimulation of transamination
was greatest in diaphragms from diabetic rats.

Leucine and valine

oxidation by control diaphragms was inhibited by pyruvate while it was
unchanged or slightly stimulated in diaphragms from fasted or diabetic
rats.

Thus

diaphragms

from

diabetic rats oxidized 2-3 fold more

branched-chain amino acids than controls when they were incubated with
pyruvate.

The specific radioactivity of extracellular a-ketoisocap-

(KIC;
*

roate

diaphragms
(fed,

the

product

of

leucine

transamination)

produced

by

incubated with

[1-14C]leucine was similar for all groups

fasted or diabetic)

in the presence or absence of pyruvate.

Oxidation of [1-14C]a-KIC by diaphragms from fasted or diabetic rats,
incubated with glucose, was the same or less than
control diaphragms.

KIC oxidation by

Incubation with pyruvate inhibited KIC oxidation

by control diaphragms to a significantly greater degree than that by
diaphragms from diabetic or fasted rats.
through

branched-chain

amino

acid

These data suggest: 1) Flux

transaminase

is

limited

by the

availability of amino group acceptors in diaphragms from normal and

*

Abbreviations used in this chapter are: KIC, a-ketoisocaproate;

HPLC, high-performance liquid chromatography.
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overnight fasted rats,
diabetic

rats.

determinant

of

2)

and to a greater extent in diaphragms from

Flux

through

accelerated

the

transaminase may be a major

branched-chain

diaphragms in fasting and diabetes.

amino

acid

oxidation

by

3) In diaphragms of fasted and

diabetic rats, flux through the branched-chain a-ketoacid dehydrogenase
complex

is

resistant

to inhibition by pyruvate, which is normally

observed in controls.
Introduction
Unlike most essential amino acids, the branched-chain amino acids,
leucine,

valine,

and

isoleucine,

skeletal muscle (126,78).
in

skeletal muscle

control (24, 93) .

are

catabolized

extensively

by

Oxidation of the branched-chain amino acids

is subject to metabolite (28,139) and hormonal

In fasting or uncompensated diabetes mellitus, the

intracellular concentrations of branched-chain amino acids in skeletal
muscle are increased (91,112), despite apparent acceleration of their
oxidation under the same conditions (24,27,70,139).
The initial steps in the catabolism of the branched-chain amino
acids are a reversible transamination to the corresponding branchedchain a-ketoacid (95) followed by irreversible decarboxylation of the
a-ketoacid catalyzed by branched-chain a-ketoacid dehydrogenase complex
(131).

Skeletal muscle has high levels of branched-chain amino acid

transaminase

activity

but

relatively

low

levels

a-ketoacid dehydrogenase activity (131,170).

of

branched-chain

It has therefore been

suggested that the activity of the branched-chain a-ketoacid dehydrogenase complex is rate-limiting for the catabolism of the branched-chain
amino acids by skeletal muscle (28,90,131,170).

The activity of this
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enzyme complex can be regulated by the availability of co-factors (NAD,
CoA), feed-back inhibition by the products (136,146) and by an ATPdependent

phosphorylation-dephosphorylation

cycle

(57,143).

Recent

evidence suggests that the complex is in a more activated state in
mitochondria prepared from muscles of fasted or diabetic rats than from
fed rats (140).

In muscles of diabetic or fasted rats, the glutamate/

a-ketoglutarate ratio is increased (30,159).

This may limit the rate

of transamination of the branched-chain amino acids since a-ketoglutarate is the most effective amino group acceptor for transamination
(131).
complex

Flux
may

through
also

be

the

branched-chain

limited

a-ketoacid

dehydrogenase

by substrate availability since the

intracellular concentrations of branched-chain a-keto acids are less
than saturating for the activity of the complex (131,136,146).
In the experiments described here we investigated the role of the
availability of amino group acceptors in regulating the flux of the
branched-chain amino acid carbon skeleton through the branched chain
a-ketoacid dehydrogenase complex.

Pyruvate was added to stimulate the

formation of a-ketoglutarate through the coupled reaction of alanine
aminotransferase (84).
diaphragms

Furthermore, we investigated whether in intact

the diabetes-induced stimulation of branched-chain amino

acid oxidation is primarily a function of accelerated transamination or
stimulated decarboxylation of the branched-chain a-ketoacids.
Materials and Methods

Animal

care~

Male Wistar WI(BR) rats (Charles River Laboratories,

Wilmington, MA) weighing 80-100 g were used in these studies.
rats were without food overn ight (18 hrs).

Fasted

All other animals were
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allowed access to standard laboratory chow (Wayne Rodent Blox), and
water ad lib.

Diabetes was induced by intraperitoneal injection of

streptozotocin (85 mg/kg) after an overnight fast.

Rats were consi-

dered diabetic if their plasma glucose was greater than 300 mg/dl and
they gained less than 1 g per day in weight.

Diabetic animals were

sacrificed 5 to 7 days after induction of diabetes.
Experimental.

Rats

diaphragms dissected,
(26).

were

sacrificed

by decapitation and their

weighed and incubated as described previously

Quarter diaphragms (30-50 mg wet weight), were incubated in the

balanced salt solution of Gey and Gey (68) equilibrated with 02/C02
(95:5,v/v) pH 7.4 at 37°C, containing a complete amino acid mixture at
concentrations found in plasma of normal, ad lib fed rats (114); thus
the branched-chain amino acids were always present at physiological
concentrations, 0.17, 0.2 and 0.1 roM for leucine, valine and isoleucine
respectively.

Quarter diaphragms were pre incubated 30 min in 2 ml of

the appropriate medium, then gently blotted and transferred to a vessel
containing 2 ml of fresh medium in which branched-chain amino or
a-ketoacid catabolism was assessed over the following 60 min.

In

experiments where a-ketoisocaproate (KIC; 4-methyl-2-oxopentanoate; the
ketoanalogue
complete

of

amino

leucine)

served

as

the

oxidative

substrate,

the

acid mixture was not included during incubation or

preincubation except where indicated in results.
Oxidation and transamination of valine and leucine were determined
by including [1_14C]L-valine or [1_ 14 C]L-leucine (0.02 mCi/I) in the
incubation medium.

Following incubation 0.3 ml Hyamine hydrochloride

was injected into small cups suspended over the medium to trap

14 C02 ,
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and 0.3 ml 20% perchloric acid was injected into the medium to release
14C02 from bicarbonate, to quantitate oxidation (decarboxylation) of
the amino acid.

Free branched-chain a-keto[1- 14 C]acid release into the

medium was estimated by suspending a fresh Hyamine hydroxide containing
cup over the medium and injecting 0.3 ml 30% H202 into the medium, the
latter results in oxidative decarboxylation of a-ketoacids but not
2-amino acids (131).

After each addition of Hyamine hydroxide incuba-

tion was continued for 1 hr at 37°C allow complete trapping of 14 C02 _
14C02 trapped in Hyamine hydroxide was measured in a Beckman L8 7000
scintillation spectrometer and corrected to 75% counting efficiency by
automatic external standardization.

Samples were counted for 10 min or

until sufficient counts were accumulated to reduce counting error to
less than 2%.

In typical one hour incubations in glucose containing

medium, quarter diaphragms released about 1000 cpm from [1-14C]leucine
and about 900 cpm were released after H202 treatment.

Background

radioactivity from incubations in the absence of tissue were typically
less than 40 cpm and less than 120 cprn, respectively. Oxidation and
transamination

rates were calculated based on the initial specific

radioactivity of the substrate in the medium and related to the wet
weight of the diaphragm determined before incubation.

Total transami-

nation was calculated as the sum of 14 C02 released after acid and after
H202 treatment.

These calculations underestimate the absolute rates of

oxidation, transamination and KIC release, since
account tracer dilution by intracellular

they do not take into

substrate.

The isotopic

measurements are presented in this manner because the specific radioactivities of the precursor pools were not determined in all experi-
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ments.

However,

released

by

measured,

we

radioactivity

the

studies

diaphragm and

found
of

where

no

the

evidence

the

specific

that

of

for

radioactivity of KIC

intracellular

differences

precursor pools

among

in

leucine were
the

treatment

specific

groups

(see

Results and Discussion).
Initial experiments established that oxidation and transamination
of

[l-14 C ]leucine by diaphragms from normal or diabetic rats were

essentially linear when incubated up to 120 min.
30

min

of

preincubation,

oxidation and

Additionally, after

transamination

rates were

constant during each of three successive 30 min incubation periods
suggesting that isotopic steady-state was achieved and maintained over
this time period.

Oxidation and transamination of leucine were also

found to be independent of glucose concentration when 5.5 or 16.5 roM
glucose was included in the incubation medium.
In experiments to determine the specific radioactivities of leucine
and KIC,

hemidiaphragrns were incubated in 2.5 ml medium as described

above, supplemented with 0.1 mM [3H]mannitol (0.5 mCi/l).

The specific

radioactivity of leucine in the medium was increased to 0.1 mCi/O.17
mmo!/l.

Diaphragms were incubated 30 or 60 min, the tissues removed,

frozen between two blocks of dry ice and 0.5 ml of 25% (w/v) trichloroacetic acid was added to the media.
frozen at -20°C until analysis.

The acidified medium samples were

Leucine was extracted by homogenizing

the frozen tissue in 3 mIl g ice-cold 5% trichloroacetic acid,

the

sample was centrifuged at 12000xg for 15 min and the supernatant frozen
at -20°C until analysis.

Specific radioactivities of leucine and

a-ketoisocaproate

determined

were

using

high

performance

liquid
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chromatography (HPLC)
corresponding

to separate and quanti tate the compounds; the

eluate

fractions

were

determined by scintillation counting.
a

Perkin-Elmer

Series

10

liquid

collected

and

radioactivity

The equipment used consisted of

chromatograph.

LClO

fluorescence

detector (370nm excitation, >418nm emission filter), LCI-lOO integrator, and "3x3"CI8 reversed phase column preceded by a 2cmx2.1nun i. d.
preeolumn containing C1S reversed phase packing .

The derivatization

and separation methods for leucine and a-ketoisocaproate were adapted
from Wassner and Li ( 190) and Kieber and Mapper (103), respectively.
Briefly, for leucine the o-phthalaldebyde derivative was

prepared and

immediately chromatographed using a solvent program of 3 min isoeratic
with 76% 0.05 M Na-citrate, pH 5.6/12% acetonitrile/12% 2-propanol, a
linear gradient to 50% Na-citrate/25% acetonitrile/25% 2-propanol over
1 min,

1.5 min isocratic at this composi tion followed by a linear

gradient to the initial solvent composition over 2 min.

Leucine eluted

at 4.5 min and was quantitated by comparison to an external standard.
KIC was determined as the quinoxalinol derivative prepared using _
a-phenylenediamine.

The solvent program consisted of 3 min isocratic

with 75% Na-citrate, pH 5.6/15% acetonitrile/l0% 2-propanol followed by
a linear gradient to 10% Na-citrate/ 80% acetonitrile/10% 2-propanol
over 3 min; this condition was maintained isocratic for 0.5 min then a
linear gradient (2 min) to the starting conditions was run.

KIC eluted

at 3.7 min and was quantitated using an external standard.

Preliminary

experiments established that recovery of radiolabelled leucine or KIC
was quantitative using these methods.

Incubation with muscle did not

significantly alter the concentration or specific radioactivity of the
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medium leucine; KIC concentrations in the medium ranged from 0.002 to

0.012 roM with the limit of detectability being 0.0005 mM.
tions of

In calcula-

intracellular leucine specific radioactivity, it was assumed

that the medium was at equilibrium with the extracellular space in
which mannitol and extracellular leucine were distributed identically.
Oxidation of KIC (0.01-0.50

mM) was determined using a-keto[l-

14 C] isocaproate (0.02 mCi/l) prepared from [1-14 C]leucine as described
previously (120).
glucose.

Oxidation of glucose was determined using [U_ 14 C]-

14C02 was trapped as described above and calculations

were

based on the initial specific radioactivity in the medium.
Sourc.e s of Materials . Radioactive amino acids, glucose and manni tol
were from New England Nuclear (Boston, MA) or ICN Chemical and Radioisotope Division

(Irvine,

Aldrich Chemical Company,
Boehringer Mannheim,

CA).

Sodium a-ketoisocaproate was from

Milwaukee, WI.

Indianapolis,

IN.

Sodium pyruvate was from
L-amino acids, aminooxyacetic

acid, and CIS reversed-phase column packing were from Sigma Chemical
Company,

St.

Louis,

MO;

Hyamine hydroxide

International, Mount Prospect, IL.

from Research Products

Streptozotocin was kindly supplied

by Dr. William Dulin of Upjohn Research Laboratories, Kalamazoo, MI.
HPLC grade solvents, and other chemicals were from Fisher Scientific,
Norcross, GA.
Statistics.

Tabulated values are means ± S. E. M.

Differences

between mean values were determined by Student's t test (two-way).
Differences between ratios were determined by a Mann-Whitney rank order
test.

Multiple comparison analyses were performed using the Peritz F

test (80).

Significance was assigned at p < 0.05.
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Results
Catabolism of leucine and valine by diaphragms of normal and diabetic
rats.
Diaphragms
medium,

from diabetic

rats,

incubated in glucose containing

produced 25-50% more 14C02 from 0.17mM

did control diaphragms (Table 1).

[1-14 C]leucine than

Total transamination by diabetic

diaphragms incubated in glucose was 33% greater than transamination by
normal diaphragms (Table 1).

The ratio of leucine oxidation to total

transamination, in glucose containing medium, was the same (about
65%) for diaphragms from normal or diabetic rats (Table 1).

mM [1- 14 C]valine,

Using 0.20

14 C02 production by control or diabetic diaphragms

was similar while transamination by diabetic diaphragms was 30% greater
than by control diaphragms when both were incubated in glucose containing medium (Table 1).
Effects of pyruvate on the catabolism of leucine and valine.
If the rate of leucine transamination is limited by the glutamate
la-ketoglutarate ratio then addition of pyruvate would be expected to
stimulate leucine transamination by its effect on glutamate-pyruvate
aminotransferase.

In pyruvate containing medium (Table 1) transamina-

tion of leucine was increased 60% in normal diaphragms and 110% in
diabetic diaphragms when compared to glucose containing medium.

14C02

production from leucine by normal diaphragms was inhibited about 40% in
pyruvate
stimulated

containing
by

about

medium
40%.

while
The

in
ratio

diabetic
of

diaphragms

it

was

oxidation/transamination

decreased in the presence of pyruvate in the control and the diabetic
group, but less in the latter.

Thus, when incubated with pyruvate,
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diaphragms from diabetic rats transaminated 80% more leucine and
oxidized 200% more leucine than the controls (Table

1).

The effects

of pyruvate on oxidation and transamination of valine were similar to
those

observed wi th

leucine

but

the magni tude of the effects was

smaller (Table 1).
An IS-hour fast affected leucine metabolism similarly to diabetes.
When diaphragms were incubated in glucose containing medium, fasting
increased

leucine

leucine (Table 1).

transamination

more

than

14 C02

production

from

The effect of pyruvate on leucine catabolism by

diaphragms from fasted rats was qualitatively similar to that observed
in diaphragms from diabetic rats (Table 1).

Incubation with pyruvate

stimulated transamination of leucine by fasted diaphragms 60% compared
to

glucose

containing medium;

oxidation

of

leucine was stimulated

slightly and the amount of a-ketoacid released was increased more than
2-fold.

Diaphragms from fasted rats therefore oxidized only 30% more

leucine than fed controls during incubation with glucose, while they
oxidized 100% more than the controls when incubated in pyruvate.
To assess possible effects of fasting, diabetes and pyruvate on
the specific radioactivity of the intracellular leucine pool available
for transamination and subsequent oxidation, the ratio of the specific
radioactivities
determined.

of
The

extracellular KIC
specific

and extracellular leucine was

radioactivity

of

extracellular

KIC

in

perfused rat hindlimbs (93) and of plasma KIC in rats infused with
leucine (109) was previously found to closely approximate the intracellular specific radioactivity of leucine in muscles.
2, although the specific radioactivity of

As shown in Table

extr~cellular

KIC

was less
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than

the

specific

radioactivity of

the

extracellular leucine pool

(range 0.49 to 0.64 of leucine specific radioactivity) there was no
significant difference after 30 or 60 min incubation between any of
the groups.
KIC release by incubated diaphragms was calculated from direct
measurements (by HPLC) of KIC concentrations in the medium (Table 2).
The values for KIC release over 60 min are about 2-fold higher than
those estimated radioisotopically based on the specific radioactivity
of leucine in the medium (Table 1).

This is consistent with the value

± 0.02 (overall mean for 65 observations) obtained for the

of 0.57

ratio of extracellular KIC to extracellular leucine specific radioactivities.
In

experiments

of

identical

design

to

those

in Table

2,

the

specific radioactivity of intracellular leucine was measured; multiple
comparison analysis of the ratios of the specific radioactivities of
intracellular and extracellular leucine found no significant difference
between the values obtained from diaphragms of fed, fasted or diabetic
rats incubated with glucose or glucose + pyruvate, nor were there
differences between measurements obtained after 30 or 60 min incubation.

The overall mean of the ratios of the specific radioactivities

of intracellular and extracellular leucine was 0.59 ± 0.04 (n

=

73)

which is not different from the ratio of the specific radioactivities
of extracellular KIC and extracellular leucine (0.57 ± 0.02).
Oxidation
concentration

and

transamination

by diaphragms

of

valine at normal physiological

of normal fed rats,

when incubated in

lactate or a mixture of pyruvate and lactate (1.1 mM and 4.4 roM,
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respecti vely) ,

were similar to the values obtained wi th diaphragms

incubated in equimolar glucose (Table 3).

Compared to glucose contain-

ing medium, the ratio of oxidation to transamination was

decreased in

the presence of lactate (0.64) and was lowest in the pyruvate-lactate
mixture (0.56).
ratio

of

These values, however, are still much greater than the

oxidation

to

transamination

(0.30)

observed with medium

containing 5.5 mM pyruvate (Table 1).
Effect of pyruvate on oxidation of a-keto-[1- 14 C]isocaproate.
Since

the

data

(Table

1)

suggested

that

pyruvate may have

a

differential effect on the oxidation of branched chain a-ketoacids by
diaphragms of normal fed and fasted or diabetic rats, the effect of
pyruvate on 14 C02 production from [1_ 14C]KIC was studied (Table 4).
Values for KIC oxidation using 0.01 or 0.05 rnM KIC (near physiological
concentrations;

91) should estimate flux through the branched-chain

a-ketoacid dehydrogenase complex while oxidation using O.5mM KIC (close
to the saturating concentration for oxidation of KIC by rat diaphragm;
186) may serve as an indicator of enzyme activity, if it can be assumed
that

enzyme

activity rather

than

transport

limits

oxidation.

In

glucose containing medium, 14C02 production by diaphragms of fasted or
diabetic rats tended to be lower than that by muscles of fed controls,
regardless of the concentration of KIC, although there was no significant

difference

Diaphragms

from

between
fed

groups

controls

in

some experiments

incubated

in

pyruvate

(Tables
or

4-6).

glucose +

pyruvate oxidized 42-67% less KIC than those incubated with glucose,
at all KIC concentrations tested (0.01-0.5 roM).
diabetic and fasted

rats,

In diaphragms from

pyruvate inhibited the oxidation of KIC
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significantly less than in controls.

At the highest KIC concentration

tested (0.5 mM), 14 C02 production by diabetic diaphragms was identical
in glucose or

in pyruvate while

at

lower

concentrations

of KIC,

pyruvate caused slight inhibition of 14 C02 production by diaphragms of
diabetic or fasted rats in some experiments.

During incubation with

pyruvate, diaphragms from diabetic and fasted rats oxidized 40-80% more

KIC than

controls

when

this

substrate was

at

low,

physiological

concentrations (0.01-0.05 roM), but oxidation rates were identical in
the two groups at 0.5 mM concentrations of the branched-chain
Inclusion of normal physiological concentrations of all

a-ketoacid.

the amino acids did not affect KIC oxidation significantly under any
condition tested.
Since the estimates of KIC oxidation could be biased by dilution
of the 14C-labelled substrate with unlabelled KIC produced by transamination

of

endogenous

leucine,

14 C02

production

from

0.05

mM

[1_14C]KIC was measured in the presence of arninooxyacetate (Table 5),
an

inhibitor

of

conducted using
physiologic

aminotransferases

(88).

These

experiments

were

0.05 mM KIC in order to assess oxidation at near

substrate concentration and to avoid activation of the

branched-chain a-ketoacid dehydrogenase which has been observed with
higher concentrations (0.5 mM) of KIC (33,193).

In glucose containing

medium, 14 C02 production by diaphragms of normal or diabetic rats was
similar and was stimulated by about 80% in the presence of aminooxyacetate.
control

Pyruvate caused about 65% inhibition of 14C02 production in
diaphragms

diaphragms.

14 C02

and

significantly

production

in

less

pyruvate

(about

35%)

containing

in diabetic
medium

was
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slightly stimulated (about 30%) in the presence of aminooxyacetate but
this effect was not significant in diaphragms from either control or
diabetic rats.
The activity of branched-chain a-ketoacid dehydrogenase complex in
several tissues (e.g. heart. muscle. liver, kidney, and adipose tissue)
is

regulated

by an ATP-dependent phosphorylation-dephosphorylation

cycle (for review see 150) • therefore the effect of the uncoupler
2,4-dinitrophenol
(Table 6).

on

14C02

production from 0.05 roM KIC was tested

Addition of dinitrophenol stimulated 14C02 production from

KIC by 65% in diaphragms of fed rats regardless of the presence of
pyruvate and in diaphragms of fasted rats when incubated in glucose
alone.

In

the

presence

of

pyruvate,

addition

of

stimulated 14 C02 production in fasted diaphragms by 37%.

dinitrophenol
The relative

inhibition of 14C02 production by pyruvate in diaphragms of fed rats
(about 60%) was constant in the presence or absence of dinitrophenol.
The inhibitory effect of pyruvate in diaphragms of fasted rats was 30%
in the absence of dinitrophenol and 40% in its presence.

In parallel

experiments this concentration of dinitrophenol was found to stimulate
oxidation of [U_ 14 C]glucose ten-fold in fasted and control diaphragms
(data

not

shown).

indicating

that

0.1

mM

dinitrophenol

uncoupled

respiration in the diaphragms.

Discussion
These data are in agreement wi th previous studies showing that
apparent

oxidation

diabetes

and

increased

in

of

fasting

leucine

by

(27,70,139).

diaphragms

skeletal muscle

is

Transamination of

increased in
leucine was

from diabetic and fasted rats despite the
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increased glutamate/a-ketoglutarate ratio (30,159).

Since the propor-

tion of available transamination product of leucine which was oxidized
was unchanged in diabetes and fasting, the amount of free a-keto acid
available for export was elevated in fasting and diabetes.
of Hutson et ale

The studies

(93) in perfused hindlimbs of rats, found increased

branched chain a-keto acid export in fasting.
The data presented here and studies of cultured myocytes (167)
indicate that the intracellular specific radioactivity of leucine is
less

than

the specific radioactivity in the medium.

We found no

evidence to suggest differences in the dilution of labelled substrates
by intracellular pools among diaphragms from fed, fasted or diabetic
rats or that pyruvate affected leucine distribution.

In diaphragms

incubated without insulin, protein synthesis is depressed and net
protein degradation prevails.

In two studies from our laboratory, net

protein degradation by diaphragms from diabetic rats incubated without
insulin was found to be the same as that by diaphragms from normal rats
when determined as tyrosine release (30) or slightly increased when
determined as leucine release (27).

The intracellular concentration

of leucine in diaphragms from normal and diabetic rats was the same
after preincubation as was the specific radioactivity of intracellular
leucine in diaphragms incubated with [l-14 C ]leucine, in agreement with
the present study.

Based on values for leucine release by incubated

diaphragms previously obtained in our laboratory (27), the relative
dilution

of

the

diaphragms would

medium

leucine

by

leucine

released

from

quarter

be negligible and possible differences in the release

of leucine/mg tissue would be offset by the diminished weight (about
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20% less) of the diaphragms obtained from diabetic rats.

Thus we would

not expect the results to be biased by dilution of the medium branchedchain

amino

supplied

acid

pool

with

endogenous

by protein degradation.

branched-chain amino

acids

Since the intracellular specific

radioactivity of leucine was lower than that of the medium, the values
shown in the Tables, based on the specific radioactivity of leucine in
the medium, underestimate the actual rates of leucine transamination
and

oxidation.

This

is

further

supported by the finding that KIC

release by diaphragms was greater in the experiments where it was
measured directly by HPLC

(Table 2), than in experiments where it was

estimated radioisotopically (Table 1).
pyruvate,

Qual i tati vely the effects of

fasting and diabetes on KIC release were identical, using

either method of analysis.

Since neither fasting nor diabetes, nor the

presence of pyruvate or glucose affected the specific radioactivity of
released KIC or of intracellular leucine, the relative changes observed
in

transamination

and

oxidation

manipulations seem valid.

in

response

to

the

experimental

Since substrate specific radioactivities

were not measured in all experiments, for consistency, the values for
oxidation and transamination were not corrected but were based on the
medium specific radioactivity of the added substrate.
The marked stimulation of leucine and valine transamination when
diaphragms were incubated with 5.5 mM pyruvate suggests that transamination of the branched-chain amino acids is restrained by the availability of endogenous amino group acceptors.

In the presence of glucose

or when excess amino group acceptors were provided, intact diaphragms
from diabetic and from fasted rats transaminated significantly more
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leucine than those of fed controls,

suggesting that the amount or

activity of the transaminase is increased under these conditions; the
effect of diabetes was greater than that of the short fast.
al.

(3)

reported

that

leucine

Adibi et

aminotransferase activity in muscle

homogenates increased with the duration of fasting.

Our data suggest

that increased flux through the transaminase resulting from increased
transaminase

activity

and/or

elevated

branched-chain

amino

acid

concentrations may be a major determinant of accelerated branched-chain
amino acid oxidation in fasting or diabetes, due to increased substrate
supply to the branched-chain a-ketoacid dehydrogenase complex.
The measurements of KIC oxidation may be complicated by differences
between

the medium and

intracellular specific radioacti vi ties.

It

seems likely that the relative values of KIC oxidation are valid since
the

presence

of

physiological

concentrations of exogenous leucine,

which readily enters the intracellular KIC pool, did not significantly
affect the apparent KIC oxidation (Table 4).
KIC concentrations,

As for leucine, at low

the actual oxidation rates are probably greater

than those estimated from the extracellular specific radioactivity.

At

high concentrations of KIC in the medium, the contribution of intracellular leucine to the KIC pool was presumably negligible.

The

increa-

sed 14 C02 production from [l_14 C]KIC in the presence of aminooxyacetate
also suggests that intracellular KIC specific radioactivity was lower
than that of KIC in the medium (at low KIC concentration), presumably
due to dilution by KIC arising from endogenous leucine.

Alternative

mechanisms which may contribute to the observed stimulation of 14 C02
production include decreased flux of intracellular KIe (both 12C and
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14 C)

into

the

intracellular

leucine

pool

(by

inhibiting

reverse

transamination) as well as metabolic effects other than inhibition of
branched-chain amino acid transaminase; e.g. blockade of the malateaspartate

shuttle

altering

the

intramitochondrial

redox

potential

(164).
Wagenmakers and Veerkamp (187) have noted a differential effect of
aminooxyacetate on oxidation of KIC by diaphragms of normal rats and
rats fasted for 3 days.

They suggest that estimates of KIC oxidation

in diaphragms from fasted rats are greater than the true rate of KIC
oxidation due to intracellular compartmentation of the precursor pool.
As regards the present study, Wagenmakers and Veerkamp did not
demonstrate a differential effect of aminooxyacetate on KIC oxidation
by diaphragms

from

rats

fasted

for

one day and the magnitude of

increase in oxidation and transamination of leucine in the diaphragms
from one-day fasted rats were similar to our observations in overnight
fasted rats (Table 1).

Furthermore, the apparent stimulation of KIC

oxidation by aminooxyacetate in diaphragms from normal or diabetic
rats was similar in the present studies.

Thus we have no evidence to

suggest that our estimates of KIC oxidation are biased by intracellular
compartmentation.
In

our

physiological

studies,

during

concentrations

incubation with
of

KIC

glucose,

by diaphragms

oxidation of

from

fasted

or

diabetic rats was not increased and at the highest KIC concentration
tested

(0.5

mM,

which may activate

the

branched-chain a-ketoacid

dehydrogenase complex (193) but minimizes pool dilution), 14 C02 production

by

diabetic

diaphragms

was

significantly

less

than

that

by
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normals.

Thus in intact diaphragms t incubated with glucose, we were

unable to obtain evidence for increased flux through the branched-chain
a-ketoacid dehydrogenase complex associated with diabetes, at any KIC
Alterations of KIC transport across the cell

concentration tested.

membrane or into the mitochondria or changes in the level of cytoplasmic

inhibitor(s)

of

branched-chain

a-ketoacid

dehydrogenase

complex (131,141) may have prevented a reflection of altered enzyme
activation state in flux measurements.
It has recently been reported that the activation state of the
branched-chain
during

a-ketoacid

incubation

(183)

dehydrogenase
with

a

in

diaphragms

is

increased

concomitant decrease

in

the total

amount of complex present in the muscle.
determined

the

dehydrogenase

activation

complex

or

state

of

the

The present studies have not
branched-chain

total enzyme activity;

a-ketoacid

if there were any

changes during incubation, they were not reflected in flux measurements, which were linear over the time period investigated.
The inhibitory effect of pyruvate on leucine oxidation in muscle
and its resistance to inhibition by pyruvate in diaphragms of diabetic
rats has previously been observed in our laboratory (27,28).

Pyruvate

induced inhibition is not mediated by increased a-ketoglutarate since
previous

studies

found

that

leucine oxidation was stimulated when

diaphragms were incubated in vitro with 1-5 mM a-ketoglutarate (28).
The present data suggest that in diabetes or fasting the branched-chain
a-ketoacid

dehydrogenase

inhibition.

Studies

mitochondria

(22)

of

complex

is

resistant

perfused hearts

indicate

(193)

to

pyruvate

and

induced

isolated heart

that addition of pyruvate results

in a
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modification of branched-chain a-ketoacid dehydrogenase which persists
when the complex is solubilized and reduces its activity.

The inabil-

ity of dinitrophenol to prevent inhibition of KIC oxidation by pyruvate
suggests that pyruvate induced inhibition may not be mediated solely
by ATP-dependent phosphorylation of branched-chain a-ketoacid dehydrogenase (140).

The apparent resistance of branched-chain a-ketoacid

dehydrogenase to inhibi tion by pyruvate in muscles of diabetic and
fasted rats may be a reflection of increased activation state of the
enzyme (140), although we have no direct evidence for such activation.
The mechanism causing pyruvate resistance is not clear.

The role of

pyruvate in regulating branched-chain amino acid catabolism under
physiological and pathological conditions, i.e. exercise and diabetes,
needs further evaluation, since the concentration of pyruvate in muscle
during exercise can attain the concentrations used in these studies
(50).

Our data emphasize the complexity of regulation of branched-chain
amino acid catabolism.

Earlier studies implicated the branched-chain

a-keto acid dehydrogenase complex as rate-limiting for branched-chain
amino

acid degradation

in muscle

(131,170).

The present results

suggest that under certain conditions flux through either the branchedchain amino acid aminotransferase or through branched-chain a-ketoacid
dehydrogenase complex can limit their rate of degradation.

Further-

more, it is remarkable that despite the increased NADH/NAD and acyl
CoA/CoASH ratios in diabetes and fasting (71,75) the apparent flux of
leucine

carbons

through the branched-chain a-ketoacid dehydrogenase

complex

is

inhibited

not

but

accelerated.

The enzyme complex is
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largely in the inactive (phosphorylated) state in skeletal muscle from
or

normal

fasted

rats

(137,184),

but

direct

measurements

of

the

phosphorylation state of the complex in muscles from diabetic animals
remains to be accomplished (137,150).
the

At present it is unclear whether

effects of diabetes and fasting on branched-chain amino acid

catabolism result from insulinopenia and/or alterations in the metabolic milieu;

addition

of

insulin

to

diaphragms

of

diabetic

incubated in vi tro does not reduce leucine oxidation (27).
context

it

is

noteworthy

dehydrogenase kinase
diabetic

or

fasted

that

is present
rats

thus

a

factor

which

activates

to

In this
pyruvate

in heart mi tochondria prepared from
rendering

the pyruvate dehydrogenase

complex refractory to activation by pyruvate (89,101).
are needed

rats

Further studies

elucidate how diabetes and fasting prevent pyruvate

induced inhibition of branched-chain a-keto acid oxidation, e.g. is
mitochondrial transport of pyruvate inhibited (104) or is the branchedchain a-ketoacid dehydrogenase complex or one of its modifiers affected.

Table 1 Legend.
Quarter diaphragms were incubated in medium containing 5.5mM glucose
oxidation

and

transamination

of

either

0.17mM

or

5.5mM

pyruvate;

[1-14 C]leucine or 0.20mM [1-14 C]valine were

determined by 14 C02 release as described in the Experimental section.

Comparisons for dia-

phragms of diabetic and fasted rats were made to fed control values obtained with concurrently
incubated diaphragms rather than the pooled means which are shown.

* All

values were calculated based on the initial specific radioactivity of the amino acid

substrate in the medium and are underestimates, since the intracellular specific radioactivity
was uniformly lower than in the medium (see Table 2 and Results).

b p < 0.05 vs. control rats;

C

a p < 0.01 vs glucose medium;

p < 0.001 vs. control rats; d p < 0.05 vs. glucose.

Table 1,

Cat.bolls. of leucine and valine by diaphragms from fed or fasted normal rats and from

fed diabetic rats.
pmal * 14 C02 / hr per mg wet weight
Group

Medium

Acid Release
"Oxidation ll

H202 Release
"Free a-ketoacid"

Total
"Transamination"

Oxidation
Transamination

n

247 ± 10'

0.65 ± 0.02
0.24 ± 0.03

21
13

328 ± 16 c
688 ± 29 a ,c

0.62 ± 0.03
0.41 ± 0.02

15

304 ± 27 b
477 ± 31 a ,b

0.58 ± 0.04
0.41 ± 0.04

5

± 0.03
± 0.02

10

10

0.56 ± 0.04
0.36 ± 0.04

6
6

Leucine
Fed

Diabetic

Fasted

87 ± 6

Glucose
Pyruvate

160 ± 8

Glucose
Pyruvate

202 ± lIb
208 ± 19 d ,c

126 ± 11 c
408 ± 24 a ,b

Glucose
Pyruvate

176 ± 19b
193 ± 13 c

127

92

±

6a

304

±

±

20 a

ISh

285 ± 34 a

396

±

20 a

9

5

Valine
Fed

Diabetic

Glucose
Pyruvate

135 ± 11
93 ± 7d

Glucose
Pyruvate

153
185

± 11
± 23 c

± 8
222 ± 16 a
82

126 ± 16 a
339 ± 37 a ,b

216
314

± 16
± 20 a

279 ± 22b

524 ± 3S a ,c

0.62
0.30

~
~

Table 2.

Specific radioactivity of extracellular a-ketoisocaproate released by diaphragms

incubated

with leucine.

KIC Specific Radioactivity
Leu Specific Radioactivity
Group

Medium
Glucose

Fed

Diabetic

Fasted

30 min

0.49 ± 0.04 (7)

60 min
0.61

± 0.03 (8)

KIC Release
pmol/60 min per
mg wet weight
187

± 13

(8)

Pyruvate

0.62 ± 0.08 (8)

0.62 ± 0.06 (7)

509 ± 45 a

(7)

Glucose

0.56 ± 0.10 (5)

0.52 ± 0.09 (4)

254 ± 17 b

(4)

Pyruvate

0.59 ± 0.03 (5)

0.55 ± 0.03 (3)

800 ± 40 a ,b (4)

Glucose

0.56 ± 0.11 (5)

0.55 ± 0.06 (4)

255 ± l1 b

(4)

Pyruvate

0.48 ± 0.04 (5)

0.67 ± 0.06 (4)

507 ± 60 a

(4)

Hemidiaphragms were incubated in medium containing 5.5 mM glucose or 5.5 mM pyruvate with
0.17 roM [1_ 14 C] leucine.
medium and

quickly frozen.

After 30 min or 60 min incubation diaphragms were removed from the
The concentrations of leucine and KIC in the medium (extracellular)

were determined by HPLC and the specific radioactivities calculated as described in the Experimental section.

a p < 0.01 vs glucose; b p < 0.05 vs control.

~
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Table 3. Effect of lactate and a mixture of lactate
and pyruvate on the catabolism of valine
by diaphragms from fed rats.

prool)'C 14C02/hr

per mg wet weight
Oxidation
Medium

Oxidation

Glucose

151 ± 7

218 ± 12

0.69 ± 0.01

Lactate

165 ± 17

257 ± 22

0.64 ± 0.02 a

Pyruvate
+ Lactate

135 ± 14

241

Quarter
5.5mM

diaphragms

were

Transamination

±

24

0.56 ± O.02 b ,c

incubated in medium with 5.5mM glucose or

lactate or 1. ImM pyruvate and 4. 4mM lactate.

Oxidation and

transamination of O.20mM (1-14C]valine was determined by 14 coZ release
as described in the Experimental section.

Values shown are the means

of five observations.

'*

Values were calculated as in Table 1 based on the initial specific

radioactivity of valine in the medium.
a p

< 0.05 versus glucose medium

b p

< 0.01 versus glucose medium

c p < 0.025 versus lactate medium

Table 4 Legend.
14 C02 production from a-keto[l-14C]isocaproate by quarter diaphragms

incubated in 5.5mM

glucose was compared to 14 C02 production during incubation with 5 roM pyruvate (in experiments
with diabetic rats) or 5.5 roM glucose + 5 roM pyruvate in experiments with fasted rats.

Fed

controls were studied in both series: since the effects of pyruvate in the presence or absence
of glucose were identical, the data in fed controls were pooled.

Incubations included normal

physiological concentrations of all the serum amino acids (86) where noted.
calculated as in Table 1 based on the specific radioactivity of KIC in the medium.
a p < 0.005 versus glucose; b p < 0.05 versus glucose;

C

p < 0.05 versus fed rats.

'1{

Values were

Table 4.

Oxidation of a-ketoisocaproate by diaphragms from fed. fasted and diabetic rats.

pmol * 14 CO 2 I hr per mg wet weight

[1-14 C]a-KIC
Group
Fed

roM

Amino
Acids

%Change

39

±4

12 ± la

-67±2

(18)

0.05

337

± 46

106 ± 12 a

-67±3

(6)

331 ± 51

108 ± 11 3

-62±6

( 11 )

+

4152 ± 508

2324

± 301 a

-42±8

(6)

3440 ± 359

1899 ± 253 a

-46±5

(6)

0.01

24 ± 4 c

20 ± 4 c

-8±IS

(6)

0.05

264 ± 36

193 ± 34 c

-26!7

(8)

228 ± 24 c

154 ± 20 b • c

-33±6

(8)

0.50
0.50

0.05

+

+

0.50
0.50
Fasted

Pyruvate
medium

0.01

0.05

Diabetic

Glucose
medium

+

2468 ± 425

2468 ± 306

+18±20

(7)

1988 ± 226 c

1825 ± 190

-13±6

(8)

-28±6

(9)

-22±6

( 11 )

0.01

]] ± 4

0.05

230 ± 29 c

20 ± 2 b • c
173 ± 21 c

~

00
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Table 5.

Effect of aminooxyacetate on the oxidation of

a-tetoisocaproate by diaphragms from normal or diabetic rats.

pmol* 14C02/hr
per mg wet weight
Pyruvate
Added

Aminooxyacetate

Normal Rats

Diabetic Rats

320 ± 39

353 ± 10

582 ± IOOa

627 ± 4S a

110 ± 20b

229 ± 45 b ,c

+
+

146 ± 17 b

+

+

Quarter diaphragms from fed normal or diabetic rats were incubated in
medium containing 5mM glucose or 5mM glucose + 5mM pyruvate, in the
presence

or

absence of

ImM aminooxyacetate.

Oxidation

of

o. 05mM

a-keto[l-14C]isocaproate was determined by 14 C02 · release as described

in the Experimental section.
tions.

*

Values are the means for 4 or 5 observa-

Values were calculated as in Table 1 based on the specific

radioactivity of KIe in the medium.

a p < 0.001 versus no aminooxy-

acetate; b p < 0.05 versus glucose; c p < 0.05 versus control rats.
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Table 6.

Effect of 2.4-dinitrophenol on the oxidation of
a-ketoisocaproate by fed or fasted rats.

Group

Pyruvate
Added

Dinitrophenol

pmol* 14C02/hr
per mg wet weight

206 ± 34

Fed Rats

+

347

79 ± 6 h

+
+

± 3S a

132 ± 13 b ,c

+

163 ± 25

Fasted Rats

269 ± 43 a ,d

+

116 ± 9 d

+
+

160 ± l1 a ,b,d

+

Quarter diaphragms were incubated in medium containing 5. 5mM glucose
or

5. 5mM glucose + 5mM pyruvate as descri bed in the Experimental

section.

Oxidation of 0.05mM a-keto[1-14 C]isocaproate was determined

as 14C0 2 release in the presence or absence of O.lrnM 2,4-dinitrophenol.
Values are the means of six observations.

*

Values

were calculated

as in Table 1 based on the specific radioactivity of KIC in the medium.
a p

< 0.05 versus no dinitrophenol; b

p

< 0.02 versus glucose;

c p < 0.005 versus no dinitrophenol; d p < 0.02 versus fed rats.

Chapter III
Leucine and Isoleucine Activate Skeletal MUscle
Branched-Chain a-Keto Acid Debydrogenase In Vivo

The contents of this chapter have been previously published in similar
form in American Journal of Physiology 250 (Endocrinol. Metabol. 13):

E599-E604, 1986.
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The

response

of

rat

skeletal

muscle

branched-chain a-ketoacid

dehydrogenase to administration of branched-chain amino acids in vivo
was

determined using

a

soluble

After

preparation of the enzyme.

detergent extraction of the complex in the presence of kinase and
phosphatase inhibitors, initial in vivo activity was typically 1 nmol/
min/g muscle, with 0.1 roM a-keto[1-14C]isocaproate as substrate.

Total

activity of the dephosphorylated complex, measured after preincubation
with 15 roM Mg 2+, typically reached a maximum of 29 nmol/min/g.
in overnight fasted rats the complex was 2-3% active.

Thus,

Initial activity

increased 3-5 fold after leucine or isoleucine (at higher concentrations)
leucine

but

not

valine

injection

increased

rapidly

(0.25
and

administration
mmol/kg)

in vivo.

initial muscle

subsequently

declined,

After intravenous
enzyme

activity

paralleling

plasma

leucine concentrations, while plasma valine and isoleucine declined.
Conclusions: Muscle branched-chain a-keto acid dehydrogenase complex is
rapidly activated when circulating leucine is increased to concentrations which may occur after meals.
valine

and

isoleucine

degradation

During hyperleucinemia accelerated
by muscle may account

observed "antagonism" among the branched-chain amino acids.

for

the
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Introduction
Skeletal

muscle

has

been considered an important site for the

disposal of the branched-chain amino acids

(BCAA)* since the early

studies of Miller (136) in eviscerated rats.

Studies of the oxidation

of BCAA by skeletal muscle have found high activities of the BCAA

transaminase but quite low activities of branched-chain a-keto acid

dehydrogenase complex (BCDH) EC 1.2.4.4 (77,131,150).

BCDH catalyzes

the first conunitted step in BCAA degradation, and is regulated by a

phosphorylation-dephosphorylation cycle analogous to that of pyruvate
dehydrogenase ( reviewed

in 150).

In homogenates of skeletal muscle

from fed or fasted rats only a small fraction of the BCDH complex was
in the active state and was essentially unresponsive to physiological
manipulations (184,185).
gent-treated

However, Kasperek et ale (100), using deter-

homogenates,

recently

skeletal muscle BCDH by exercise.

reported

marked

activation

Studies of muscle homogenates

of

(184,

185) and isolated intact mitochondria (140) cannot distinguish between

changes in mitochondrial transport and BCDH activation.
measure

the

activity

state

of

Attempts to

BCDH solubilized from rat skeletal

muscle mitochondria have been unsuccessful due in part to the low
initial activity of the complex, but it was estimated that less than
20% of

the complex was active (77 t 137 t 150).

Since several groups

failed to demonstrate significant activation of BCDH in muscle in vivo
'/(

amino

The abbreviations used in this chapter are: BCAA, branched-chain
acids;

BCDH,

polyethylene glycol.

branched-chain a-keto

acid

dehydrogenase;

PEG,
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the

relative

contribution

of

skeletal muscle to whole

body BCAA

catabolism has been questioned (77,184,200).
Administration of leucine to rats and man results in decreased
circulating valine and isoleucine, as well as increased valine oxidation by the intact organism (reviewed in 77).

Oxidation of valine by

perfused rat hindlimbs (200) and by isolated epitrochlearis muscles
(124) was markedly increased by the addition of increasing concentrations

of

leucine.

These results suggest that muscle BCDH may be

activated in the presence of leucine, as reported in adipose tissue
(64).

Due to its mass,

skeletal muscle contains a large pool of

inactive BCDH which could be recruited to oxidize the BCAA in the
presence of increased circulating BCAA, such as occurs after a protein
meal (52,145).

In this communication we describe a method to determine

the activity state of BCDH in a solubilized preparation from skeletal
muscle.

Using this method we show for the first time rapid, in vivo

activation of the muscle BCDH complex after administration of leucine
and to a lesser extent isoleucine.

Materials and Methods
Male Wistar (WI)BR rats (Charles River Laboratories, Wilmington,
MA) were allowed access to standard rodent chow (Wayne Rodent Blox,
Continental Grain Co.,

Chicago,

IL) and water ad libitum, food was

removed 14-18 hours prior to sacrifice, between 9 and 11 AM.
receiving

i. v.

Rats

treatments had chronic intravenous catheters inserted

into a jugular vein the afternoon prior to infusion, using the procedure of Harms and Ojeda (76).

Intravenous infusions were performed
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with the animals under light anesthesia induced with methoxyflurane
vapor.
Rats were anesthetized with methoxyflurane and the hindlimb skinned
to expose the muscles.

The Achilles tendon was secured with a hemostat

and severed, the gastrocnemius and soleus were dissected free of underlying tissue, frozen with metal tongs cooled in liquid nitrogen, cut
free of their origins and immersed in liquid nitrogen until further
processed, usually within 4 hr.

The frozen muscles were powdered with

a porcelain mortar and pestle precooled with liquid nitrogen.
of

the

frozen

A sample

powdered muscle was weighed into a precooled glass

homogenizer tube, 4 ml of ice-cold extraction buffer per g of tissue
added and the slurry homogenized with 10 strokes of a motor-driven
Teflon pestle.

Extraction buffer consisted of: 100 roM KH2P04' 5% WI,

2 roM Na2EDTA, 5 roM dithiotreitol, 0.5 mM thiamine pyrophosphate, 1 mM
TLCK,

20

~g/ml

leupeptin,

50 mM KF,

(phosphatase inhibitor),

5 mM

dichloroacetic acid (kinase inhibitor; 143), adjusted to pH 7.4 at 4°C
with KOH.

(In preliminary studies, dichloroacetic and a-chloroiso-

caproic acids were both effective in inhibiting the kinase.)

Insoluble

material was removed by centrifugation (5 min at 27000xg), and 0.5
volume of 27% PEG-6000 was added to the supernatant, resulting in a
final PEG concentration of 9%.

After standing 20 min on ice the

precipitate was collected by centrifugation (10 min at 12000xg), and
resuspended in 1 ml assay buffer per g tissue homogenized.
buffer consisted of:

25 mM Hepes,

0.2 mM Na2EDTA, 0.4 mM thiamine

pyrophosphate, 1 mM dithiothreitol, 20
adjusted to pH 7.4 with KOH at 37°C.

Assay

~g/ml

leupeptin, 0.1% Brij 58,
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BCDH activity in muscle preparations was measured as 14cOZ released
from

0.1

roM

a-keto[1-14 C ]isocaproate

(1.5

Ci/mol).

Assays

were

conducted in triplicate, at 37 oC, in 0.35 ml total volume of the assay
buffer described above, supplemented with 0.5 mM CoASH, 0.5 mM NAD, and
1.2 roM MgS04.

Assays were quenched with 0.2 ml 25% trichloroacetic

acid, 14 C02 collected in 0.2 ml Hyamine hydroxide, and radioactivity
determined by liquid scintillation spectrometry as described previously

(6,120).

Initial BCDH activity (an estimate of in vivo activity) was

determined using the enzyme preparation from muscle directly in the
assay described above; for measurements of total enzyme activity (an
estimate of

enzyme amount) the preparation was diluted with assay

buffer supplemented with MgS04 (final concentration 15 mM) and preincubated 60 min at 37°e to activate the complex before assay (see
Results).

The activation state of BCDH was determined as the ratio of

initial activity to total activity.
Blood was removed by heart puncture inunediately after removal of
muscle samples and added to heparinized tubes.

After centrifugation

plasma samples were deproteinized by addition of 0.1 volume of 50%
sulfosalicylic acid and stored frozen at -20 o e until analysis.

BCAA

were measured by reversed-phase high-performance liquid chromatography
separation and fluorescent detection of their o-phthalaldehyde derivatives as described previously (6).

Materials were obtained as described previously (7).

WI, a linear

polyoxyethy1ene ether detergent, and hog kidney D-amino acid oxidase
were' obtained from Sigma Chemical Co. (St. Louis, MO).
was

obtained

from Pitman-Moore,

Inc.

Methoxyflurane

(Washington Crossing,

N.J.).
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a-Keto-[1- 14C)isocaproate

was

prepared

from

DL-[1-14C]leucine

(ICN

Radiochemicals, Irvine, CA), as described previously (120) but with the
addition of D-amino acid

oxidase~

Dr. Ronald Simpson of Sandoz

Pharmaceuticals (E. Hanover, NJ) kindly donated a-chloroisocaproate.
Results and Discussion

Published methods for determining the activity state of muscle BCDH
either did not have adequate sensitivity to determine initial activities of the complex or were complicated by membrane barriers between
the substrate and the enzyme complex.
to circumvent these difficulties,
(69,131,144).

We therefore developed a method

guided by several earlier studies

Attempts to prepare detergent extracts directly from

skeletal muscle in the presence of detergent and inhibitors of kinase
(dichloroacetate) and phosphatase (F-) failed to detect BCDH activity.
Only after precipitation of the complex with PEG could we measure
initial BCDH activity.

Measurable initial activity was obtained by

precipitation with greater

than

6%

PEG while the maximal

rate of

activation required about 9% PEG and diminished as the PEG concentration

was

increased

above

12%.

The

recovery of measurable BCDH

activity after PEG precipitation, as opposed to the lack of activity

in detergent-treated homogenates, may result from concentration of the
complex by precipitation (about 5-fold) or perhaps removal of

an

inhibitory factor from the homogenates as suggested by Odessey and
Goldberg (131), and Paul and Adibi (141).

The initial activity of the

preparation was stable for at least 90 min when stored on ice and for
at least 75 min when incubated at 37°C (data not shown), showing no
evidence of activation.

58
Preincubation of the enzyme preparation with 15 mM Mg 2+ at 37°C

resulted in a time-dependent increase in the activity of the complex,

o. 7

from an initial acti vi ty of

nmal/min/ g muscle to a maximum of 29

nmol/min/g muscle after 40-60 min

of

incubation; maximal activity

remained stable until at least 80 min of incubation (Figure lA).
increase in activity upon

The

incubation with Mg 2+ presumably reflected

conversion of the complex from the phosphorylated (inactive) to the

dephosphorylated

(active)

(77,137).

form

This

suggests

that

in

skeletal muscle of rats fasted overnight about 2% of the BCDH was in
the active state.

Activation of the complex was unaffected by 10

~g/ml

insulin or 2 mM MnC12 (data not shown).

The

protamine sulfate, 1

~M

relatively high PEG concentration (9%) necessary to maximize activation
of

the

complex may

phosphatase,

be

due

to

coprecipitation of a specific BCDH

although the rate of activation in our preparation was

unaffected by protamine sulfate which activated the specific phosphatase purified from bovine kidney (33).
The assay of BCDH activity was linear up to 7.5 min for initial
BeDH

activity and up

to 3 min for assay of total activity after

activation of the complex with Mg 2+ (Figure

IB); measurements were

independent of the volume of enzyme preparation assayed in the range
of Q.06 to 0.18 ml of initial enzyme preparation and 0.008 to 0.02 ml

of enzyme preparation after activation with Mg2+ (data not shown).
later experiments

In

initial activity was routinely assayed over 5 min

using 0.15 ml of enzyme and total activity was assayed over 1 min after
60 min preincubation with 15 roM Mg 2+, using 0.025 ml of diluted enzyme
preparation

(equal

parts

of

initial

preparation and assay

buffer
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supplemented with 30 mM MgS0 4 ).

BCDH activity assayed either before or

after incubation with Mg 2+ was unchanged by the addition of lipoarnide
dehydrogenase (data not shown).

Kinetic parameters of the BCDH complex

after activation with Mg 2+ were determined from reaction velocities
with eight substrate concentrations between 0.01 and 0.6 mM a-ketoisocaproate.

The data were analyzed using non-linear least squares fit to

the Michaelis-Menten equation (150) and the apparent parameters found
to be: Km 0.09 ± 0.01 roM, Vrnax 79 ± 2 nmol/min/g muscle (mean ± SE from
5 preparations).

Due to the low activity of the enzyme preparation in

its initial state it was not possible to determine the kinetics of the
complex prior to activation.
Our method of preparation of branched-chain a-keto acid dehydrogenase may result in some loss of the complex during the precipitation
step (133,144), thus the total amount of enzyme complex may be greater
than our measurements indicate; losses of complex would not be expected
to bias measurements of the activity state of the complex since samples
for initial and total activities would be subject to the same losses.
Despite this possibility, our measurements of the initial and total

BCDH activity and activation state are similar to the values obtained
by Wagenmakers et a1.

in muscle homogenates (184,185) and the total

BCDH activity obtained by Patston et a1.
muscle mitochondria (137).

in detergent solubilized

The BCDH activities obtained by Kasperek

et al. (100) are also similar to ours and other investigators (137,184,

185) although their assay used 1 roM a-ketoisocaproate (a saturating
concentration) while the other assays use 0.1 mM substrate (subsaturating) .

In light of the low values we have obtained for the initial
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activity of BCDH, which precluded generation of kinetic data, we cannot
distinguish

between

the possibilities

that

the

initial

activities

measured represent either 1) the activity solely of a small fraction of
active (i.e. dephosphorylated) complex or 2) that initial activity is
comprised principally of residual activity of the phosphorylated (i.e.
inactive complex) which could exhibit different kinetic properties.
We first attempted to modulate the activity of BCDH in vivo by
injecting rats

i.p.

with leucine or valine (2 nunol/kg) and taking

muscle samples for the assay of BCDH complex one hour later.

As shown

in Figure 2A treatment with leucine resulted in a nearly four-fold
increase in the activity state of BCDH (from 2.1% to 7.87.) while after
valine treatment the activity state was the same as that in saline
treated controls.
could have

Since the lack of effect of valine on BCDH activity

been due to differences in the rate of absorption and

clearance, we investigated the effect of i.v. administration of the
BCAA on the acti vi ty of the muscle complex.

Figure 2B shows that

valine administration had no effect on the activity state of BCDH even
at the highest dose tested (0.5 mmol/kg), which resulted in a 2.2 fold
increase in the whole blood valine concentration (data not shown).
Within 15 min of administering a large dose (0.5 mmol/kg) of isoleucine
or leucine the complex was activated from 3% in controls to 12% and 22%
active, respectively; whole blood isoleucine and leucine concentrations
increased 3.5- and 1.9-fold, respectively, with these treatments (data
not shown).

With smaller doses (0.25 mmol/kg) only leucine activated

BCDH, to about 10% active.
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Branched-chain a-keto acids, the products of the transamination of
BCAA, are known inhibitors of BCDH kinase, and their levels in plasma
and muscle generally parallel those of circulating BCAA (52).

Our

results are consistent with the potency of the a-keto analogues of the
branched-chain amino acids as inhibitors of BCDH kinase:

> a-keto-a-methylvalerate »

caproate

a-ketoisovalerate

a-ketoiso-

(107,142).

Rapid activation of BCDH after leucine administration in our studies
may

explain

the

accelerated valine oxidation observed

in muscles

exposed to high leucine concentrations (124,200).
The time course of activation of muscle BCDH by leucine is shown in
Figure 3A.

The initial activity of the complex increased rapidly

(within 10 min) after i.v. administration of leucine, from 0.7 to 2.1
nmol/min/g

muscle

(1.8%

to

6.6% active complex).

BCDH activity

declined within 20 min after leucine treatment, decreasing to about 1
nmol/min/g (about 3.3% active) at 40 min and remained unchanged at 60
min.

The changes in muscle BCnH activity with time after administra-

tion of leucine closely parallel the changes in the plasma leucine
concentration shown in Figure 3B; plasma leucine increased from 0.165
roM in saline controls to 0.329 mM by 10 min after leucine injection and

then declined to the initial value at 40 min.

The plasma concentra-

tions of valine and isoleucine declined steadily after leucine administration reaching a nadir at 40 min with valine concentrations depressed by 25% and isoleucine concentrations depressed by 30%; no further
change occurred at 60 min.
The

circulating

concentrations

of

leucine

which

resulted

activation of muscle BCDH were not very great and should be

in

easily
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attained post-prandially after protein ingestion (52,145).

Indeed, the

activi ty of muscle BCDH responds to consumption of a meal and to the
protein content of the diet (unpublished observations) .

Thus, the

contribution of skeletal muscle to BCAA catabolism may be markedly
increased post-prandially.
Feeding
leucine

animals

results

in

diets

supplemented

growth

impairment,

with

excessive

increased

amounts

of

concentrations

of

circulating leucine and depressions in valine and isoleucine; feeding
excesses of isoleucine or valine does not result in depression of
plasma leucine or growth impairment.

This apparent antagonism among

the BCAA has been extensively studied (for review see 77).

In our

experiments an i.v. bolus of leucine resulted in decreased circulating
valine and isoleucine and concomitant activation of muscle BCDHj the
activation state of BCDH appeared to parallel changes in circulating
leucine.

Thus, during hyperleucinemia, accelerated oxidation of valine

and isoleucine by muscle may result in the observed depressions of
these amino

acids

in

plasma.

We cannot exclude however possible

changes in protein turnover contributing to the altered amino acid
profile observed here after leucine injection (reviewed in 77).
The precise role of the various tissues in branched-chain amino
acid catabolism is not well understood.

The non-uniform distribution

of transaminase and BCDH in different tissues suggests the existence
of interorgan cooperativity in their catabolism (reviewed in 77,150).
In contrast to muscle, BCAA transaminase is low in liver, but BCDH is
abundant.

Hepatic BCDH in rats fed an adequate protein diet is nearly

fully active and is not further activated by increasing the protein
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content of the diet (69) or administering BCAA (16).
latter in the present study.

We confirmed the

In the experiments shown in Fig. 2 the

activation state of hepatic BCDH was measured as described in (4); it
was found to be 80-83% active and unchanged after the administration of
leucine, isoleucine, or valine.

However a role for the liver in the

disposal of excess BCAA cannot be discounted since increased branchedchain a-keto acid export from peripheral tissues rich in BCAA transam.inase may increase avai lable substrate for 1 i ver BCDH (112).
Recent studies suggest that extrahepatic tissues (e.g. muscle) must
contribute to the leucine induced stimulation of BCAA oxidation in vivo

(16,77);

the present observations,

showing activation of the rate

limi ting enzyme in muscle after leucine administration, support this
hypothesis.

Our method for measuring the activity state of BCDH in

muscle should prove a valuable adjunct to studies of BCAA
and its regulation by dietary and hormonal treatments.

degradation
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Figure 1.

Activation of muscle branched-chain a-keto acid
dehydrogenase by Hg 2+ and assay linearity.

Branched-chain a-keto

acid

dehydrogenase

was prepared as described

under "Materials and Methods". In panel A 0.15 ml of enzyme preparation
was assayed for 5 min as described under "Materials and Methods" to
obtain the zero time point.

A sample of enzyme preparation was mixed

with an equal volume of assay buffer supplemented with 30 mM MgS04 and
incubated at 37 oC; at the indicated times 0.025 rnl samples were taken
and assayed for 1 min.

Values shown are the means ± SEM from 6 enzyme

In panel B initial (unactivated) BCDH activity (-) was

preparations.

determined using 0.15 ml of enzyme preparation and assayed for the
times indicated.

Total BCDH activity (41) was measured using 0.025 ml

of diluted enzyme after incubation for 60 min wi th Mg 2+ as described
above, and assays terminated at the times indicated.

Results shown are

the means ± SEM from 4 enzyme preparations .
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Figure

Activity

2.

state

of

muscle

branched-chain

a-keto

acid

dehydrogenase after treatment with branched-chain amino acids in vivo.
In
nunol/kg)

panel
or

A rats were

injected

i.p.

an equal volume of saline.

with leucine or valine
One hour after

(2

injection

muscle samples were taken and initial and total BCDH activity assayed
as described under "Materials and Methods" and Fig 1.
was

determined as

Percent activity

the ratio of initial activity to total activity,

results shown are means ± SEM; 6 animals were treated with valine or
saline and

11 with leucine. Total activities were the same for all

groups, 18 ± 2 nmol/min/g muscle (n=23).
i. v.

In panel B rats were injected

through a jugular venous catheter as described under "Materials

and Methods" with amino acids at the dose shown or an equal volume of
saline.

Muscle samples were taken

15 min after treatment for the

determination of BCDH activity as described above.

Total activities

were the same for all groups, 28 ± 1 nmol/min/g muscle (n=39), with 4
to 9 animals in each group.

*

p < 0.05 compared to saline control;

** p < 0.001 compared to saline control, p < 0.05 compared to 500
~mol/kg

isoleucine, p < 0.05 compared to 250 ~mol/kg leucine.
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Figure 2.
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Piaure 3.

course of muscle branched-chain a-keto acid dehydro-

Time

genase activation and plasma

branched-chain amino

acid concentrations

after leucine infusion in vivo.
Rats

were

injected

i.v.

with

0.25

mmol/kg leucine or an equal

volume of saline (time 0 points), muscle and
at various times after injection as indicated.

blood samples

were taken

A. Initial activity

( . ) , total activity, and % activity (e) of branched-chain a-keto acid
dehydrogenase were determined as described in

Fig. 2B.

Total activi-

ties were the same for all groups, 33.9 ± 1.3 nmol/min/g tissue
(n = 28).

B. Leucine (e), valine (.) and isoleucine (A) in plasma were

determined as described under ttMaterials and Methods".
values

shown

are

compare d to tlme
·
0;

the

**

means
p

In both panels

± SEM from 4-8 animals.

< 0.01 compared
to ·
tlme 0 .

*p

< 0.05
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Chapter IV
Modulation of Rat Skeletal MUscle Branched-Chain
a-Keto Acid Dehydrogenase In Vivo:

Effects of Dietary Protein and Heal Consumption

The contents of this chapter have been published in similar form in
Journal of Clinical Investigation 79: 1349-1358, 1987.
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SUlllllary

The effects of dietary protein on the activity of skeletal muscle
branched-chain a-keto

acid dehydrogenase (BCDH)* were investigated.

BCDH is rate-limiting for branched-chain amino acid (BCAA) catabolism
by muscle;

lation.

its activity is modulated by phosphorylCition-dephosphory-

In rats fed an adequate protein (25% casein) diet, BCDH was

-2% active postabsorptively and increased to 10% or 16% active after a
25% or 50% protein meal, respectively.
days)

increased

postabsorptive

BCDH

Feeding a 50% protein diet (10
activity

increases to 40% active postprandially.

to

7%

with

further

On a low protein (9% casein)

diet (10 days) BCDH remained -2% active regardless of meal feeding.
Dose-dependent activation of BCDH by intravenous leucine in postabsorptive rats was blunted by a low protein diet.

Conclusions: Excesses

of dietary protein enhance the capacity of skeletal muscle to oxidize
BCAA;

when

protein

intake

is

inadequate,

muscle

conserves

BCAA;

skeletal muscle may play an important role in whole body BCAA homeostasis.
Introduction

Chronic consumption of high protein diets results in induction of
rate-1imi ting degrading enzymes for most essential amino acids (79,

106).

Hence, the concentrations of most amino acids do not increase

markedly in body fluids after long term high protein feeding and may
actually decrease as more protein is consumed (145).

*
keto

When dietary

Abbreviations used in this chapter are: BCDH, branched-chain a-

acid

dehydrogenase;

branched-chain a-keto acids.

BCAA,

branched-chain

amino

acids;

BCKA,
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protein intake is restricted to less than the requirement for growth
and maintenance,

these enzymes decrease (79,106), resulting in con-

servation of essential amino acids.
branched-chain amino acids (BCAA) -

The catabolic system for
leucine,

the

isoleucine and valine -

appears to be an exception to this homeostatic scheme for essential
amino acids in that a) their concentrations in blood and tissues rise

in direct proportion to the protein content of the diet (109,118,145)
and b) BCAA aminotransferase, the initial enzyme in BCAA catabolism, is
relatively

refractory

to

changes

in

dietary

protein

(96).

This

apparent lack of adaptation has prompted some investigators to conclude
that the body is unable to maintain the free body pools of BeAA by
increasing oxidation during times of surfeit or by decreasing oxidation
during times of deficiency.

However, studies in man and rat have shown

that BCAA oxidation in vivo is increased markedly after high protein
feeding (109,129,182), and is severely depressed after consumption of
low protein diets
alterations
studies

The mechanisms responsible for these

BCAA oxidation are

in

suggest

manipulations

(109 t 129).

that

cannot

principle (129a).

fluctuations
be

incompletely understood.
in

BCAA

oxidation

with

explained based solely on the mass

Recent
dietary
action

Control of BCAA metabolism by dietary protein is

of particular interest as branched-chain amino and keto acids are being
used

in the treatment of hepatic encephalopathy and renal insuffic-

iency,

conditions

in which low protein diets are usually indicated

(19,189).
The first connnitted reaction in the metabolism of BeAA is catalyzed by branched-chain a-keto acid dehydrogenase (BCDH), a multienzyme
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complex

located

on

membrane of most
oxidative

the

inner

surface of

cells (77,150).

decarboxylation

a-ketoisocaproate

of

BeDH

the

catalyzes the irreversible

branched-chain a-keto acids

(ketoleucine),

a-keto-a-methylvalerate

leucine), and a-ketoisovalerate (ketovaline) their

inner mitochondrial

(BCKA)
(ketoiso-

which are formed from

respective BeAA through the action of BeAA aminotransferase.

Both BCDH and BCAA aminotransferase are distributed ubiquitously but
non-uniformly throughout the body.
kidney,

and heart,

BCDH activity is highest in liver,

but very low in skeletal muscle (77,150).

In

contrast, BeAA aminotransferase activity is highest in skeletal muscle

but very low in liver (77,150).

BCDH is believed to limit the rate of

BCAA catabolism in vivo (117).
BCDH is unusual among amino acid-degrading enzymes in that it is
regulated

by

a

phosphorylation

(inactivation)-dephosphorylation

(activation) mechanism similar to that which exists for the pyruvate
dehydrogenase complex (195).

As with pyruvate dehydrogenase, a protein

phosphatase and kinase are believed to be associated with BCDH in vivo.
Alteration of the phosphorylation state of BCDH permits rapid changes
in enzyme activity which are not possible via an induction-repression
mechanism (77).

The physiological significance of BCDH modulation by

phosphorylation is currently an active area of study (199).
In normally fed rats, BCDH from liver is essentially fully active
(i.e. dephosphorylated) (69,77,81,185).

In contrast, less than 20% of

skeletal muscle BCDH is in the active form (5,77,137,150,185).

As

skeletal muscle comprises approximately 40% of the rat's body weight
(73), changes in the phosphorylation state of muscle BCDH could have
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However, efforts to

profound effects on BCAA metabolism in vivo.
detect

changes in the activity state of muscle BCDH in response to

physiological manipulations have been largely unsuccessful (77,137,

184).

In view of the high BCAA aminotransferase and low BCDH activity

of muscles,

it was proposed that muscle may primarily deaminate BCAA

release BCKA into the circulation for eventual oxidation by liver

and

where BCDH is found in abundance (77,112,150).

Uncertainty about the

role of muscle in BCAA metabolism has stenuned in part from the diffi-

culty in measuring activities of BCDH from solubilized muscle preparations (131,137,140,181).

Therefore, intact muscle mitochondria were

used in most studies to assay BCDH activity (77,140,150,184).

Problems

associated with substrate transport, quantitation of precursor specific
radioactivity, and possible activation of the enzyme during mitochondrial

isolation

studies.

or

Recently,

incubation

complicate

we described an assay

interpretation
for

of

such

measuring BCDH

in

solubilized rat muscle tissue and showed that the enzyme was activated
in vivo after intravenous leucine administration (5).

We have used

this assay in the present study and found that muscle BCDH is activated
rapidly in vivo after consumption of meals containing adequate to high
levels of protein, and that the activation state of the enzyme is
responsive both acutely and chronically to the protein content of the
diet.
Materials and Methods
Animals.
Wilmington,
studies.

Male Wistar (WI) BR rats (Charles River Laboratories,

MA).

initially

weighing

140-160 g,

were used

in all

Rats were kept in a room maintained at 24°C with a reverse 12
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hour light - 12 hour dark cycle.
3:00 PM.

The dark period was from 3:00 AM to

Rats were offered their daily allotment of food within the

last 6 hours of the dark cycle (9:00 AM - 3:00 PM).

This meal-feeding

regimen minimized variations in enzyme and metabolite measurements due
to fluctuations in food intake (145).
Diets and Treatments.

Water was supplied ad libitum.

All diets were specially prepared in pellet

form by United States Biochemical Corp. (Cleveland, OH) and contained
in percentage by weight: Rogers and Harper's mineral mix, 5 (155); AIN
76 vitamin mix, 1; corn oil, 5; choline chloride, 0.2; vitamin-free
casein, 0, 9, 25 or 50; and equal amounts of glucose monohydrate (A.E.
Staley Manufacturing

Co.,

Oak

Brook,

IL)

Maize, Hammond, IN) to make up 100%,

and cornstarch (American

The 9% casein diet was supple-

mented with methionine, 0.3% (w/w) (48).
Rats were first acclimated to the 25% casein diet ad libitum for 2
days; then rats were trained to consume the 25% casein diet during the

last 6 hours of the dark cycle for 2 weeks (meal-feeding).

After this

training period, both chronic and acute effects of dietary protein on

BeAA metabolism were studied,
the 0,

9,

In the chronic study, rats were meal-fed

25 or 50% casein diets for 10 days.

measured each day.

On the tenth day, rats were killed before or 3

hours after presentation of the meal.
circulating

Body weights were

Previous studies have shown that

levels

of BeAA are greatest 3 hours postprandially in

meal-fed rats (48).

In the acute studies, rats previously fed the 25%

casein diet for 2 weeks were offered a single meal containing 9, 25 or
50% casein.

Rats failed to consume a single meal of the 0% casein
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diet, hence this group was omitted.

Rats were killed before and 3. 6

and 12 hours after presentation of the meal.
Previous studies (17,48,145) have shown that during the first few
days of offering an adequate protein diet for 6-8 hrs a day (mealfeeding), food consumption is less than that of ad libitum-fed rats.
However, food intake increases gradually and after one week, meal-fed
and ad libitum-fed rats consume equal amounts of food.

Rats maintained

chronically on casein diets similar to those used here consume equal
amounts of food except for those given a protein-free diet, which
consume 43% less (17).

In the present study, food intake was measured

in the acute experiments and was not significantly different between
rats fed 9%, 25% or 50% casein diets (14

± 1 g/meal).

In a separate experiment, the effects of leucine infusions on
muscle BCDH activity were investigated in rats fed 25% or 9% casein
diets ad libitum for 2 weeks.

Rats were anesthetized with methoxy-

flurane (Metofane) after an overnight fast (5) and L-leucine was
infused via the tail vein at doses of 0, 10, 25, 50, and 100
body weight.

~mol/100

g

Muscles were excised 15 minutes after injections.

BCDH Assay.

Our method for determining BCDH activity in muscle

has been described in detail previously (5,15).
involved freeze-clamping whole muscle in situ.

Briefly, the method

BCDH was extracted from

powdered frozen muscle in the presence of protease, phosphatase,. and
kinase
Basal

inhibitors
(in vivo)

and

then precipitated with polyethylene glycol.

BCDH activities were

determined irmnediately after

redissolving the precipitated proteins and total (fully-active) enzyme
activities were measured after preincubation of the extract at 37°C
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with 15 mM Mg 2+ prior to assay.

In these studies BCDH activity was

determined by 14C0 2 release from O. 1 mM
37°C.

Q-

keto [ 1_ 14C] isovalerate at

Percentage of BCDH in the active form was calculated as the

ratio of basal to total BCDH activities.
Amino Acids, Protein and DNA.

Heparinized plasma was deprotein-

ized by adding ice cold sulfosalicylic acid (0.1 volumes of a 50% w/v
solution).

After standing 20 minutes on ice, samples were centrifuged

at 30, 000 X g for 10 minutes.

Muscle samples were deproteinized by

adding 4 volumes of ice cold 5.9% w/v sulfosalicylic acid to powdered
muscle samples.

Muscles were then homogenized with a Polytron tissue

homogenizer and left on ice for 20 minutes.

The mixture was then

centrifuged at 30 J 000 X g at 4°C for 10 minutes.
BCAA

concentrations

in

deproteinized

samples

Plasma and muscle

were

measured

using

reversed-phase high performance liquid chromatography separation of the
~-phthalaldehyde

concentrations

derivatives

(~molig)

and

fluorescent

detection

(6).

BCAA

were expressed per milliliter of intracellular

water assuming that muscle contains 80% water: 60% intracellular and
20% extracellular, the latter at equilibrium with plasma (30).

Muscle protein concentrations were determined according to the
method

of

Lowry

(113)

with bovine serum albumin as the standard.

Muscle DNA concentrations were measured using a modification of the
Burton assay (191) with herring sperm DNA as the standard.
Statistical analyses of differences between groups were performed
by Student's t test or by the Peritz multiple range F test (80) and
were considered significant if p < 0.05.

Values for % active complex

were subjected to the inverse sine transformation prior to statistical
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analysis as percentages are distributed binomially rather than normally
(173).

This transformation is especially recommended for values in the

range of most of the present observations (0-20%).

Regression analysis

was performed by the linear least squares method and slopes compared by
Student's t test (173).

All values shown are means ± SEM.
Results

BCDH Assay.

As others have shown diet-mediated changes in BCDH

activities from liver, kidney and heart (69,77,81,137,150), we first
sought to optimize the assay for BCDH isolated from muscles of rats fed
differing levels of protein. Rats were meal-fed 0%, 25% (normal) or 50%

(high) casein diets for approximately 2 weeks.
hours after presentation of the meal.
vivo)

BCDH

increased.

activity

increased as

The assay for

As shown in Figure 1, basal (in

the protein content of the diet

basal BCDH activity was linear up to 5

minutes in all diet groups whether 100 or 150
used.

To

ensure

that

Muscles were excised 3

no more

~1

of muscle extract was

than 10% of a-ketoisovalerate was

utilized during the reaction (168), basal activities from 0% and 9%
casein groups were routinely assayed for 5 minutes using 150 ..,.1 of

extract.

Basal BCDH activities from 25% and 50% casein groups were

assayed for 2-5 minutes,

utilizing 100 fJl of extract.

Total BCDH

activities were linear up to 3 minutes in all diet groups; therefore,
total activities were routinely assayed over 1 minute (5,15).
Recently, Randle and associates have shown that BeDH from liver of
rats fed low protein diets is refractory to dephosphorylation (138).
To investigate whether dietary protein might affect the rate of muscle
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BCDH activation, total BCDH activities were measured 20, 40, 60 and 80
minutes after preincubation at 37°C in a buffer containing 15 mM Mg2+.
The time required to attain maximal BCDH activities in muscle extracts
from rats fed diets containing 0%,
Figure 2.

25% or 50% casein are shown in

Maximal activities for rats fed the 25% or 50% casein diets

were obtained after 40 minutes of preincubation.

In contrast, maximal

BCDH activities in muscles of rats fed the 0% casein diet were not
obtained until 60 minutes of preincubation.

This lag phase of muscle

BCDH activation was also observed in rats fed the 9% casein diet (data
not

shown).

tissue)

Fully activated

were not

(total)

significantly

enzyme activities (ronol/minig

different among the groups.

Chronic Effects of Dietary Protein.

Rats fed the protein-free diet

failed to thrive and lost approximately 40 grams of weight during the
10 day study (Table 1).

Addition of 9%, 25% or 50% casein to the diet

resulted in growth rates of 4-6 grams/day.

Rats fed the 9% casein diet

attained 60% of the weight gain observed in rats fed the 25% casein
diet.

Continued growth on the 9% casein diet was most probably due to

its supplementation with methionine, the first limiting amino acid in
casein; hence this diet constituted a protein restricted rather than an
essential amino acid deficient diet.

The changes in growth due to

dietary protein were accompanied by alterations in the protein and DNA

concentration in skeletal muscle (Table 1).

The proteini DNA ratio, an

estimate of cell size, was significantly depressed when protein was

omitted from the diet (g protein/g DNA
and 464

= 336 ± 16;

418 ± 16; 458 ± 18;

± 17 for rats fed 0%, 9%, 25% or 50% casein respectively).
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The effect of consuming 0%, 9%, 25% or 50% casein diets for 10

days on the percentage of active BCDH in muscle are shown in Figure 3A.
Measurements

were

made

before

(postabsorptive)

(postprandial) presentation of the meal.
food

in their

stomachs

at

sacrifice.

or

3

hours

after

All postprandial rats had
Compared to postabsorptive

values, consumption of the 0% or 9% casein diets had no significant
effect on the activity state of the complex.

In contrast, the activity

state of BCDH increased markedly (-7-fold) after consumption of the 25%
or 50% casein diets.

The postabsorptive activity of BCDH was identical

in rats fed 9% or 25% casein; however the postprandial activity was 80%

lower in the former group.

Consumption of the diet

containing 50%

casein resulted in greater than 3-fold increases in both postabsorptive
and postprandial BCDH activities when compared to the group fed the
normal protein diet (25% casein).

The postabsorptive BCDH activity in

rats fed 50% casein was significantly higher than the activity in the
9% or 25% casein-fed rats.

Interestingly, consumption of a protein-

-free diet resulted in significantly higher postabsorptive activities
than observed in the 9% and 25% casein groups.
The effects of dietary protein on total BCDH activity (an estimate
of enzyme content) are shown in Table 1.

Total BeDH activity was not

significantly different in rats fed the 25%, 9% or 0% casein diets.

In

contrast, consumption of high levels of protein resulted in increases
in total BCDH activity when expressed per mg DNA or per g protein
(Table 1).

Hence, the apparent amount of BCDH complex per muscle cell

increased -35% after feeding a high protein diet for 2 weeks.
We have recently demonstrated that infusions of leucine result in
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activation of rat muscle BCDH (5).

Therefore, plasma BCAA concentra-

tions were measured in the present study.

As shown in Figure 3B, the

concentration of plasma leucine increased in direct proportion to the
protein content of the diet.

In general, the increases in plasma

leucine paralleled the changes in the activation state of the complex
(r

= 0.781

; n

= 62;

p < 0.001).

Similar relationships were observed

between the activity state of BCDH and the plasma concentrations of
isoleucine or valine (r

= 0.783

for both; n

= 62;

P < 0.001).

However,

a causal relationship between these amino acids and the activity of the
complex is unlikely as we have shown previously that infusions of equimolar amounts of valine or isoleucine fail to activate BCDH (5).

The

intracellular concentrations of leucine were measured in muscles of
some

rats

before

and

after

consuming

the

four

diets

(Table

2).

Intracellular leucine concentrations were significantly correlated (r
0.498;

n = 40;

intracellular

P

< 0.01) with the activity of muscle BCDH.

concentrations

=

The

of leucine increased postprandially in

rats fed 9%, 25% or 50% casein, but not in rats fed the protein free
diet.

The

postabsorpti ve intracellular leucine concentrations were

similar among the groups

fed 0%,

9% or 25% casein diets, but were

increased in the group fed the 50% casein diet.

The postprandial

intracellular leucine concentrations were significantly higher in the
groups fed 25% and 50% casein, than in those fed 0% casein.

Meal

consumption had no significant effect on the ratio of leucine concentrations between muscle and plasma in any of the diet groups.

Inter-

estingly, the highest muscle/plasma ratios were observed in the group
fed the protein-free diet.

Postprandially this ratio was significantly
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higher in the 0% casein group than in any of the groups fed protein
containing meals.
Acute Effects of Dietary Protein.

To examine the effects of acute

protein consumption on muscle BCDH, rats previously fed a 25% casein
diet for 2 weeks were offered a single meal of 9%, 25%, or 50% casein.
No differences in food intake were observed between the three groups.
As shown in Figure 4A, consumption of the 9% casein meal had no effect
on muscle BCDH activity 3, 6, or 12 hours after feeding.

In contrast,

consumption of the 25% and 50% casein meals resulted in 6 and I1-fold
increases in the percentage of active complex 3 hours after presentation of the meal (postabsorptive 1.6 ± 0.1% active; postprandial 9.4

± 2.0 and 17.2 ± 3.6% active respectively).

By 6 hours, the proportion

of BCDH in the active form in rats offered the 25% casein meal returned
towards baseline and changed little after 12 .hours.

The percentage of

active complex in rats offered the 50% casein meal decreased in a
linear fashion between 3 and 12 hours after presentation of the meal.
By 12 hours, BCDH activity in the high protein group was still 50%
greater than baseline.
The effect of consuming single meals of varying protein content on
the plasma concentrations of leucine is illustrated in Figure 4B.
strong correlation (r

= 0.852;

n

= 45;

A

P < 0.001) was observed between

the percentage of active BCDH and the concentration of leucine in
plasma.

Significant correlations were also observed between the acti-

vity of BCDH and the plasma concentrations of isoleucine (r

= 0.854;

n = 45; P < 0.001) and valine (r = 0.906; n = 45; p < 0.001).
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The

relationship

between

the

percentage

of

active

BCDH

and

circulating leucine in both the chronic and acute studies is shown in
Figure 5.

Linear regression analysis between % active complex and

plasma leucine concentration demonstrated a significant direct correlation between these values (r = 0.788. n

= 107,

p

< 0.001).

A better

linear least squares fit was obtained by semilog transformation of the
data (i.e. log % active complex vs. plasma leucine concentration) which
gave a correlation coefficient of 0.848 (p < 0.001).

The solid line in

Figure 5 represents the best fit line for the semilog transformation.
Leucine Infusion Studies.
days,

In rats fed a 9% casein diet for 10

consumption of the meal resulted in an approximate doubling in

plasma and intracellular leucine without a change in the activity of
the complex (compare Figures 3A, 3B and Table 2).

Also, the enzyme

from rats fed a protein-free diet required a longer period of incubation to attain maximal activity (Figure 2).

To study the apparent

refractoriness of the enzyme from low protein-fed rats to activation,
rats previously fed adequate (25% casein) or low (9% casein) protein
diets for

approximately 2 weeks were infused with varying doses of

leucine (Figure 6).

BCDH activity was closely correlated with the dose

of leucine infused

(r

leucine

=

0.92 for each diet group, p

< 0.001) and

infusions at doses of 25 J..lmol/lOOg body weight or greater

resulted in activation of muscle BCDH in both diet groups (Figure 6A).
However,

the

leucine-mediated

protein-fed rats was
amounts of protein (p
regression

lines for

activation

of muscle

BCDH

less than that observed in rats

< o. 001),

from

low

fed adequate

by comparison of the slopes of the

leucine dose vs. BCDH activity).

Plasma BCAA
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concentrations were essentially identical in the two groups (Figure 6B
and C).

Discussion
The body pools of most amino acids are enlarged in animals immediately after they have consumed a high protein diet (106,145).

Contin-

ued consumption of amino acids in quantities greatly in excess of
requirements would result in death if no homeostatic controls were
present.

The relatively high Kro's of amino acid-degrading enzymes

enable the

rate of

oxidation of

surplus amino acids

to

increase

initially as the result of increased substrate concentrations (106).
However,

if

a

high

influx of amino acids continues,

the organism

synthesizes more of many of the rate-limiting amino acid-degrading
enzymes found in liver.
threonine

dehydratase;

Prominent among these inductions are: serinehistidase;

tryptophan

pyrrolase;

tyrosine-

a-ketoglutarate aminotransferase; glutamate-oxaloacetate and glutarnate-pyruvate

aminotransferases;

(reviewed

in

and

63,66,79,106).

catabolized and in the process t
nesis

(i.e.

pyruvate,

all

Hence,

of

the

urea

excesses

cycle

enzymes-

of amino acids are

essential precursors for gluconeoge-

tricarboxylic acid cycle

intermediates)

are

formed.

A similar control mechanism for BCAA is believed to be absent

(106).

Reports of BCAA aminotransferase induction by diet are incon-

sistent and the observed effects are relatively small compared to other
amino acid-degrading enzymes (77,106).

Yet, BCAA oxidation in vivo is

increased markedly after high protein feeding (109,129a,182a).

In rats

adapted to a high protein diet J the protein content of the body does
not increase, and BeAA excretion in urine and feces is negligible (79).
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Based on these considerations, Harper et a1. (17, 77) calculated that
when rats are switched from a 20% to 50% protein diet, 12,000

~mol

BCAA

are available for degradation, while the increase of BCAA in bodily
fluids is only -100
occurring.

~mol.

Hence, extensive oxidation of BCAA must be

In the present study,

a small increase in total BCDH

activity/mg DNA was observed in rats after feeding a high protein diet
for two weeks.

This may represent stimulation of enzyme synthesis

and/or decreased degradation of the complex.

However, the major effect

of protein intake was exerted at the level of enzyme activation.
BCDH activity is thought to be the major regulator of BCAA oxidation in vivo (117).

As liver BCDH is fully active in normally-fed rats

(69,77,81,185), activation of extrahepatic BCDH would be expected to
result in enhanced oxidation of BCAA in vivo.

In the present study,

skeletal muscle BCDH was only 1-2% active during the postabsorptive
period in rats fed 25% casein (Figures 3A and 4A).

Increasing the

casein content of the diet from 25% to 50% for 10 days resulted in a
greater than 3-fold increase in the percentage of active muscle BCDH
measured either before or 3 hours after feeding (Figure 3A).

Further-

more, compared to postabsorptive values, consumption of the 25% or 50%
casein diet resulted in a greater than 7-fold activation of muscle
BCDH.

The proportion of BCDH in the active form rose from 2% in

postabsorptive rats fed adequate amounts of protein to greater than 40%
in rats 3 hours after consuming a high protein diet.

That a single

normal or high protein meal could also activate muscle BCDH is shown in
Figure 4A; the duration and magnitude of activation was proportional to
the protein content of the diet.

86

Considering all available data, we observed a strong correlation
between circulating leucine and the activity of muscle BCDH.

Inspec-

tion of the points in Figure 5 suggests that a threshold phenomenon
may obtain at leucine concentrations less than 0.2 roM with a fairly
steep slope for activation of muscle BCDH at leucine concentrations
greater than 0.2 mM.

At low circulating leucine concentrations, liver

would, therefore, assume greater importance in BCAA homeostasis but as
circulating BCAA and muscle BCDH activity increase the latter may
become the predominant tissue in BCAA metabolism.

The correlation

between plasma leucine and muscle BCDH activity (5) is most simply
explained by inhibition of BCDH kinase by a-ketoisocaproate (150), the
transamination product of leucine.

In studies of rats it was found

that the concentrations of BeKA in muscle paralleled those of the BCAA
in rats fed low, normal or high protein diets (91) and plasma a-KIe was
found to increase in man after a protein meal (165).
however that

this

simple explanation for

muscle BCDH and plasma leucine is inadequate.

It is clear

the relationship between
Despite similar circula-

ting leucine concentrations, muscle BCDH in rats fed a 9% protein diet
activated less than BCDH from rats fed a 25% protein diet (Figure 6).
Furthermore,
observed

meal-induced activation of BCDH was greater than that

after

concentrations

leucine

infusions

(compare Fig.

4

achieving

and 6).

similar plasma

leucine

The two studies are not

directly comparable however because the duration of hyperleucinemia
before sacrifice was much longer in the former experiments.

It is also

noteworthy that the postprandial activation of BCDH by a high protein
meal

(40% active) was -2.5X greater in rats maintained on a high
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protein diet than in those maintained on a normal diet although plasma
leucine was only 50% higher in the former group after consumption of
the protein meal (compare Fig. 3 and 4).

It seems unlikely that rneal-

induced insulin release played a role in the postprandial activation of
BCDH, as treating

postabsor~tive

rats with large doses of insulin and

glucose did not activate the complex in muscle (15).
perfused

hindlimbs

of

postabsorptive

rats,

insulin

Furthermore, in
added

to

the

perfusate decreased flux through BCDH (93).
Despite a marked activation of muscle BCDH in rats fed a high
protein

diet,

plasma

and

tissue

elevated (Figures 3,4; Table 2).
readily

reversible

and

concentrations

of

BCAA

remained

The BCAA aminotransferase reaction is

indeed 80-90% of

leucine transaminated

to

a-ketoisocaproate is reaminated to leucine in humans in vivo (117).
High levels of tissue

glutamat~

in animals fed high protein diets would

favor maintenance of elevated BCAA by restraining their transamination
and favoring reamination of BeKA (77,93).

The physiological advantage

of maintaining enlarged BCAA pools during high protein feeding is
unknown.
tive

Elevated BCAA concentrations in blood could act as a protec-

buffer,

tyrosine,

competing with other large neutral amino acids (e.g.

tryptophan

and

phenylalanine)

for

transport

across

the

blood-brain barrier (135,145), thus preventing increased synthesis of
certain neurotransmitters (61,197).

The toxic effects of elevated

brain aromatic amino acids are well documented (11).

SCAA have been

used clinically to reduce the levels of brain aromatic amino acids in
hepatic encephalopathy (189) and phenylketonuria (12).
Consumption of protein deficient diets results in inactivation of
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liver BCDH (69,81,137,138).

Recently, increased BCDH kinase activity

was reported in livers and hearts of rats fed a protein-free diet (55).
The decrease in the percentage of active complex in livers of rats fed
low protein diets presumably represents a mechanism by which essential

BCAA are conserved during periods of protein depletion.
oxidation

is

severely depressed

feeding (109,121,129,153,171).

Indeed, BeAA

in man and rat after low protein

In the present study, switching from an

adequate to a low protein diet for 10 days had no significant effect on
muscle BCDH activity in the postabsorptive state (Figure 3A).

This is

not surprising as most of the complex was already in an inactive form
in postabsorptlve rats fed the adequate protein diet (i.e. 2% active).

However, the following observations were of interest:
from rats

1) muscle BCDH

fed protein-free or low protein diets required a

longer

period of preincubation with Mg 2+ to attain maximal activity than BCDH
from rats fed adequate protein diets (Figure 2) and

2) plasma leucine

concentrations increased approximately 2-fold after consumption of the
low protein diet, but muscle BCDH activity remained unchanged (Figure
3) .

To

further invest igate these di fferences , varying amounts of

leucine were infused into rats fed adequate or low protein diets.
Despite similar circulating leucine concentrations, the complex from
rats fed the low protein diet was less responsive to leucine activation
than the enzyme isolated from rats given adequate amounts of protein
(Figure 6).
fed

The refractoriness of muscle BCDH to activation in rats

low protein diets may be of

physiological

significance.

An

activation-resistant complex in muscle from low protein-fed rats, along
with an inactivated complex in liver, would ensure efficient conserva-
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tion of BeAA during periods of protein depletion.

The mechanism of

this resistance is not clear; in view of the findings of Espinal et al.
increased skeletal muscle BCDH kinase activity in response to

(55)

protein depletion is an attractive hypothesis.
We have no explanation for the increased basal BCDH activity
observed in postabsorptive rats maintained on the protein-free diet
(Fig. 3).

These animals were in a protein-catabolic state but intra-

cellular leucine concentrations were not significantly different from
the values in the 9% and 25% casein groups (Table 2).

The ap-

parent increase in the muscle/plasma leucine ratio in this group (Table
2)

may be a

protein.

reflection of accelerated net degradation of muscle

a-Ketoisocaproate is compartmentalized in muscle cells (94);

whether intramitochondrial a-ketoisocaproate is increased in muscles of
protein-starved rats or if other mechanisms lead to the relatively
modest activation of the complex in the postabsorptive state is not
known.
Our studies were carried out in rats trained to consume their
daily caloric requirements during a relatively short period of time.
Since rats are predominantly nocturnal "nibblers" rather than "mealeaters", the postprandial activation of BCDH may be less marked when
normal feeding patterns are maintained.

In rats fed a normal diet ad

libitum the plasma leucine concentration cycles between a nadir of 170
~M

at 6 PM and a peak of 275

eater;

following

a

~M

at 6 AM (60).

Man however is a meal

protein meal most of the absorbed amino acids

(except for the BCAA) are taken up by the liver, while a large fraction
of BCAA is taken up by muscle (188).

Since BCAA concentrations in

muscle generally parallel plasma concentrations (reviewed in 77) and
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the latter increase 2-3 fold after a protein meal in man (129,165,188),
muscle BCDH may be activated and likely contributes to the postprandial
increase
practical

in BeAA oxidation
implications

for

(129) •

Our

nutritional

studies

therapy

in rats may have
in

some

patients.

Distribution or presentation of dietary protein in a manner to avoid
large increases in circulating BCAA, or slowing the rate and extending
the duration of amino acid infusions, may prevent or decrease activation of muscle BCDH and spare BCAA for protein synthesis.
Our data support an active role
disposal and conservation of BCAA.

for

skeletal muscle

in

the

Muscle releases BCKA to the blood

stream for eventual uptake and oxidation by the liver (77 J 184).

In

addition, during periods of protein surfeit, the capacity to oxidize
BCAA carbon increases markedly in skeletal muscle, while during periods
of protein inadequacy, skeletal muscle, along with liver, adapts to
conserve essential BCAA.

Table 1. Effects of Dietary Protein on Total Muscle BCDH Activities Expressed on a Wet Weight,
Protein, or DNA Basis.
Casein

(%)

Body Wt Chg

DNA
(~g/g)

(g/10 days)

0

-41 ± 2a

537

9

+40 ± 4 b

448 ± ISh

± 2c

25

+64

50

+S9 ± 2c

466

± 16 a
± 13 b

432 ± 16 b

Total BCDH Activity in (nmol/min) x

Protein

(g tissue)-l

(mg/g)

(mg

DNA)-l

(g protein)-l

174 ± 7a

64 ± 5a

120 ± lOa

368 ± 23 a ,b

188 ± 12 a ,b

63 ± 6a

140 ± 9a

332 ± 14 a ,b

222 ± 11 b

63 ± Sa

135 ± 14 a

304

200 ± IOa,b

78 ± 4a

185 ± ISh

406 ± 3S b

± 35 a

Rats were trained to meal-feeding on a 25% casein diet as described in Materials and
Methods, then changed to diets with varying casein content as shown for a period of 10 days.
Starting weights were not different between rats fed the four diets (205 ± I g, n

= 64).

DNA,

protein, and total BCDH activities expressed per gram of tissue were unaltered 3 hours after
feeding.

Therefore, postabsorptive and postprandial values for each diet group were pooled.

Numbers represent mean ± SEM for n
rats/group.
Methods.

=

13 (0% casein), 15 (9% and 50% casein) or 21 (25% casein)

DNA, protein and total BCDH activities were measured as described in Materials and
Values

in vertical columns with different superscript letters are significantly

different (p < 0.05).

\.0

......
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Table 2.

Effects of Dietary Protein on Muscle Intracellular Leucine

Concentrations and Intracellular MUscle/Plasma Leucine Ratios Before or

After the Meal.
Intracellular
Leucine Concentration *
(nmol/ml)
Casein (%)
0

9'

Muscle/Plasma Leucine

A

B

B

A

134 ± 24 a

106

± 16 a *

1.61

94 ± lOa

162

± 8a *

1.25 ± O.31 a ,b

1.02 ± 0.13 b

24 a

300

± 17 b *

1.00 ± 0.12 b

0.95 ± O.03 b

371 ± 52 b *

1.02 ± 0.14 b

0.70 ± 0.07 b

±

25

128

so

244 ± 53 b

Casein diets were fed for

± 0.26 a

1.64

± 0.35 a

10 days and values listed are from

before (B) or three hours after (A) presentation of the meal.
and muscle

leucine

concentrations were

Materials and Methods.

Values are means

±

determined

Plasma

as described in

SEM for 5 rats/group. Values

in vertical columns with different superscript letters are significantly different (p < 0.05).

*

Intracellular concentrations of leucine were calculated according to

the following formula:
intracellular [leu]

*

=

(nmol leu/g muscle) - (0.2)(nmol leu/ml plasma)
0.6

p < 0.05 compared to before meal values.
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Figure 1.

Linearity of Basal Muscle BCDH From Rats Fed Differing

Levels of Protein.

Rats

were

meal-fed

approximately 2 weeks.
feeding.
~l

diets

containing

0,

25 or 5070 casein for

Muscles were frozen in situ after 3 hours of

Basal BCDH activity was measured for 1, 2 or 5 min using 150

of enzyme extract, as described in Materials and Methods.

Values

represent mean ± SEM for enzyme activities from 4 rats per diet group.
~l

Identical values were obtained when 100

of enzyme extract was used

(data not shown).

1SO

~

I Enzyme

50%

25%

0%

o

2

1

MInutes

4

5

Figure 2.

Effect

of Preincubation Time on The Activation of MUscle

BCDH Isolated From Rats Fed Differing Levels of Protein.
Rats were treated as described in Figure 1.
was measured

as described in Materials and Methods.

were measured after 20, 40, 60 or 80
Mg+.

Total

Values represent

per diet group.

mean

BCDH activity

Enzyme activities

minutes preincubation

with 15 mM

± SEM for enzyme activities from 3-4 rats
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:Figure 3.

Chronic Effects of Dietary Protein on the Percentage of

Active MUscle BCDB and the Plasma Concentration of Leucine.

Rats were meal-fed diets containing 0, 9, 25 or 50% casein for 10
days.

On the tenth day, rats were killed before (open bars) or 3 hours

after (hatched bars) presentation of che meal.
had food

All postprandial rats

in their stomachs at the time of sacrifice.

Muscle BCDH

activity was measured as described in Materials and Methods and the
percent active complex (Panel A) computed as basal (in vivo) activity

divided by total (fully-active) activity x 100.
for each diet group are given in Table 1.

Total BCDH activities

Plasma leucine concentra-

tions (Panel B) were measured as described in Materials and Methods.
Before meal values represent means ± SEM for n = 5 (0%, 9%, 50% casein)
or 11 (25% casein) rats per group.
SEM for 8-10 rats per group.

*p

After meal values represent means ±

< 0.01 compared to before meal values.
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Effects of Sinale Meals of Varying Protein Content on Muscle

BCDB and the Plasma Concentration of Leucine.
Rats were meal-fed a diet containing adequate amounts of protein
(25% casein) for approximately 2 weeks, then killed before or 3, 6 or
12 hours after presentation of meals containing 9%, 25% or 50% casein.
Food was wi thdrawn 3 hours after presentation.

All rats had food in

their stomachs after 3 hours and no difference in food intake was
observed (14 ± 1 grams consumed, n

= 15

rats).

Muscle BCDH activity

(Panel A) and plasma leucine concentrations (Panel B) were measured as
described in Materials and Methods.
4-5 rats per group.

Values represent mean ± SEM for
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Figure 5.

Relationship of Skeletal Muscle BCDH Activity to the

Concentration of Circulating Leucine.
Values from the chronic (closed circles) and acute (open circles)
protein studies were taken from Figures 3 and 4 respectively.

The

curve shown was calculated from the best linear least squares fit which
was obtained after semi log transformation of the data (i. e.

log %

active complex vs plasma leucine) and yielded a linear correlation
coefficient of 0.848 (p < 0.001; n

= 107).

Analysis of the non-trans-

formed data by linear regression yielded a correlation coefficient of
0.788 (p < 0.001, n = 107).
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Figure 6.

Leucine-Mediated Activation of Muscle BCDB Isolated From

Rats Fed Adequate or Low Protein Diets.
Rats were fed a 9 or 25% casein diet ad libitum for approximately

2 weeks.

After an overnight fast, rats were infused with saline or 10,

25, 50 or 100

~mol

L-leucine per 100 g body weight via the tail vein.

Rats were killed 15 minutes after infusion and the percentage of BCDH
in the active state (Panel A) and plasma BCAA concentrations (Panels B
and C)

were measured as described in Materials and Methods.

represent means

± SEM for 4 rats per group.

Values

BCDH activation

in

response to leucine was significantly depressed in rats fed the low

protein diet (p < 0.01 after injection of 50 or 100
p <

o. 001

~mol

leucine/IOO gj

by comparison of the slopes of the regression lines for

leucine dose vs. BCnH activity).
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Chapter V
Effects of Diabetes and Starvation on Skeletal MUscle
Branched-Chain a-Keto Acid Dehydrogenase Activity
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SUJIIIDary

Branched-chain a-keto acid dehydrogenase (BCDH)* is rate limiting
for

branched-chain amino

regulated

by

acid

(BCAA)

catabolism

phosphorylation-dephosphorylation.

in muscle

and is

Circulating

BCAA

increase with insulinopenic diabetes and starvation despite accelerated
oxidation.

The activation state of BCDH was studied in rat hindlimb

muscles.

Diabetes

increased

circulating

(streptozotocin-induced
BCAA

4-5

-fold

and

and
BCDH

spontaneous
activity

BB/W)

·-3-fold.

Insulin treatment caused near normalization of circulating BCAA without
correcting

BCDH

activity.

Adrenalectomy

of

diabetics

(without normalizing) circulating BCAA and BCDH activation.

decreased
Starvation

caused mild, progressive increases in circulating BCAA and significant
activation of BCDH only after 4 days.

Leucine infusion activated BCDH

in control, fed rats; the response was blunted by diabetes and to a
lesser degree by starvation.

In isolated perfused hindlimbs (control

and diabetic) insulin did not affect BCDH significantly; perfusion with
leucine

activated

BCDH,

this

response

was

blunted

in

diabetics.

Activation of muscle BCDH may contribute to increased BCAA catabolism
in diabetes; blunted activation response to hyperleucinemia may spare
BCAA and contribute to their persistent elevation in plasma.
Introduction

Starvation and diabetes mellitus are conditions associated with
elevated circulating concentrations and increased metabolism of the
essential

'*

branched-chain

amino

acids

(BCAA),

leucine,

valine

and

Abbreviation used in this chapter are: BCAA, branched-chain

amino acids; BCDH, branched-chain a-keto acid dehydrogenase.
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isoleucine,

in

humans

(154,178,179)

and animal models

(6,139,182).

BCAA are unique among the essential amino acids as they are catabolized
extensively by extrahepatic tissues (77); skeletal muscle is thought to
playa major role in their disposal (5,67,77).

Skeletal muscles from

diabetic or starved rats incubated in vi tro (6,27,139) and perfused
hindlimbs from starved rats exhibit accelerated oxidation of BCAA (93).
Insulin addition had no effect on the oxidation of medium leucine by
diaphragms from diabetic (27) or normal (115) rats incubated in vitro
but

in

perfused hindlimbs insulin caused an inunediate increase in

leucine oxidation in preparations from starved rats but not from fed
rats (93).
In humans with type I diabetes mellitus the total body oxidation
of BCAA is markedly increased after insulin withdrawal (154,179).
BCAA uptake

by tissues

of

Yet,

the leg (predominantly muscle) after a

protein meal was greatly diminished in insulinopenic patients (188).
In normal humans BCAA uptake by the leg was found to be independent of
the

insulin

techniques

concentration
insulin

(53);

decreased

dose-dependent manner

but

in

experiments

leucine oxidation

in normal

humans

(175).

and

using

tracer

turnover

Similarly,

in a

insulin

decreased leucine release by liver and muscle in normal dogs (1).
The activity of branched-chain a-keto acid dehydrogenase complex
(BCDH), which catalyzes the irreversible oxidative decarboxylation of
the three branched-chain a-keto acids produced by reversible transamination of the BCAA, is considered rate-limiting for BCAA catabolism
by skeletal muscle (77,131).

BCDH, is an intrarnitochondrial multi-

enzyme complex analogous to other a-keto acid dehydrogenase complexes
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(e.g. pyruvate).

The activity of BCDH is regulated by a reversible

phosphorylation (inactive)-dephosphorylation (active) cycle, catalyzed
by

specific

enzymes.

BCDH

kinase

(77,142,150)

and

BCDH

phosphatase

(152)

In the postabsorptive state, BCDH is nearly totally inactive

in skeletal muscle of fed rats (Chapter 4,5,15,77,150,184), but muscle
BCDH activity increases rapidly following a protein meal (Chapter 4) or
i.v. infusion of small doses of leucine (5).

The activity of muscle

BCDH also increases after administration of large doses of isoleucine
but valine administration had no effect; this presumably reflects the

relative efficacy of the ketoanalogues of the BCAA at inhibiting BCDH
kinase (ketoleucine > ketoisoleucine

» ketovaline; refs. 142,150).

The activity of BCDH in rat kidney, and liver decreased while the
heart activity was unaffected by alloxan diabetes (151),

but BCDH

activity decreased in each of these tissues after 2 days of starvation

(151).

BCDH acti vi ty in rat muscle homogenates was unaffected by 3

days of starvation (184).

Considering that under physiological condi-

tions muscle BCDH is activated in response to increases in circulating

BCAA (Chapter 4,5), increased muscle BCDH activity would be expected in
diabetes or starvation.

Using diaphragm muscles incubated in vitro no

evidence for this could be obtained (6).

As mentioned above, the role

of insulin in regulating BCAA oxidation in muscle is not clear (1,27,
93,151); there is considerable evidence however that insulin retards

whole body BCAA catabolism (1,65).
protein

anabolic

effects

of

Whether this is due solely to the

insulin

(i.e.

stimulation of protein

synthesis and inhibition of protein degradation) decreasing BCAA flux
through BCDH, or BCDH activity is also affected remains unresolved.

In
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the

present

study a recently developed method for determining the

activity state of skeletal muscle BCDH in vivo was used to assess
changes in the activity of this enzyme complex during insulinopenic
diabetes and starvation t and to determine whether the activity of BCDH
is subject to acute regulation by insulin.

Materials and Methods.
Animals and Animal Treatments.

Male Wistar rats t strain WI(BR)t

were obtained from Charles River Laboratories t Wilmington t MA.

In some

studies a spontaneously diabetic strain of Wistar rats (BB/W) was used
(116); these were kindly supplied by Dr. Arthur Like of the University
of Massachusetts t

Worcester,

MA.

Rats were housed

in

an

animal

facility maintained at 25°C with a 12 hour light-12 hour dark cycle
(light from 0600 - 1800).
(Continental Grain t

Animals were maintained on Wayne Rodent Blox

Chicago, 1L) chow (2470 protein) and water, both

supplied ad libitum.
Diabetes mellitus was induced by a single intraperitoneal injection
of streptozotocin (120 mg/kg body weight in 0.05 M sodium citrate, pH
4.5).

Rats were tested for glycosuria with Tes-Tape (Eli Lilly & Co.,

Indianapolis t IN) the day following streptozotocin injection.

All rats

having greater than 2+ glycosuria were started on a regimen of 2 units
Humulin R insulin + 2 units Humulin N insulin (Lilly) injected subcutaneously each morning and evening.

Insulin therapy was maintained for

at least 60 hours then was discontinued 72 hours prior to sacrifice
when

untreated

diabetic

animals

were

studied;

these animals were

presumed to have been insulinopenic for about 60 hours.

Insulin-

treated animals were continued on the above insulin therapy but the
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morning of the experiment they received only 2 units Humulin R insulin
2-3 hours prior to sacrifice.
BB/W

rats were checked daily for glycosuria;

after glycosuria

developed plasma glucose was determined on blood obtained from the tail
veins.

Diabetic BB/W rats were treated with single daily injections of

1.2-2 units of protamine zinc insulin (Lilly), with the dose being
adjusted

to

maintain

glycosuria

less

than

3+ by Tes-tape and no

ketonuria as determined with Ketostix (Ames Division, Miles Laboratories, Elkhart, IN).

When untreated BB/W diabetic rats were studied

insulin therapy was discontinued 72 hours prior to sacrifice.
Adrenalectomy of diabetic rats was performed on the day of their
last

insulin

injection under

ether anesthesia either by bilateral

subcostal approaches or a dorsal approach.

Adrenalectomized animals

were supplied 0.9% (w/v) NaC! to drink ad libitum, and killed on the
third day after operation.

Rats weighed between 150 and 220 g at the

time of sacrifice, except for BB/W rats and the rats used for hindlimb
perfusions which typically weighed 280 to 350 g.
In some experiments central venous catheters were placed, under
light ether anesthesia, in an internal jugular vein of rats as previously described (6,76).
infusions.
volume

of

Catheters were placed -20 hrs prior to leucine

Leucine (0.1 M in 0.9% NaCl, 250

~mol/kg

b.w.) or an equal

saline was infused by jugular catheter or by tail vein

injection while rats were under light methoxyflurane (Pitman-Moore,
Washington Crossing, NJ) anesthesia.

Muscle and blood samples were

obtained as described below 15 min after leucine or saline infusion.
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BCDH Assay.

The method

to

assess

described in detail previously (5,15).
with

methoxyflurane

and

muscle

BCDH activity in vivo was

Briefly, rats were anesthetized

samples

frozen

in

situ at

liquid

nitrogen temperature. BCDH complex was extracted from powdered frozen
muscle in a detergent solution containing protease, phosphatase and
kinase inhibitors.

In vivo BCDH activity was estimated using the

freshly prepared complex and total (dephosphorylated) activity estimated after incubation at 37°C with 15 roM Mg2+; % active complex was
calculated from the ratio of in vivo to total BCDH activities in the
same muscle sample.

Enzyme acti vi ty was estimated as 14C02 release

from 0.1 mM a-keto[1- 14 C]isocaproate, as described previously (5,15).
Preliminary experiment established that total BCDH activity in muscle
extracts prepared from diabetic rats reached a maximum after 60 min
incubation with Mg2+, as previously found in normal rats (5).
Hindlimb

Perfusions.

Isolated

rat

hindlimb preparations were

prepared under pentobarbital anaesthesia and perfused essentially as
described by Jefferson (98).

The perfusion medium consisted of Krebs-

Henseleit buffer containing aged, rejuvenated human erythrocytes (12 g
hemoglobin per 100 m!),

4% (w/v) bovine serum albumin, and 5.5 mM

D-glucose; insulin when present was added at a concentration of 10 mU I
ml.

During preparation an additional tie was loosely placed around the

internal iliac vessels on one side.

After 15 min of perfusion one limb

was skinned, the gastrocnemius freeze-clamped in situ and removed. then
the flow rate was reduced, the internal iliac tie knotted and the limb
isolated by an umbilical tape tie at the level of the hip.

Leucine

infusion was started via a second pump connected piggy-back to the main
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perfusion line set to produce a final concentration of 1 mM in the
perfusate.

After 15 min additional perfusion the remaining gastroc-

nemius was frozen in situ and removed.
Amino acid and glucose determinations.

Blood samples were col-

lected by cardiac puncture using a heparin-treated syringe and plasma
deproteinized by addition of 0.1 volume of 50% (w/v) sulfosalicylic
acid.

Amino acids were extracted from frozen powdered muscle samples

by addition of -4 ml/g ice-cold 6% sulfosalicylic acid.

Particulate

material in all preparations was removed by centrifugation and the
samples stored at -20 oe or below until amino acid concentrations were
determined by reversed-phase high performance liquid chromatography of
the 2--phthalaldehyde derivatives with fluorescent detection as described previously (6).

Plasma glucose concentrations were determined by a

glucose oxidase method using a Beckman Glucose Analyzer 2 (Beckman
Instruments Inc .• Fullerton. CA).

Reagents were obtained from sources

described previously (5,6,15) and were reagent grade or higher quality.
Statistics.

All values are presented as mean ± SEM.

Comparisons

were conducted using either Student 1st test or analysis of variance
followed by a multiple comparison test (Peritz F test;
appropriate.

80), where

Analysis of values expressed in per cent was conducted

after angular transformation, to assure normal distribution (173).

Results
Muscle BCDH activity in stretozotocin-diabetic rats.

The in vivo

activity of muscle BCDH in rats rendered diabetic with streptozotocin
was about 2.S-fold greater than in normal, fed rats whether expressed
as

actual

activity or % active complex (Table 1, without leucine

112

infusion).

Plasma leucine was increased more than 5 fold by diabetes,

similar increases were observed in plasma valine and isoleucine
not shown).

(data

Insulin treatment of diabetic rats markedly decreased

plasma glucose concentrations (from 512 ± 37 mg/dl in diabetic rats to
70 ± 13 mg/dl in insulin treated diabetic rats compared with 171 ± 8 in
normal

rats) and decreased plasma leucine concentrations to normal

values (Table 1).

BCDH activity remained about 2-fold greater in

insulin-treated diabetic rats compared to normal rats; BCDH activity in
insulin-treated diabetic rats was greater than in normals, while the %
active complex in insulin-treated diabetics was between the values for
normals

and diabetics

and not different from ei ther.

Total BCDH

activities were the same in control, diabetic and insulin-treated rats.
Muscle BCDH activity in spontaneously diabetic rats.

Considering

the possibility that streptozotocin could have a direct effect on BCDH
or one of its regulatory enzymes, causing activation of BCDH which
could not be reversed wi th insulin therapy, the acti vi ty of BCDH was
investigated in a spontaneously diabetic strain of rats.

In the BB/W

diabetic rat BCDH activity was increased more than 3-fold over the
activity in non-diabetic litter-mate rats (Table 2).

Insulin therapy

did not return BCDH activity to the low levels present in non-diabetic
BB/W rats; in vivo BCDH activity in insulin-treated diabetics was not
different

from activities in either diabetic or non-diabetic rats,

while the % active complex in insulin-treated diabetics was different
from non-diabetic values

only.

In BB/W diabetic rats total BCDH

activity tended to be lower than in non-diabetic and insulin-treated
diabetic rats but this effect was not significant (Table 2).
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As in the streptozotocin-diabetic rats plasma BCAA were dramatically elevated in the BB/W diabetic rats compared to the non-diabetic
controls (Table 3).

Insulin therapy restored the plasma concentrations

of valine and isoleucine to normal.
in

insulin-treated BB/W diabetic

The plasma leucine concentration
rats was much lower than in the

diabetic rats but remained about 30% greater than in the non-diabetic
rats.

The calculated intracellular concentrations of BCAA in muscles

of non-diabetic rats were lower than the plasma concentrations, while
in the BB/W diabetic rats the calculated intracellular BeAA were not
significantly

different

from

the

plasma

concentrations.

Insulin

therapy decreased intramuscular BCAA concentrations to values that were
not different from the values in the non-diabetic rats.
Muscle BCDH activity in adrenalectomized streptozotocin-diabetic
rats.

Glucocorticoid administration was reported to activate muscle

BCDH (15) suggesting that endogenous corticosterone might contribute to
the activation of BCDH in diabetes; this possibility was investigated
in adrenalectomized,

streptozotocin-diabetic rats (Table 4).

BcnH activity was unaffected by adrenalectomy.

Total

In vivo BCDH activity

in diabetic rats was reduced by adrenalectomy but remained greater than
in normal, fed rats.

Similarly, plasma leucine in diabetic rats was

markedly reduced by adrenalectomy but remained greater than in the
control rats.
Effect of leucine infusion on muscle BCDH activity in streptozotocin-diabetic rats.

In previous studies muscle BCDH was activated by

moderate increases in circulating leucine concentration from dietary
protein intake (Chapter 4) or intravenous administration (Chapter 4,5).
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In view of the marked elevations in circulating and intracellular BCAA
in diabetic rats a greater increase in muscle BCDH activity than was
observed might be expected.

This suggests that diabetes renders muscle

BCDH refractory to activation by increased leucine.
of

leucine

(250

~mol/kg)

was

administered

i.v.

Therefore, a bolus
and BCDH activity

determined in muscle samples taken 15 minutes later (Table 1).
normal,

fed

rats

leucine

infusion

increased BCDH activity 4-foldj

plasma leucine increased about 50% from 151
zotocin-diabetic

rats

leucine

In

infusion

~M

to 234

~M.

In strepto-

increased BCDH activity and

plasma leucine by about 50% but neither increase was significantj

BCDH

activity increased only about 20% when expressed as % active complex.
Muscle BCDH activity increased greater than 2.S-fold in insulin-treated
streptozotocin-diabetics after leucine infusion and was indistinguishable from the activity observed in normal rats after leucine infusion.
Plasma leucine increased from 164 J..1M to 219 J..IM in insulin-treated
diabetic rats after leucine infusion which was similar to the increase
in normal rats.
Muscle BCDH activity in starved rats.

BCDH activity increased

slightly after one day of starvation, significant only when comparing %
active complex.

BCDH activity then was constant until the fourth day

of starvation when it increased abruptly (Table 5).

Plasma leucine

increased slowly over the time course of starvation and was significantly different from the value in the fed rats on the fourth day of
starvation (Table 5); a significant positive correlation was observed
between plasma BCAA and duration of starvation from 0 to 4 days (r =
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0.48, 0.56, 0.56 for valine, isoleucine and leucine, respectively; n

=

32; P < 0.01).
To assure that measurements of total BCDH activity in these studies
were not biased by different rates of BCDH activation in vitro as
reported for liver BCDH in rats fed a protein-deficient diet (138) and
for muscle BCDH in rats fed a low protein diet (Chapter 4), the time
course of activation of BCDH in vitro in the presence of Mg 2+ was
determined (Figure 1).

No apparent differences in the rate of activa-

tion or the total activity attained were observed between fed rats and
rats fasted 1 to 4 days; maximum BCDH values were attained at 60 min
and all

further determinations used 60 min incubations for determi-

nation of total BCDH activity.

In the small group of animals shown in

Figure 1, total BCDH activity per g muscle increased with the duration
of starvation; but when larger numbers of animals were analyzed the
trend toward increased total BCDH activity per g muscle remained but
was not significant (Table 5).
The response of BCDH to i.v. infusion of leucine was determined in
fed rats and after 2 or 4 days of starvat ion.

Muscle BCDH activity

increased

of

starvation.

after

leucine

infusion,

regardless

the

duration

of

The BCDH activity after 4 days of starvation was similar

to that in fed rats after leucine infusion and plasma leucine concentrations were similar in these two groups.
after

The BCDH activity attained

leucine infusion was indistinguishable in the fed and starved

rats but progressively greater plasma leucine concentrations were found
in the rats starved for 2 or 4 days (Table 5).
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Effect of insulin and leucine on perfused hindlimbs of normal and
streptozotocin-diabetic rats.
on

the

activity

of

BCDH

The acute effects of insulin and leucine

in muscle were

investigated

in

isolated,

perfused hindlimbs of normal and streptozotocin diabetic rats (Table
6).

Addition of insulin to the perfusate resulted in slightly higher

BCDH activities both in the absence and presence of leucine in hindlimbs from control and diabetic rats, but the insulin effect was not
significant in any of the groups (Table 6).

When BCDH activities in

all hindlimbs from diabetic rats were compared to all hindlimbs from
normal rats, in vivo BCDH activity in diabetic hindlimbs was doubled
(p

<

0.01); the effect of diabetes was not significant when values for

% active complex were compared, presumably due to differences in the
total BCDH activities.

Addition of leucine to the perfusate resulted

in activation of BCDH in hindlimbs from both control and diabetic rats;
no additional effect of insulin was observed.

After leucine infusion,

BCDH activity in hindlimbs from diabetic rats was less than in hindlimbs from normal rats; the effect was significant only when values for
% active

complex for

(Table 6).

all hindlimbs

receiving

leucine were compared

In this group of experiments total BCDH acti vi ty per g

muscle was greater in muscles from diabetic rats than in those from
normal

rats;

there

was

no

effect

of

insulin or

leucine on total

activity.

Discussion
The present

studies establish that muscle BCDH is activated in

diabetes as would be anticipated in view of the marked increases in
BCAA concentrations in plasma and intracellularly.

The degree of BCDH
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activation

observed

in

diabetic muscles was

less

than

previously

observed in normal rats with similar increases in plasma leucine from
dietary protein or leucine infusion.

For example, rats maintained on a

50% protein diet had postprandial plasma leucine concentrations greater
than 600

~M

and muscle BCDH greater than 40% active (Chapter 4) and in

fed rats maintained on a 24% protein diet infusion of 250

~mol

per kg body weight increased plasma leucine to 200 - 230
post infusion, with BCDH 7-10% active (Tables 1,5; ref. 5).

~M

leucine
15 min
Further-

more, muscle BCDH in diabetic rats did not activate after infusion of a
leucine dose which clearly activated BCDH in normal and insulin-treated
diabetic rats (Table 1), and BCDH in perfused hindlimbs of diabetic
rats activated less than in controls when leucine was added to the
perfusate (Table 6).

The latter observation suggests that decreased

activation of muscle BCDH by leucine in diabetes is not due to alterations in a hormonal response to leucine infusion, and this refractoriness persists for at least 30 min after the muscles are removed from
their metabolic milieu.

The activation of muscle BCDH in hindlimbs of

diabetic rats by perfusion with a leucine concentration which did not
activate muscle BCDH in vivo in diabetic rats (compare Tables 1 and 6)
suggests however that the metabolic milieu in vivo is at least partly
responsible for the blunted response to leucine.

Since the isolated

hindlimbs were perfused without added amino acids (except for leucine)
it is unlikely that the decreased response to leucine in diabetic rats
in vivo results solely from competition of leucine with other large
neutral amino acids (especially valine and isoleucine) for transport
across

the

plasmalemma.

Competition

for

transport

could however
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contribute

to

the

blunted

response

to leucine in vivo.

Impaired

activation of muscle BCDH by increased BCAA in diabetes may contribute
to the decreased clearance of exogenous leucine (51) and the decreased
BeAA uptake

by legs of diabetic patients following a protein meal

(188).
Insulin-therapy of diabetic rats tended to decrease plasma BCAA
toward normal values (Tables 1,3,4), but did not restore BCDH activity
despite nearly complete normalization of plasma BCAA by insulin in one
experiment (Table 1).

Persistent activation of muscle BCDH despite

insulin therapy was not due to a toxic effect of streptozotocin since
similar results were obtained in spontaneously diabetic rats (Table 2).
Increased BCDH activity in diabetic rats treated with insulin could be
due to elevation of the intracellular leucine concentration as suggested in the studies of BB/W rats (Table 3), coupled with improved
response of muscle BCDH to increased leucine (Table 1).

Plasma BCAA

were considered poor indicators of normalization of amino acid metabolism by skeletal muscle in humans with type I diabetes mellitus since
the

intramuscular

BCAA

(and

presumably branched-chain a-keto acid)

concentrations remained elevated despite their normalization in plasma
(18).

Furthermore, the intramitochondrial concentration of ketoleucine

(the transamination product of leucine, which is the substrate for BCDH
and

an

inhibitor

of

BCDH kinase)

may remain elevated even after

intracellular leucine has returned toward normal (92).

Our results are

consistent with reports in patients with type I diabetes demonstrating
that restoration of the metabolic parameters of leucine (catabolism and
flux as assessed by tracer techniques in vivo) to normal values was
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difficult to achieve with conventional or with insulin pump therapy
(154,179).

Based on measurements in heart, liver and kidney, Randle

estimated that whole body BCDH active complex decreased by 50% in
alloxan diabetes (151).

The increase in muscle BCDH activity reported

here suggests that muscle (and perhaps brain, ref. 21) are the probable
sites of increased BCAA oxidation in insulinopenic diabetes.
The near normalization of plasma BCAA in diabetic-adrenalectomized
rats

highlights the important role of glucocorticoids unopposed by

insulin in the dramatic increases in plasma BCAA observed in diabetes.
The nature of the glucocorticoid effect on circulating BCAA is not
clear.

The predominant effect of exogenous corticosterone on skeletal

muscle

protein

turnover in the rat was found to be inhibition of

protein synthesis with a much lesser effect on protein degradation
(130), although the effect of corticosterone on protein degradation was
enhanced in diabetic rats (177).

Protein synthesis was depressed by

50% or more in skeletal muscles of diabetic rats after about 72 hours
of insulinopenia and protein degradation was increased (134) but the
role of endogenous unopposed glucocorticoids in these changes remains
undefined.

The possibility of differences in food consumption between

the diabetic and diabetic-adrenalectomized rats was evaluated in one
experiment.

During the 24 hour period immediately prior to sacrifice

sham-operated diabetic rats consumed significantly more food than the
adrenalectomized group; 20.6 ± 1.6 g and 9.1 ± 2.6 g, respectively,
wi th 6 animals per group (p < 0.01).
period, (24

48 hours

after

During the preceding 24 hour

operation)

food

intakes were similar

between the two groups, 8.6 ± 1.9 g for adrenalectomized and 9.3 ± 1.6
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g for sham-operated diabetic rats.
assess

At present it is not possible to

the relative importance of these factors

protein synthesis

and protein degradation)

in

(food consumption t
the contribution of

corticosterone to BCAA elevation in the diabetic rat.

It appears

however that glucocorticoids contribute to diabetes associated hyperphagia.
In starvation, muscle BCDH activity was not increased significantly
until the fourth day (Table 5); previous studies also found no change
in muscle BCDH acti vi ty after 3 days of starvation (184) .
results

contrast

with

studies

of muscles

These

incubated in vitro and

perfused rat hindlimbs where oxidation of leucine was increased earlier
in starvation (6,93).

Recent studies of leucine metabolism in the rat

in vivo have established that whole body oxidation of leucine is indeed
accelerated after three days of starvation (182).

It seems unlikely

that the small increment in muscle BCDH activity observed in rats
starved for one to three days accounts for accelerated leucine oxidation early in starvation.

Accelerated oxidation of BCAA may be due to

increased flux through BCDH resulting from increased substrate supply,
since muscle and plasma branched-chain a-keto acids (and BCAA) were
increased in rats starved for three days (93,182) and leucine transamination was increased in diaphragm muscles after an overnight fast
(6).

The clearance of infused leucine is markedly decreased by three or
four days of starvat ion in man (51).

A dose-response relationship

between leucine infused and muscle BCDH activity has been reported in
rats (Chapter 4;5), and there was a direct correlation between plasma
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leucine concentration and BCDH activity (Chapter 4).

In the present

studies muscle BCDH in starved rats was readily activated by leucine
infusion,
plasma

unlike muscle BCDH in diabetic rats.

leucine

concentrations

in

the

starved

Comparison of the
rats

after

leucine

infusion (Table 5) with those in fed rats (Tables 1,5) suggest that in
starvation the normal relationship between plasma leucine and muscle
BCDH activity may be disturbed (i.e. BCDH in starved rats may be less
active after leucine infusion than it would be in fed rats at similar
plasma leucine concentrations).

Blunted response of muscle BCDH to

infused leucine was previously observed in rats fed a protein-restricted diet (Chapter 4).

Activation of muscle BCDH may play a greater

role in the accelerated oxidation of BCAA in diabetes than in starvation (compare Tables 1 and 2 to Table 5).

Although activation of BCDH

by increased BCAA (leucine probably being most important) apparently
can occur in both diabetes and fasting,

the response is less than

normal and may contribute to decreased clearance of exogenous leucine
in these states.
The

tendency toward

increased

total muscle BCDH activity with

duration of starvation (Table 5) is consistent with previous studies
which found increased total BCDH activity in the gastrocnemius after 3
days of starvation (184).
tissue weight

basis

Since the BCDH values are presented on a

it seems likely that increased total activity

represents sparing of BCDH from catabolism relative to other cellular
constituents rather than increased synthesis of BCDH during starvation.
Increased

total

BCDH activity per

g muscle was

also

observed

in

diabetic rats (Table 6) but this was not confirmed in other experiments
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(Tables

1,2).

There

is

no

apparent explanation for these discre-

pancies.
We were unable to detect a significant acute effect of
the activity
leucine in
diabetic

of muscle
studies

rats

BCDH or

of

its response to increased circulating

perfused

(Table

6).

insulin on

hindlimhs

Studies

from

normal, fed

or from

of leucine fluxes reported that

insulin rapidly stimulated leucine

oxidation by

rats starved

decreased oxidation by hindlimbs of

for three

fed rats (93).
through

The latter effect was thought to reflect decreased flux

BCDH

synthesis.

days, but

secondary

to

increased leucine utilization for protein

In a previous study, the BCDH

was unaffected

activity of

The

control rats,

present

studies

insulin is

(53).

by

skeletal

muscle

is

suggest

not required

muscle BCDH by increased leucine, supporting
catabolism

insulin withdrawal

that leucine

fasting or after

in diabetes, and the ensuing net protein catabolism

BCAA is
BCAA

in fed

relatively independent of insulin

increases BCAA available for oxidation, the

circulating

that,

for activation of

the concept

However, as insulin concentrations wane during

by increased

skeletal muscle

by administering large doses of insulin with glucose to

normal, fed rats (15).
diabetic or

perfused hindlimbs of

normal activation

of BCDH

blunted; this may contribute to the elevation of

observed

during

starvation

and

more

markedly in

insulinopenic diabetes.
The

mechanism

of

diminished

diabetes and starvation is

muscle

unresolved.

BCDH response to leucine in

The system

appears to become

refractory to normal regulation, e.g. in incubated diaphragms of fasted
and diabetic rats flux

through

BCDH

is

resistant

to

inhibition by
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pyruvate, which is normally observed in controls (6).

Since activity

of BCDH is dependent on the balance of the kinase and phosphatase
reactions alterations in the activity of these enzymes may be important.

Indeed, increased BCDH kinase activity was demonstrated in heart

mitochondria of rats starved for two days (55).

BCDH kinase is subject

to inhibition by branched-chain a-keto acids (particularly ketoleucine
(142), presumably accounting for the direct relationship between BCnH
activi ty and leucine concentration; Chapter 4, ref. 5), hence alterations

in mitochondrial branched-chain a-keto acid transport could

affect the relationship between leucine and BCDH activity.

Recent

reports indicate that branched-chain a-keto acid transport across the
mi tochondrial membrane is a regulated process (92,94) and may be a
rate-limiting step for BeM oxidation (94).

The phos.phatase reaction

appears to be regulated in a complex fashion involving an inhibitory
protein (152) but alterations in BCDH phosphatase activity in physiologic or pathologic states have not been reported.

Other factors which

may be altered in muscle cells by diabetes and fasting and may modulate
activation of BCDH directly or indirectly include: redox potential
(27), mitochondrial
protein

inhibitors

Further work

is

pH (94), acyl-CoAs (142,150,151), and possible
and

activators

of

the

complex

(131,141,150).

required to elucidate the mechanism(s) of altered

muscle BCDH response to leucine in diabetes and fasting.

Legend for Table 1.
Muscle BCDH

activity and plasma leucine concentration were deter-

mined in

normal, streptozotocin-diahetic

rats

described

as

under

Materials

received a leucine infusion
catheter as

described under

15 min after infusion.
group were

(250

values

for

an equal

all

Total BCDH activities were
or treatments

(40

±

compared to control;
compared to
e p < 0.05

Methods.
through

rats

for infusion,
volume of

a

jugular venous

were

some rats

saline.

not

in each

The results in

significantly different

not receiving leucine were combined.

not significantly

different between groups

= 43).

a

p < 0.005

p < 0.025 compared to control;

c

p

2 nmol / min / g muscle, n
b

One group of rats

Materials and Methods; samples were taken

saline-infused and non-infused rats
therefore

and

~mol/kg)

As a control

infused with

and insulin-treated diabetic

no leucine infusion;

d

< 0.025

p < 0.005 compared to diabetic;

compared to no leucine infusion.
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Table

1.

Effect of streptozocin-diabetes. insulin therapy and leucine

infusion on muscle BCDH activity and plasma branched-chain amino acids.

BCDH activity
(nmol/min/g muscle)

% Active
complex

Plasma
leucine
(uM)

n

Without leucine infusion
Control

0.9 ± 0.1

2.8 ± 0.3

151 ± 8

7

Diabetic

2.6 ± O.3 a

7.1 ± 1.1 h

819 ± 202 8

9

Insulintreated

2.1 ± 0.4 b

6.0 ± 1.2

164 ± I7 d

6

With leucine infusion
Control

4.1 ± O.3 c

11.4 ± 2.7 c

234 ± 13 c

6

Diabetic

4.1 ± 0.6

8.6 ± 1.1

1255 ± 251 8

8

Insulintreated

5.5 ± 1.3 c

14.5 ± 2.7 c

219 ± 13d ,e

7
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Muscle BCDH activity in BB/W rats.

Table 2.

BCDH Activity
(nmol/min/g muscle)

% Active

In vivo

Group

Total

complex

Control

1.2 ± 0.2

46 ± 7

2.7 ± 0.4

Diabetic

4.1 ± O.9 a

29 ± 5

11.7 ± 3.2 b

2.3 ± 0.6

38 ± 2

6.6 ± 1 . 6 a

Insulintreated

Muscle

BCDH activity was

determined in control,

diabetic,

and

insulin-treated diabetic BB/w rats as described under Materials and
Control rats were non-diabetic I i ttermates of the diabetic

Methods..

BB/w rats.
a

p

<

Values represent mean ± SEM from 6 animals in each group.
0.05

control value.

compared to control value; b

p

< 0.005 compared to

127

Table 3.

Plasma and muscle branched-chain amino acid concentrations in

BB/W rats.

Amino Acid Concentration (~M)
Leucine

Valine

Isoleucine

Plasma
Control

156 ± 14

248 ± 22

102 ± 10

Diabetic

648 ± lOla

886 ± 141 a

378

204 ± I1 b ,c

250 ± 14 c

120 ± Be

52 ± gd

Insulintreated

±

51 a

Muscle
Control

112 ± 13 d

158 ± 24d

Diabetic

660 ± 107 a

837 ± 120 a

Insulintreated

160 ± 23 c

207 ± 25 c

371

±

48 a

Sl± 13 c ,d

Plasma branched-chain amino acid concentrations were determined as
described under Materials and Methods.

Muscle intracellular branched-

chain amino acids were calculated from amino acid concentrations in
muscle extracts according to the formula:
intracellular

[BCAA]

(nmol BCAA/g muscle) - (O.2)(nmol BCAA/ml plasma)

=

0.6

Values represent the mean ± SEM from six animals.
to control value;

b p

a p

< 0.001 compared

< 0.05 compared to control value;

compared to diabetic value; d p

c p

< 0.005

< 0.05 compared to plasma value.
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Table 4.

Bffect of streptozotocin-diabetes and adrenalectomy on muscle

BCDB activity.

BcnH activity
(nmol/min/g muscle)

% Active
complex

Control

1.0 ± 0 . 1

2.7 ± 0.2

Diabetic

3.4 ± 0.5 a

9.3

Diabetic +
Adrenalectomy

± 1.7 a

5 . 2 ± 0 . 9a

Plasma
leucine

n

153 ± 6

12

719 ± 102 a

19

226 ± 20 a ,h

12

Muscle BCDH activity and plasma leucine concentration were determined

in

control,

streptozotocin-diabetic,

and

adrenalectomized

streptozotocin-diabetic rats as described under Materials and Methods.
Normal and streptozotocin-diabetic rats were subjected to sham operation with no differences in BCDH activity or plasma leucine results
compared to

unoperated animals,

the values

shown for

control and

diabetic animals were pooled from sham-operated and unoperated animals.
Total BCDH activities were not different between groups, 38 ± 1 nmol I
min I g muscle (n

= 43).

compared to diabetic.

a

p

< 0 . 025 compared to control; b p < 0.05

Legend for Table 5.
Muscle BCDH

activity and

plasma leucine

mined in fed rats and rats starved for 1 to
Materials and
(250

~mol/kg).

Methods.

concentration was deter4 days

as described under

One group of rats received a leucine infusion

samples were taken 15 min after infusion.

As a control

for infusion. some rats in each group were infused with an equal volume
of saline.

The results in saline-infused rats were not

different from

those in rats which received no infusion, therefore values for all rats
not receiving leucine were combined.
starvation; b

p < 0.05

no leucine infusion;

< 0.05

compared

a p < 0.01

compared to 4 days of

compared to fed rats; c p < 0.05

compared to

d p < 0.001 compared to no leucine infusion;

to 4

days of starvation; f p < 0.01

concentration in each group

of

rats

receiving

leucine

e p

plasma leucine
infusion was

different from the leucine concentrations in the remaining two groups.
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Table

5.

Effect of starvation on muscle BCDH and its activation by

leucine infusion.

BCDH activity
(nmol/min/g muscle)
Days of
starvation

Initial

Total

% Active
complex

Plasma
leucine

Without leucine infusion
39 ± 3

1.5 ± 0.2 a (7)

145 ±

1.0 ± 0.2

40 ± 2

2.5 ± 0.4 b (9)

158 ± lOe

(4)

2

0.9 ± 0.18

40

2.2 ± 0.3 a (14)

160 ± 8

(9)

3

0.9 ± 0.2a

43 ± 5

± 0.2 a

(7)

178 ± 8

(4)

4

2.2 ± 0.4

48

(13)

207 ± 20

(8)

(7)

0

0.6

1

± 0.18

±3

±4

2.0

4.6 ± 0.9

Be

(7)

With leucine infusion
0

2.6 ± O.4 d

37 ± 2

7.2 ± l.Od (8)

206 ± 6d ,f

2

2.2 ± O.2 d

40

±2

5.4 ± 0.6 d (8)

266 ± I1 d ,f (8)

4

4.2 ± O.Se

49

±2

9.1 ± 2.1

322 ± lS d ,f (7)

(8)

Legend for Table 6.
BCDH activity

was determined

in muscle samples from hindlimbs of

normal and streptozotocin-diabetic
Materials and

Methods.

rats

perfused

as

described under

Hindlimbs were perfused in the presence (+) or

absence (-) of 10 mU/ml insulin.

A first sample was taken after 15 min

of perfusion (before leucine addition) and a second sample was taken 15
min later after exposure to 1 mM leucine.
no difference

normal

experiments showed

in BCDH activity between samples obtained after 15 or 30

min of perfusion.
for

Initial

or

Combined values
diabetic

(+/-) represent

hindlimbs

the pooled values

perfused both in the presence and

absence of insulin.

Total BCDH activity was significantly different

(p < 0.01) between

hindlimbs of

(n

= 22)

normal and diabetic rats. 25.6 ± 1.5

vs. 34.9 ± 1.5 nmol/min/g muscle (n

BCDH activity
a p < 0.001

was unaffected
compared to

leucine addition;

C

respectivelYi total

by insulin or leucine in either group.

normal rat;

p < 0.01

= 20),

b p

< 0.001

compared to normal rat.

compared to before
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Table 6.

Effects of leucine and insulin on muscle BCDB activity in

isolated perfused rat

Insulin

bindl~bs.

BCDH Activity
{nmol/ min Ig muscle}

% Active

complex

n

Before leucine addition
0.9 ± 0.2

3 .. 6 ± 0.7

6

+

1.3 ± 0.3

4.9 ± 1.0

5

-/+

1.1 ± 0.2

4 . 2 ± 0.6

11

1 .. 9 ± 0.4

4.9 ± 0.6

5

+

2.4 ± 0 .. 2

6 . 5 ± 0.9

5

-1+

2.2 ± O.Za

5.7 ± 0.6

10

Normal

Combined
Diabetic

Combined

After leucine addition
10.8 ± 2.Sb

42.6 ± lO.4 b

6

+

12.4 ± 1.9 b

52.7 ± 7.0 b

5

-/+

11.5 ± 1.7 b

43.2 ± 3.S b

11

o.a b

18.6 ± 3.0 b

5

+

9.3 ± 2.3 b

30.6 ± 5.6 b

5

-/+

7.7 ± 1.3 b

24.6 ± 3.6 btc

Normal

Combined

6.4 ±

Diabetic

Combined

10
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Table 6.

Effects of leucine and insulin on muscle BCDB activity in

isolated perfused rat

Insulin

bindl~bs.

BCDH Activity
(nmoll min Ig muscle)

% Active
complex

n

Before leucine addition
0. 2

3.6 ± 0.7

6

+

1.3 ± 0.3

4.9 ± 1.0

5

-/+

1.1 ± 0.2

4.2 ± 0.6

11

1.9

± 0.4

4.9 ± 0.6

5

2.4

± 0.2

6.5 ± 0.9

5

5.7 ± 0.6

10

0.9

Normal

Combined
Diabetic

+
Combined

-/+

±

2.2 ± O.2 a
After leucine addition
10 . 8 ± 2.Sh

42.6 ± lO.4 b

6

+

12.4 ± 1.9 b

52.7 ± 7.0 b

5

-/+

11.5 ± 1.7 b

43.2 ± 3.S b

11

6.4 ± O.Sb

18.6 ± 3.0 b

5

+

9.3 ± 2.3 b

30.6 ± S.6 b

5

-/+

7.7 ± 1.3 b

24.6 ± 3.6 b ·,c

Normal

Combined
Diabetic

Combined

10
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Figure 1.

Time course of in vitro activation of muscle BCDH from fed

and starved rats.
Muscle BCDH was prepared from fed rats and rats starved for 1 to 4
days as described under Materials and Methods.

BCDH was incubated at

37°C in the presen ce of 15 mM Mg 2+ and samples removed every 20 minutes
for

determination

of

BCDH

activity

Methods and in references 2 and 4.
per group .

as

described

in Materials and

Values are mean ± SEM for 3-7 rats

Curves are shown for fed animals and from the means of all

starved animals at each point.
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Concluding Remarks
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The previous chapters have presented studies of certain aspects of
branched-chain amino acid catabolism by skeletal muscle.

At this point

some consideration will be given to how these findings relate to the
whole body economy of the BCAA.

Since synthesis de novo is not an

option (BCAA being essential), homeostasis of the BCAA must involve
disposal of the amino acids during times of surfei t and conservation
during times of deficiency.
regulation

of

In this framework it should be clear that

branched-chain

a-keto

acid

central to homeostatic control of the BCAA.

dehydrogenase

(BCDH)

is

To better understand the

role of skeletal muscle in whole body disposal of BCAA the interactions
between muscle and other tissues is also necessary.
In the postabsorptive fed rat, which might be considered a neutral
(i.e.

no

deficiency and no

excess) condition with regard to BCAA

homeostasis, the activity of BCDH in muscle is very low (Chapters 3-5)
while hepatic and

renal

BCDH

is very active (69,137,185).

Under

postabsorptive conditions it is likely that muscle is a relatively
unimportant site for BCAA oxidation and instead is a source of circulating branched-chain a-keto acids which are oxidized by liver, kidney
and perhaps other tissues.

Once protein is ingested and BCAA enter the

systemic circulation BCDH activity in muscle increases rapidly (Chapter
4), but except for adipose tissue (64) there is no evidence indicating
that BCDH activity in other tissues increases postprandially.
importance of muscle,

relative to other tissues, as a site of BCAA

oxidation should therefore increase in the postprandial period.
must

The

It

be noted however that circulating branched-chain a-keto acids

increase in the postprandial period thus indicating that BCAA disposal
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by liver may also increase during this period.

As circulating BCAA

decline during the postprandial period BCDH activity in muscle declines
in parallel (Chapter 4) and so should its role in BCAA oxidation.
When rats were fed a high protein diet chronically, muscle BCDH
activity~

along with circulating BCAA concentrations, increased to a

new "steady-statetl value during the postabsorptive period (Chapter 4).
BCDH activity in liver and kidney however were decreased slightly by a
high protein diet (137,151).

Muscle therefore may be a central organ

in the disposal of excesses of BCAA.

The capacity of muscle to dispose

of excess BCAA may be counterproductive when leucine alone is in
excess. Under these conditions muscle BCDH activity increases (Chapter
2) but since valine and isoleucine are also catabolized by BCDH they
may be removed in excess and become limiting.

Indeed, this may be the

explanation for the observed depression of growth rate in animals fed
diets' with excesses of leucine alone (77).
In times of diminished supply, such as chronically feeding a low
protein diet postabsorptive muscle BCDH activity was the same as in
rats fed a normal diet (Chapter 4), it should be recalled though that
this activity is very low (1-2% of total).

BCDH activity in liver and

kidney was markedly decreased by a low-protein diet (137,151).

More

remarkable though is the observation that the activation response of
muscle BCDH to circulating BCAA from meal ingestion or leucine infusion
is impaired (Chapter 4).

This suggests that muscle adapts to times of

diminished BCAA supply in a manner to slow or diminish muscle oxidation
of BCAA when they are acquired.
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The results of studies of BeAA catabolism in diabetes or during
starvation (Chapter 2 and 5) suggest that the response of muscle BCDH
to BCAA is blunted as it is in rats fed a low protein diet.

Further-

more, BCDH activity in liver and kidney is also decreased in diabetes
and

during

starvation

(137,151).

Despite the

changes

in muscle

response to BCAA in diabetes and starvation, when BCAA concentrations
are markedly elevated, muscle BCDH acti vi ty increases.

Under these

conditions diminished BCDH activity in liver and kidney may be more
important

to

conservation of

increased

capacity

of

the BeAA,

muscle

to

especially in view of the

transaminate

BCAA

(Chapter

2).

Although whole body BCAA oxidation increases in insulinopenic diabetes
(154,179) and starvation (4), plasma BCAA concentrations also increase
suggesting that their oxidation must nonetheless be restrained.

It is

unclear why the balance of oxidation and supply in diabetes and fasting
is altered from the steady-state which obtains in normal rats, thus
increasing plasma BCAA.

It was postulated that increased BCAA may be

beneficial in these conditions by maintaining basal insulin secretion
which along wi th direct effects of BCAA could serve to maintain or
augment protein synthesis (151).

Furthermore, increased catabolism of

BCAA in muscle may serve to restrain proteolysis (127) which is
increased in these conditions (154,178).

List of References
1. Abumrad NN, Jefferson LS, Rannels SR, Williams PE, Cherrington AD,
Lacy WW.

Role of insulin in the regulation of leucine kinetics in

the conscious dog.

J Clin Invest 70: 1031-1041, 1982

2. Abumrad NN, Robinson RP, Gooch RR, Lacy WW.

The effect of leucine

infusion on substrate flux across the human forearm.

J

Surg Res 32:

453-463, 1982
3.

Adibi SA,

Peterson JA, Krzsik BA.

Am J Physiol 228: 432-435, 1975

aminase activity by dietary means.

4. Adibi SA, Stanko RT, Morse EL.

Modulation of leucine trans-

Modulation of leucine oxidation and

turnover by graded amounts of carbohydrate intake in obese subjects.
Metabolism 31: 578-588, 1982
5.

Aftring RP,

Block KP, Buse MG.

Leucine and isoleucine activate

skeletal muscle branched-chain a-keto acid dehydrogenase in vivo.
J Physiol

Am

250: E599-E604, 1986

6. Aftring RP, Manos PN, Buse MG.

Catabolism of branched-chain amino

acids by diaphragm muscles of fasted and diabetic rats.

Metabolism

34: 702-711, 1985
7. Aftring RP, May ME, Manos PN, Buse MG.

Regulation of a-ketoiso-

caproate oxidation in liver mitochondria by adenine nucleotides and
calcium.

J Biol Chern 257: 6156-6163, 1982

8. Aki K, Ogawa K, Ichihara A.

Transaminases of branched-chain amino

acids. IV. Purification and properties of two enzymes from rat liver.
Biochem Biophys Res Comm 159: 276-284, 1968

139

9. Albina JE, Shearer J, Mastrofrancesco B, Caldwell MD.
metabolism after

~-carrageenan

Amino acid

injury to rat skeletal muscle.

Am J

Physiol 250: E24-E30, 1986

10. Anderson HL, Benevenga NJ, Harper AE.

Associations among food and

protein

plasma amino acids.

intake,

serine dehydratase and

Am J

Physiol 214: 1008-1013, 1968

11. Benevenga NJ, Steele RD.
of amino acids.

Adverse effects of excessive consumption

Ann Rev Nutr 4: 157-181, 1984

12. Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB.

Reduc-

tion of cerebrospinal fluid phenylalanine after oral administration of
valine, isoleucine, and leucine.
13. Block KP, Harper AE.

Pediatr Res 16: 751-755, 1982

Valine metabolism in vivo: Effects of high
Metabolism 33: 559-566, 1984

dietary levels of leucine and isoleucine.

14. Block KP, Heywood BW, Buse MG, Harper AE.

Activation of rat liver

branched-chain

vivo

adrenaline.

2-oxo

acid

dehydrogenase

in

by

glucagon

and

Biochem J 232: 593-597, 1985

15. Block KP, Richmond WB, Hehard WB, Buse MG.

Glucocorticoid-mediated

activation of muscle branched-chain a-keto acid dehydrogenase in vivo.

Am J Physiol 252: E396-E407, 1987
16. Block KP, Soemitro S, Heywood BW, Harper AE.

Activation of liver

branched-chain a-ketoacid dehydrogenase in rats by excesses of dietary
amino acids.

J Nutr 115: 1550-1561, 1985

11. Block KP.

acid metabolism

Dietary and hormonal control of branched-chain amino
in the rat.

Wisconsin-Madison pp 1-258, 1983

Ph.D.

dissertation.

University of

140
18. Borghi L, Lugari R, Montanari A, Dall'Argine P, Elia GF, Nicolotti

V, Simoni I,Parmeggiani A, Novarini A, Gnudi A.

Plasma and skeletal

muscle free amino acids in type I, insulin-treated diabetic subjects.
Diabetes 34: 812-815, 1985
19. Bower RH, Fischer JE.

Nutritional management of hepatic encepha-

Adv Nutr Res 5: 1-11, 1983

lopathy.

20. Brosnan JT, Forsey RGP, Brosnan ME.

Uptake of tyrosine and leucine

in vivo by brain of diabetic and control rats.

Am

J Physiol 247: C450-

C453, 1984
21.

Brosnan ME t

fraction

of

Lowry A,

Brosnan JT.

branched-chain

Diabetes

increases

2-oxoacid dehydrogenase

active

in rat brain.

Diabetes 35: 1041-1043, 1986

22. Buffington CK, Waymack PP, DeBuysere MS, Olson, MS.

The regulation

of the branched chain alpha-keto acid dehydrogenase complex in heart.
In Walser,

M, Williamson, JR (eds.): Metabolism and Clinical Impli-

cations of Branched Chain Amino and Ketoacids, New York,

Elsevier

North Holland, pp 85-90, 1981

23. Buse MG, Atwell R, Mancusi V.

In vivo effect of branched chain

amino acids on the ribosomal cycle in muscles of fasted rats.

Horm

Metabol Res 11: 289-292, 1979
~4~ ~~~e MG~ B!i~ers

JF\ Drier C\ Buse JF.

The effect of epinephrine,

glucagon and the nutritional state on the oxidation of branched chain
amino acids and pyruvate by isolated hearts and diaphragms of the rat.
J

BioI Chern 248: 697-706, 1973

25. Buse MG, Biggers JF, Friderici KH, Buse JF.

Oxidation of branched

141
chain amino acids by isolated hearts and diaphragms of the rat .. The
effect of fatty acids, glucose, and pyruvate respiration.

J BioI Chern

247: 8085-8096, 1972
26. Buse MG, Buse J.
synthesis

Effect of free fatty acids and insulin on protein

and amino acid metabolism of

isolated rat

diaphragms.

Diabetes 16: 753-764, 1967

27. Buse MG, Herlong HF, Weigand DA.

The effect of diabetes, insulin

and the redox potential on leucine metabolism by isolated rat hemidiaphragm.

Endocrinology 98: 1166-1175, 1976

28. Buse MG, Jursinic 5, Reid SC.
acid oxidation

in

Regulation of branched chain amino

isolated muscles,

nerves,

and aortas of rats ..

Biochem J 148: 363-374, 1975
29.

Buse MG,

Reid SSe

turnover in muscle.

Leucine.

A possible

regulator of protein

J Clin Invest 56: 1250-1261, 1975

30. Buse MG, Weigand DA, Peeler D, Hedden MP.

The effect of diabetes

and the redox potential on amino acid content and release by isolated
rat hemidiaphragms.

Metabolism 29: 605-616, 1980

31. Buse MG, Weigand DA.

Studies concerning the specificity of the

effect of leucine on the turnover of proteins in muscles of control
and diabetic rats.

32. Buse MG.

Biochim Biophys Acta 475: 81-89, 1977

In vivo effects of branched chain amino acids on muscle

protein synthesis in fasted rats.
33. Buxton DB, Olson MS.

Horm Metabol Res 13: 502-505, 1981

Regulation of the branched chain a-keto acid

and pyruvate dehydrogenases in the perfused rat heart.

257: 15026-15029, 1982

J

BioI Chem

142
34.

New Eng J Med. 282: 668-675,

Starvation in man.

Cahill GF Jr.

1970
35. Chaplin ER, Goldberg AL, Diamond I.

slices and nerve endings.
36.

Cohen P.

Leucine oxidation in brain

J Neurochem 26: 701-707, 1976

The role of protein phosphorylation in the hormonal

control of enzyme activity.

Eur J Biochem 151: 439-448, 1985

37. Cook KG, Bradford AP, Yeaman SJ, Aitken A.
kidney

branched-chain

phosphorylation.

2-oxoacid dehydrogenase complex by reversible

Eur J Biocbem 145: 587-591, 1984

38. Cook KG, Bradford AP, Yeaman SJ.
bovine

kidney

Regulation of bovine

branched-chain

2-oxo

Resolution and reconstitution of
acid

dehydrogenase

complex.

Biochem J 225: 731-735, 1985
39. Damuni Z, Humphreys JS,

inhibitor of

Reed LJ.

[branched-chain a-keto

from bovine kidney mitochondria.

A potent, heat-stable protein

acid

dehydrogenase]-phosphatase

Prod Natl Acad Sci USA 83: 285-289,

1986

40. Damuni Z, Merryfield ML, Humphreys JS, Reed LJ.
properties

of

branched-chain a-keto

from bovine kidney.
41.

Damuni

Z,

Purification and

acid dehydrogenase

phosphatase

Froe Natl Aead Sci USA 81: 4335-4338, 1984

Tung HYL,

Reed LJ.

Specificity of the heat-stable

inhibitor of the branched-chain a-keto acid dehydrogenase phosphatase.
Biochem Biophys Res Comm 133: 878-883, 1985

42. Dancis J, Hutzler H, Cox RP.

Enzyme defect in skin fibroblasts in

intermittent branched-chain ketonuria and in maple syrup urine disease.
Biochem Med 2: 407-411, 1969

143
43. Dancis J t

Levitz M.

metabolism.

In:

The

Abnormalities of branched-chain amino acid
Metabolic

Basis

for

Inherited Disease,

3rd

Edition, eds. Stanbury JB, Wyngaarden JB, Frederickson JS. New York:
Mc-Graw Hill Book Co., pp 426-439 , 1972
44.

Daniel PM,

Pratt DE,

Spargo E.

Metabolic homeostatic role of

muscle and its function as a store of protein.
45.

Danner DJ,

characterization

Lancet 2: 446-448, 1977

Lenunon SK, Besharse Je, Elsas LJ.
of

branched

chain

a-ketoacid

Purification and
dehydrogenase

from

bovine liver mitochondria.

J BioI Chern 254: 5522-5526, 1979

46. Dawson AG, Hird FJR.

Oxidation of L-valine by rat kidney prepa-

rations.

Arch Biochem Biophys 127: 622-626, 1968

47. Dawson AG, Hird FJR, Morton DJ.
and kidney.

Arch Biochem Biophys 122: 426-433, 1967

48. Dixon JL, Harper AE.
and

hepatic

Oxidation of leucine by rat liver

Effects on plasma amino acid concentrations

branched-chain

a-keto

acid

dehydrogenase

feeding rats diets containing 9 or 50% casein.

activity

of

J Nutr 114: 1025-1034,

1984

49. Duggleby RG.

A nonlinear regression program for small computers.

Anal Biochem 110: 9-18, 1981
50. Edington DW, Ward GR,

Saville WA.

Energy metabolism of working

muscle: concentration profiles of selected metabolites.

Am J Physiol

224: 1375-1380, 1973

51. Elia M, Farrel R, Ilic V, Smith R, Williamson DH.

The removal of

infused leucine after injury, starvation and other conditions in man.
Clin Sci 59: 275-283, 1980

144

52. Elia M, Livesey G.

Effects of ingested steak and infused leucine

on forelimb metabolism in man and the fate of the carbon skeletons and
amino groups of branched-chain amino acids.

Clin Sci 64: 517-526, 1983

53. Eriksson LS, Hafenfeldt L, Felig P, Wahren J.

Leucine uptake by

splanchnic and leg tissues in man: relative independence of insulin
levels.

Clin Sci 65: 491-498, 1983

54. Eriksson S, Hagenfeldt L, Wahren J.

A comparison of the effects of

intravenous infusion of individual branched-chain amino acids on blood
amino acid levels in man.

Clin Sci 60: 95-100, 1981

55. Espinal J, Beggs M, Patel H, Randle PJ.
diet

and

starvation

on

the activity of

Effects of low-protein

branched-chain 2-oxo acid

dehydrogenase kinase in rat liver and heart.

Biochem J 237: 285-288,

1986

56. Espinal J, Patston PA, Fatania HR, Lau KS, Randle PJ.

Purification

and properties of a protein activator of phosphorylated branched-chain
2-oxo acid dehydrogenase complex.
57.

Fatania HR,

Lau KS,

Biochem J 225: 509-516, 1985

Randle PJ.

Activation of phosphorylated

branched chain 2-oxoacid dehydrogenase complex.

FEBS Letts 147: 35-39,

1982

58. Fatania HR, Lau KS, Randle PJ.
branched-chain

Inactivation of purified ox kidney

2-oxoacid dehydrogenase complex by phosphorylation.

FEBS Lett 132: 285-288, 1981
59. Feller DD,

Feist E.

The conversion of leucine carbon into C02,

fatty acids and other products by adipose tissue.

Acta 62: 40-44, 1962

Biochim Biophys

145

60.

Fernstrom

JD,

Larin F,

Wurtman

RJ.

Daily variations in the

concentrations of individual amino acids in rat plasma.

Life Sci 10:

813-819, 1971

61.

Fernstrom JD.

Dietary effects

relationship to appetite regulation.

on brain

serotonin synthesis:

Am J Clin Nutr 42:

1072-1082,

1985

62. Fischer JE, Funovics J, Aguirre At James JH, Keane JM, Wesdorp RIC,
Yoshimura N, Westham Th.
encephalopathy.

The role of plasma amino acids in hepatic

Surgery 78: 276-290, 1975

63. Freedland RA, Szepsei B.
factors.

Control of enzyme activity: Nutritional

In: Enzyme Synthesis and Degradation in Manunalian Systems,

M. Recheigl, ed., University Park Press, Baltimore, 103-140., 1971
64.

Frick GP,

Tai L-R, Blinder L, Goodman HM.

L-Ieucine activates

branched-chain a- keto acid dehydrogenase in rat adipose tissue.

J

BioI Chern 256: 2618-2620, 1981

65. Fukugawa NK, Minaker KL, Rowe JW, Goodman MN, Matthews DE, Bier DM,
Young VR.

Insulin-mediated reduction of whole body protein breakdown.

Dose-response effects on leucine metabolism in postabsorptive men.

J

Clin Invest 76: 2306-2311, 1985
66. Fulks RM, Li JB, Goldberg AL.

Effects of insulin, glucose, and

amino acids on protein turnover in rat diaphragm.

J BioI Chem

250: 290-298, 1975

67. Gelfand RA, Glickman MG, Jacob R, Sherwin RS, DeFronzo RA.

Removal

of infused amino acids by splanchnic and leg tissues in humans.
Physiol 250: E407-E413, 1986

Am J

146

68. Gey GO, Gey MK.

The maintenance of human normal and tumor cells in

continuous culture.

Am J Cancer 27: 45-76, 1936

69. Gil1im SE, Paxton R, Cook GA, Harris R.

Activity state of the

branched-chain a-ketoacid dehydrogenase complex in heart, liver. and
kidney of normal, fasted, diabetic, and protein-starved rats.

Biochem

Biopbys Res Carom 111: 74-81, 1983
70. Goldberg AL, Odessey R.

from fed and fasted rats.

Oxidation of amino acids by diaphragms

Am J Physiol 223: 1384-1391, 1972

Goodman MN, Berger M, Ruderman NB.

71.

skeletal muscle at rest.
and free fatty acids.

Glucose metabolism in rat

Effect of starvation, diabetes, ketone bodies

Diabetes 23: 881-888, 1974

72. Goto M, Shinno H, Ichihara A.

Isozyme patterns of branched-chain

amino acid transaminase in human tissues and tumors.

Gann 68: 663-667,

1977
73.

Guyton

AC.

Textbook

of

Medical

Physiology,

Sixth

Edition.

Philadelphia: WB Saunders Company, p.122, 1981
Hagg S, Morse EL, Adibi SA.

74.

Effect of exercise on rates of

oxidation, turnover, and plasma clearance of leucine in human subjects.

Am

J Physiol 242: E407-E410, 1982

75. Hagg SA, Taylor SI, Ruderman NB.
skeletal

muscle.

Pyruvate

diabetes and exercise.

dehydrogenase

activity

in

starvation,

Biochem J 158: 203-210, 1976

76. Harms PB, Ojeda SR.

A rapid and simple procedure for chronic

cannulation of rat jugular vein.

J Appl Physio! 36: 391-392, 1974

77. Harper AE, Miller RH, Block KP.
lism.

Glucose metabolism in perfused

Ann Rev Nutr 4: 409-454, 1984

Branched-chain amino acid metabo-

147

78. Harper AE, Zapalowski C.
lism of

the

branched

Interorgan relationships in the metabo-

chain amino and

«-ketoacids.

In Walser M,

Williamson JR (eds.): Metabolism and Clinical Implications of Branched
Chain Amino and Ketoacids, New York, Elsevier/North Holland, pp 195-

203, 1981
79. Harper AE.

Effect of variations in protein intake on enzymes of

amino acid metabolism.
80.

Harper,

JF .

Can J Biochem 43: 1589-1603, 1965

Peritz'

F

test:

Basic program of robust multiple

comparison test for statistical analyses of all differences among group
means.
81.

Comput BioI Med 14: 437-445, 1984

Harris RA,

Paxton R, Goodwin GW, Powell

SM.

Regulation of the

branched-chain 2-oxo acid dehydrogenase complex in hepatocytes isolated
from rats fed on a low-protein diet.
82. Harris RA,

Biochem J 234: 285-294, 1986

Paxton R, DePaoli-Roach AA.

Inhibition of branched-

chain a-ketoacid dehydrogenase kinase activity by a-chloroisocaproate.
J

BioI Chern 257: 13915-13918, 1982

83. Hayashi M, Ohnishi H, Kawade Y, Muto Y, Takahashi Y.
utilization

of

branched-chain

amino

acids

by

skeletal

Augmented
muscle

in

decompensated liver cirrhosis in special relation to anunonia detoxication.

Gastroenterol Jap 16: 64-70, 1981

84. Hedden M, Buse MG.
synthesis in muscle.

Leucine transamination rates may affect protein
In Walser M, Williamson JR (eds.): Metabolism and

Clinical Implications of Branched Chain Amino and Ketoacids, New York,
Elsevier/North Holland, pp 233-238, 1981

85. Heffelfinger SC, Sewell ET, Danner DJ.

Identification of specific

148

subunits

of

highly

purified

bovine

liver

branched-chain

ketoacid

Biochern 22: 5519-5522, 1981

dehydrogenase.

86. Herlin PM, James JH, Gimmon Z. Fischer JE.

Combined or individual

administration of branched-chain amino acids following total hepatectomy in the rat: Effects on amino acids and indoleamines in brain.

J

Par Ent Nutr 6: 383-387, 1982

87. Hoffer LJ, Yang RD, Matthews DE, Bistrian BR, Bier DM. Young VR.
Effects of meal consumption on whole body leucine and alanine kinetics
in young adult men.

Br J Nutr 53: 31-38, 1985

88. Hopper S, Segal HL.
transaminase.

Kinetic studies of rat liver glutamic-alanine

J BioI Chern 237: 3189-3195, 1962

89. Hutson NJ, Kerbey AL, Randle PJ, Sugden PH.

Conversion of inactive

(phosphorylated) pyruvate dehydrogenase complex into active complex is
inhibited by alloxan diabetes or starvation in the rat. Biochem J 173:

669-680, 1978
90. Hutson SM, Cree TC, Harper AE.

Regulation of leucine and a-keto-

isocaproate metabolism in skeletal muscle.

J BioI Chern 253: 8126-8133,

1978
91. Hutson SM, Harper AE.

Blood and tissue branched-chain amino and

a-keto acid concentrations: effect of diet, starvation and disease.

Am

J Clin Nutr 34: 173-183 , 1981

92.

Hutson

SM,

Rannels

SL.

Characterization of

transport system for branched-chain a-keto acids.

a mitochondrial
J BioI Chern 260:

14189-14193, 1985
93. Hutson SM, Zapalowski C, Cree TC, Harper AE.

Regulation of leucine

149
and a-ketoisocaproic acid metabolism in skeletal muscle.
J BioI Chern 255: 2418-2426, 1980

starvation and insulin.
94. Hutson SM.
skeletal

95.

Branched-chain a-keto acid oxidative decarboxylation in

muscle

mitochondrial

Effects of

Effect

mitochondria.

of

isolation

procedure and

J Biol Chern 261: 4420-4425, 1986

pH.

Ichihara A, Noda C, Tanaka K.

Oxidation of branched chain amino

acids with special reference to their transaminase.

In Walser M,

Williamson JR (eds): Metabolism and Clinical Implications of Branched
Chain

Amino

and

Ketoacids,

New

York,

Elsevier/North

Holland,

pp

227-231, 1981
96. Ichihara A.
Transaminases.

Aminotransferases of branched-chain amino acids.

P. Christen, and D.E. Metzler, editors.

In:

John Wiley and

Sons; New York, 430-439. , 1985
97. Ikeda T, Konishi Y,

amino

acids.

mitochondria.

XI.

Leucine

(methionine)

transaminase

of

rat

liver

Biochim Biophys Acta 445: 622-631, 1976

98. Jefferson LS.
of rat hemicorpus.
99.

Transaminase of branched-chain

Ichihara A.

A technique for perfusion of an isolated preparation

Meth Enzymol 29: 73-82, 1975

Kadowaki H, Knox WE.

Cytosolic and mitochondrial isoenzymes of

branched-chain amino acid aminotransferase during development of the
rat.

Biochem J 202: 777-783, 1982

100. Kasperek GJ, Dohm GL,

Snider RD.

keto acid dehydrogenase by exercise.
101. Kerbey AL, Randle PJ.

dehydrogenase kinase
alloxan-diabetic rats.

Activation of branched-chain

Am J Physiol 248: R166-R171, 1985

Thermolabile factor accelerates pyruvate

reaction

in heart mitochondria of starved or

FEBS Lett 127: 188-192, 1981

150

102.

Khatra

BS,

Chawla RR,

Sewell CW,

Rudman D.

Distribution of

branched-chain a-keto acid dehydrogenases in primate tissues.

J Clin

Invest 59: 558-564, 1977

103.

Kieber

DJ,

K.

Mopper

chromatographic analysis of

Reversed-phase high-performance liquid
Q

-keto acid quinoxalinol derivatives.

J

Chromatog 281: 135-14, 1983

104. Kielducka A,

Paradies G,

A comparative study of the

Papa S.

transport of pyruvate in liver mi tochondria from normal and diabetic
rats.

J Bioenerg Biomemb 13: 123-132, 1981

105. Krebs HA, Lund P.

Aspects of the regulation of the metabolism of

branched-chain amino acids.

106. Krebs HA.

Some

omnivorous animals.
107. Lau KS J

kidney

aspects of the regulation of fuel supply in

Adv Enzy Regul 10: 397-420, 1972

Fatania HR, Randle PJ.

branched

triphosphate.

Adv Enzyme Reg 15: 375-394, 1977

chain

2-oxoacid

Inactivation of rat liver and

dehydrogenase complex by adenosine

FEBS Lett 126: 66-70, 1981

108. Lau KS, Phillips CE, Randle PJ.

Multi-site phosphorylation in

ox-kidney branched-chain 2-oxoacid dehydrogenase.

FEBS Lett 160: 149-

152, 1983

109. Laurent BC, Moldawer LL, Young VR, et ale
muscle protein kinetics

Whole-body leucine and

in rats fed varying protein intakes.

Am J

Physiol 246: E444-E451, 1984
110. Lemon PWR, Nagle FJ, Mullin JP, Benevenga NJ.

In vivo leucine

oxidation at rest and during two intensities of exercise.
Physio! 53: 947-954, 1982

J Appl

152

120. May ME, Mancusi VJ, Aftring RP, Buse MG.

Effects of diabetes on

Am

oxidative decarboxylation of branched-chain keto acids.

J Physiol

239: E215-E222, 1980
121. McFarlane IG, von Holt
calorie-deficient rats.

c.

Metabolism of amino acids in protein-

Biochem J 111: 557-563, 1969

122. McMenamy RH, Vang J J
concentrations in plasma

Drapanos T.

Amino acid and a-keto acid

Am

and blood of the liverless dog.

J Physiol

209: 1046-1052, 1965

123. McNurlan MA, Fern EB, Garlick PJ.
protein synthesis in vivo.

Failure of leucine to stimulate

Biochem J 204: 831-838, 1982

124. Meguid MM, Schwarz H, Matthews DE, Karl IE, Young VR, Bier DM.
vivo and in vitro branched-chain amino acid interactions.
Acids. Metabolism and Medical Applications, edited by G.L.
J.P. Grant, and V.R. Young.

125. Meister A.

In

In: Amino
Blackburn,

Boston, John Wright, pp 147-154, 1981

Biochemistry of the Amino Acids. Volume II. 2nd Ed.

New York, Academic Press, pp 742-757, 1965
126. Miller, LL.

The role of the liver and the non-hepatic tissues in

the regulation of free amino acid levels in the blood.

In: Amino Acid

Pools, edited by J.T. Holden. Amsterdam, Elsevier, pp 708-721, 1962

127. Mitch WE, Clark AS.

Specificity of the effects of leucine and its

metabolites on protein degradation in skeletal muscle.

Biochem J

222:

579-586, 1984

128. Morgan HE, Jefferson LS, Wolpert EB, Rannels DE.

Regulation of

protein synthesis in heart muscle. II. Effect of amino acid levels and
insulin on ribosomal aggregation.

J BioI Chern 246: 2163-2170, 1971

153

129. Motil KJ, Matthews DE, Bier DM, Burke JF, Munro HN, Young VR.
Whole-body leucine and lysine metabolism: response to dietary protein

Am J Physiol 240: E712-E721, 1981

intake in young men.

129a. Nissen S, Haymond MW.

Changes in leucine kinetics during meal

absorption: effects of dietary leucine availabilty.

Am

J Physiol 250:

E695-E701, 1986
Effect of corticosterone treatment on

130. Odedra BR, Millward DJ.

muscle protein turnover in adrenalectomized rats and diabetic rats
maintained on insulin.

Biochem J 204: 663-672, 1982

131. Odessey R, Goldberg AL.
of skeletal muscle.

Leucine degradation in cell-free extracts

Biochem J 178: 475-489, 1979

132. Odessey R, Goldberg AL.
muscle.

Am

J Physio! 223: 1376-1383, 1982

133. Odessey R.
oxo-acid

Oxidation of leucine by rat skeletal

Direct evidence for the inactivation of branched-chain

dehydrogenase

by

enzyme phosphorylation.

FEBS Lett 121:

306-308, 1980

134. Pain VM, Albertse EC, Garlick PJ.
muscle,

diaphragm,

Protein metabolism in skeletal

and heart of diabetic rats.

Am J Phys iol 245 :

E604-E610, 1983

135. Pardridge WM.
acid

transport

Kinetics of competitive inhibition of neutral amino

across

the

blood-brain

barrier.

J

Neurochem 28:

103-108, 1977
136. Parker PJ,

Randle PJ.

Partial purification and properties of

branched-chain 2-oxoacid dehydrogenase of ox liver.

751-757, 1978

Biochem J

171:

154

137. Patston PA, Espinal J, Randle PJ.

Effects of diet and alloxan

diabetes on the activity of branched-chain 2-oxo acid dehydrogenase
complex and

of activator protein in rat tissues.

Biochem J 222 :

711-719, 1984
138. Patston PA, Espinal J, Shaw JM, Randle PJ.

Rat tissue concen-

trations of branched-chain 2-oxo acid dehydrogenase complex. Re-evaluation by immunoassay and bioassay.
139. Paul HS, Adibi SA.

Biochem J 235: 429-433, 1986

Leucine oxidation in diabetes and starvation:

effects of ketone bodies on branched chain amino acid oxidation in
vitro.

Metabolism 27: 185-200, 1978

140. Paul HS, Adibi SA.

Role of ATP in the regulation of branched-

chain a-keto acid dehydrogenase activity in liver and muscle mitochondria of fed, fasted and diabetic rats.

J BioI Chern 257: 4875-4881,

1982
141. Paul HS, Adibi SA.

Activation of hepatic branched chain a-keto

acid dehydrogenase by a skeletal muscle factor.

J BioI Chern 257:

12581-12588, 1982
142.

Paxton R,

Harris RA.

dehydrogenase kinase.

Regulation of branched-chain a-ketoacid

Arch Biochem Biophys 231: 48-57, 1984

143. Paxton R, Harris RA.

Clofibric acid, phenylpyruvate, and dichlo-

roacetate inhibition of branched-chain a-ketoacid dehydrogenase kinase
in vitro and in perfused rat heart.

Arch Biochem Biophys 231: 58-66,

1984
144. Paxton R, Harris RA.

Isolation of rabbit liver branched-chain

a-keto acid dehydrogenase and regulation by phosphorylation.
Chern 257: 14433-14439, 1982

J BioI

155
145.

Peters Je,

Harper AE.

Adaptation of rats to diets containing

different levels of protein: Effects on food intake, plasma and brain
amino acid concentrations and brain neurotransmi tter metabolism.

J

Nutr 115: 382-398, 1985
146. Pettit FB, Yeaman SJ, Reed, LJ.

Purification and characterization

of branched chain a-keto acid dehydrogenase complex of bovine kidney.
Proc Natl Acad Sci USA 75: 4881-488, 1978
147.

Poston

catabolism.

JM.

Leucine

and

enzyme

of

leucine

J BioI Chern 251: 1859-1863, 1976

148. Poston JM.

Cobalamin-dependent formation of leucine and

by rat and human tissue.
149.

2,3-aminomutase,

~-leucine

J BioI Chern 255: 10067-10072, 1980

Pryor Je, Buse MG. Tunicamycin prevents stimulation of protein

synthesis

by

branched-chain

amino

acids

in

isolated rat muscles.

Biochem Biophys Res Comm 125: 149-156, 1984
150. Randle PJ, Fatania HR, Lau KS.

Regulation of the mitochondrial

branched-chain 2-oxoacid dehydrogenase complex of animal tissues by
reversible phosphorylation.
151. Randle PJ.

Mol Asp Cell Regul 3: 1-26, 1984

a-Ketoacid dehydrogenase complexes and respiratory

fuel utilisation in diabetes.

152.

Reed LJ,

pyruvate

and

Damuni

Z,

Diabetologia 28: 479-484, 1985

Merryfield ML.

branched-chain a-keto

phosphorylation-dephosphorylation.

Regulation

of mammalian

acid dehydrogenase complexes by
Curr Topics Cell Reg 27: 41-49,

1985

153. Reeds PJ.

The catabolism of valine in the malnourished rat.

Studies in vivo and in vitro with different labelled forms of valine.
Br J Nutr 31: 259-270, 1974

156
154. Robert JJ, Beaufrere B, Koziet J, Desjeux JF, Bier DM, Young VR,
Lestradet H.

Whole body de novo amino acid synthesis in type I

(insulin-dependent)

diabetes

leucine, alanine, and glycine.
155. Rogers QR, Harper AE.
rat.

studied

with

stable

isotope-labeled

Diabetes 34: 67-73, 1985

Amino acid diets and maximal growth in the

J Nutr 87: 267-273, 1965

156. Rose we, Oesterling MJ, Womack M.

Comparative growth on diets

containing ten and nineteen amino acids, with further observations upon
the role of glutamic and aspartic acids. J BioI Chem 176: 753-762, 1948
157. Rose WC,

Wixom RL, Lockhart HB, Lambert HB.

The amino acid

requirements of man. XV. The valine requirement; surrunary and final
observations.

J BioI Chern 217: 987-995, 1955

158. Rose WC.

Amino acid requirements of man.

Fed Proc 8: 546-552,

1949
159.

Ruderman NB,

Schmahl FW,

Goodman MN.

Regulation of alanine

formation and release in rat muscle in vivo: effect of starvation and
diabetes.

Am J Physiol 233: EI09-E114, 1977

160. Ryan NT, George BC, Harlow CL, Hiebert JM, Egdahl RH.

Endocrine

activation and altered muscle metabolism after hemorrhagic shock.

Am J

Physiol 233: E439-E444, 1977
161.

Sabourin PJ, Bieber LL.

characterization

of

and

Subcellular distribution and partial

a-ketoisocaproate

formation of a-hydroxyisovaleric acid.

oxidase

of

rat

liver:

Arch Biochem Biopbys 206:

132-144, 1981
162.

Sabourin PJ,

Bieber LL.

The mechanism of a-ketoisocaproate

157
oxygenase. Formation of

~-hydroxyisovalerate

from a-ketoisocaproate.

J

Bio! Chern 257: 7468-7471, 1982
163. Sabourin PJ, Bieber LL.

Purification and characterization of an
J BioI Chern 257: 7460-7467,

a-ketoisocaproate oxygenase of rat liver.
1982
164. Safer B, Smith CM, Williamson JR.

Control of the transport of

reducing equivalents across the mitochondrial membrane in perfused rat
heart.

J Mol Cell Cardiol 2: 111-124, 1971

165. Schauder P, Schroeder K, Langenbeck U.

Serum branched-chain amino

.

and keto acid response to a protein-rich meal in man.

Ann Nutr Metab

28: 350-356, 1984
166. Schimke RT.

Control of enzyme levels in mammalian tissues.

Adv

Enzymol 37: 135-187, 1973
167. Schneible PA, Airhart J, Low RB.

Differential compartmentation of

leucine for oxidation and for protein synthesis in cultured skeletal
muscle.

J BioI Chern 256: 4888-4894, 1981

168. Segel IH.

Enzyme Kinetics.

John Wiley and Sons, New York, 78,

1975
169. Sherwin RS.

Effect of starvation on the turnover and metabolic

response to leucine.

J Clin Invest 61: 1471-1481, 1978

170. Shinnick FL, Harper AE.

Branched-chain amino acid oxidation by

isolated rat tissue preparations.

Biochim Biophys Acta 437: 477-486,

1976
171. Sketcher RD, James WPT.

Branched-chain amino acid oxidation in

relation to catabolic enzyme activities in rats given a protein-free
diet at different stages of development.

Br J Nutr 32: 615-623, 1974

158

172. Smith RJ Elia M.

Branched-chain amino acids in catabolic states.

Proc Nutr Soc 42: 473-487 J 1983
173. Steel RGD, Torrie JH.

Principles and procedures of statistics.

McGraw-Hill Book Company, Inc., New YorkJ 157, 1960
174. Taylor RT t Jenkins WT.
and characterization.

Leucine aminotransferase. II. Purification

J BioI Chern 241: 4396-4405 J 1966

175. Tessari P, Trevisan RJ Inchiostro SJ

Biola G, Nosadini R, de

Kreutzenberg SV J Duner E, Tiengo A, Crepaldi G.

Dose-response curves

of effects of insulin leucine kinetics in humans.

Am J Physio! 251:

E334-E342, 1986
176. Tischler ME, Desautels M, Goldberg AL.

Does leucine J leucyl-tRNA

or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle?
177.

Tomas

FM.

Effect

of

J Biol Chern 257: 1613-1627, 1982

corticosterone on myofibrillar protein

turnover in diabetic rats as assessed by N~-methylhistidine excretion.
Biochem J 208: 593-601, 1982
178. Tsalikian E, Howard C, Gerich JE, Haymond MW.
flux

in

short-term

proteolysis.

fasted human

subjects:

Increased leucine

evidence for

increased

Am J Physiol 247: E323-E327, 1984

179. Umpleby AM, Boroujerdi MA, Brown PM, Carson ER, Sonksen PH.

The

effect of metabolic control on leucine metabolism in type I (insulindependent) diabetic patients.

Diabetologia 29: 131-141, 1986

180. van Hinsbergh VW, Veerkamp JH, Engelen PJM, Ghijsen WJ.

Effect of

L-carnitine on the oxidation of leucine and valine by rat skeletal
muscle.

Biochem Med 20: 115-124, 1978

159

181.

van Hinsbergh VWM,

Veerkamp JH, Glatz JFC. 4-Methyl-2-oxopent-

anoate oxidation by rat skeletal muscle mitochondria.

Biochem J 182:

353-360, 1979
182. Vazquez JA, Paul HS, Adibi SA.

Relation between plasma and tissue

parameters of leucine metabolism in fed and starved rats.

Am J Physiol

250: E615-E621, 1986
182a.

Vazquez JA, Morse EL, Adibi SA. Effect of dietary fat, carbohy-

drate,

and

protein

caloric restriceion.
183.

on

branched-chain

amino

acid catabolism during

J Clin Invest 76: 737-743, 1985

Wagenmakers AJM,

Schepens

JT,

Veerkamp JR.

Increase of the

activity state and loss of total activiy of the branched-chain 2-oxo
acid dehydrogenase in rat diaphragm during incubation.

Biochem J 224:

491-496, 1984
184. Wagenmakers AJM, Schepens JTG, Veerkamp JH.

Effect of starvation

and exercise on actual and total activity of the branched-chain 2-oxo
acid dehydrogenase complex in rat tissues.

Biochem J 223: 815-821,

1984

185. Wagenmakers AJM, Schepens JTG, Veldhuizen JAM, Veerkamp JR.

The

activity state of the branched-chain 2-oxo acid dehydrogenase complex
in rat tissues.

Biochem J 220: 273-281, 1984

186. Wagenmakers AJM, Veerkamp JH.

Degradation of branched-chain amino

acids and their derived 2-oxo acids and fatty acids in human and rat
heart and skeletal muscle.
187.

Wagenmakers

AJM,

Biochem Med 28: 16-31, 1982

Veerkamp

JH.

The effect of

branched-chain 2-oxo acid oxidation in rat muscle.

253-260, 1984

starvation

on

Biochem J 219:

160
188. Wahren

J, Felig

P, Hagenfeldt L.

splanchnic and leg

metabolism

diabetes mellitus.

J Clin Invest 57: 987-999, 1976

189. Walser

M.

in

Effect of protein ingestion on

normal

man

and

in

patients with

of branched-chain amino and keto

Therapeutic aspects

Clin Sci 66: 1-15, 1986

acids.

SJ,

190. Wassner

separation of

Li

JB.

High

six essential

diagnosis of

performance

amino acids

liquid chromatographic

and its use as an aid in the

J

branched-chain ketoaciduria.

Chromatog 227: 497-502,

1982
191. Waterborg JH, Matthews HR.

in Molecular Biology.

The Burton assay for DNA.

Nucleic Acids,

Volume 2,

In: Methods

Walker, J.M., editor.

Humana Press, New Jersey, 1-3, 1984
192. Waterlow

protein.

JC.

Metabolic adaptation

to low intakes of energy and

Ann Rev Nutr 6: 495-626, 1986

193. Waymack PP, DeBuysere MS, Olson,

MS.

Studies on

the activation

and inactivation of the branched chain a-keto acid dehydrogenase in the
perfused rat heart.
194. White TP,

J BioI Chern 255: 9773-9781, 1980

Brooks

GA.

[U-14C)glucose,

-alanine,

and -leucine

oxidation in rats at rest and two intensities of running.

Am J Physiol

240: E155-E165, 1981
195.

Wieland

Structure and

OH.

The

regulation.

mammalian

pyruvate

dehydrogenase

complex:

Rev Physiol Biochem Pharmacol 96: 123-170,

1983

196. Wolfe RR, Goodenough RD, Wolfe MH,

analysis of

leucine and

Physiol 52: 458-466, 1982

Royl~

GT, Nadel

ER.

urea metabolism in exercising humans.

Isotopic
J Appl

161
197. Wurtman RJ, Hefti F, Melamed E.

mitter synthesis.

Precursor control of neurotrans-

Pharmacol Rev 32: 315-335, 1981

198. Yeaman SJ, Cook KG, Boyd RW, Lawson R.

Evidence that the mito-

chondrial activator of phosphorylated branched-chain 2-oxoacid dehydrogenase complex is the dissociated E1 component of the complex.

FEBS

Lett 172: 38-42, 1984
199.

Yeaman SJ.

family.

The manunalian 2-oxoacid dehydrogenases: a complex

Trends Biochem Sci 11: 293-296, 1986

200. Zapalowski C, Miller RF, Dixon JL, Harper AE.

Effects of perfu-

sate leucine concentration on the metabolism of valine by the isolated
rat hindquarter.

Metabolism 33: 922-927, 1984

